Citations

Citations to this article as recorded by  

• Bridging Evidence and Practice: A Consensus Statement from the Korean Diabetes Association on Diabetes Screening, Pharmacological Treatment and Severe Diabetes
  Jong Han Choi, Shinae Kang, Soo-Kyung Kim, Won Jun Kim, Ji Min Kim, Jaehyun Bae, Jae-Seung Yun, Eonju Jeon, Young-Eun Kim, Jae Hyun Bae, Hun Jee Choe, Young Min Cho, Seung-Hyun Ko, Sang Yong Kim, Hae Jin Kim, You-Cheol Hwang, Min Kyong Moon, Suk Chon, Seo
  Diabetes & Metabolism Journal.2025; 49(6): 1155.     CrossRef

Citations

Citations to this article as recorded by  

• Assessing the Impact of Glucagon-like Peptide-1 and Glucagon-like Peptide-1/glucose-dependent Insulinotropic Polypeptide Receptor Agonist Shortages on Glycemic Control: A Single Center Study
  Christian Dacon, Pramodini Kale-Pradhan, Melissa Lipari
  Journal of Pharmacy Practice.2026;[Epub]     CrossRef
• Metabolic rebound and weight cycling following incretin mimetic drug withdrawal: a cause for concern?
  Sarah E. Alexander, Erin J. Howden
  Current Opinion in Clinical Nutrition & Metabolic Care.2026; 29(4): 395.     CrossRef
• Addressing the Shortage of GLP-1 RA and Dual GIP/GLP-1 RA-Based Therapies—A Systematic Review
  Velimir Altabas, Zrinka Orlović, Maja Baretić
  Diabetology.2025; 6(6): 52.     CrossRef
• Use of gastric ultrasound to identify GLP-1RA users at high risk of aspiration during surgery
  Alessandra T. Ayers, Cindy N. Ho, Nicole Y. Xu, Sergio D. Bergese, Ana Costa, David Kerr, David C. Klonoff
  Perioperative Care and Operating Room Management.2025; 41: 100562.     CrossRef
• Glucagon‑like peptide‑1 receptor agonists in multiple sclerosis: therapeutic promise, challenges, and future directions
  Afsaneh Shirani, Olaf Stuve
  Expert Opinion on Investigational Drugs.2025; 34(11): 929.     CrossRef
• Harnessing the gut-brain axis in the treatment of type 2 diabetes mellitus and obesity
  Kornela Kotucha, Katarzyna Kapłon, Magdalena Moś, Jakub Fiegler-Rudol, Alina Pietryszyn-Bilińska, Klaudia Dynarowicz, David Aebisher, Rafał Wiench, Aleksandra Kawczyk-Krupka
  European Journal of Clinical and Experimental Medicine.2025;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• GLP-1-derived therapies and sarcopenia: plea for a specific focus on at risk special populations
  André J. Scheen
  Diabetes & Metabolism.2026; 52(1): 101708.     CrossRef
• Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies
  Mokhtar Rejili, Md Sadique Hussain, Yumna Khan, Faouzi Haouala, Subbulakshmi Ganesan, Samir Sahoo, Amrita Pal, Vimal Arora
  Vascular Pharmacology.2026; 162: 107563.     CrossRef
• Time-restricted feeding in rodent obesity models: impact on body weights, lipid profile and glucoregulation
  Joyce Argaistieng, Bavani Visha Doraisamy, Hasseri Halim, Sharifah Sakinah Syed Alwi, Aida Azlina Ali, Sandra Maniam
  International Journal of Obesity.2026; 50(3): 507.     CrossRef
• BIOTECHNOLOGY AND BIOENGINEERING INNOVATIONS IN PRECISION OBESITY MANAGEMENT: MECHANISTIC INSIGHTS, EMERGING PLATFORMS, AND TRANSLATIONAL PATHWAYS
  MIN HO HAN, YOUN SEON HWANG, DO HYEON JIN, JIN WOO KIM
  Journal of Mechanics in Medicine and Biology.2026;[Epub]     CrossRef
• A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass
  Federica Moscucci, Francesco Baratta, Daniele Pastori, Danilo Menichelli, Anna Vittoria Mattioli, Sabina Gallina, Ilaria Lospinuso, Susanna Sciomer, Gianfranco Piccirillo, Giovambattista Desideri
  Nutrients.2026; 18(4): 632.     CrossRef
• Nonsurgical Aesthetic Treatment of the Face and Neck in GLP-1 Receptor Agonist Weight Loss Patients: Experience-Based Considerations
  Amir Moradi, Radina Denkova, Katherine Holcomb, Anthony Rossi, Nazanin Ashourian
  Aesthetic Surgery Journal Open Forum.2026;[Epub]     CrossRef
• The potential for complex interplay between GLP-1 receptor agonists, gut microbiome, and obesity management
  Abigail J. Johnson, Erin N. O’Sullivan, Peerada Valyasevi, Breanna Metras, Subin Jang, Robin Shields-Cutler, Katherine R. Hendel, Tasma Harindhanavudhi, Levi Teigen
  Canadian Journal of Physiology and Pharmacology.2026; 104: 1.     CrossRef
• GLP-1 receptor and Mitochondria-ER Contact Sites: an emerging mechanism of metabolic regulation
  Pablo Cruz, Andrea Puebla-Huerta, Mayarling F. Troncoso, Eduardo Silva-Pavez, Yessia Hidalgo-Fadic, Ulises Ahumada-Castro
  Frontiers in Physiology.2026;[Epub]     CrossRef
• Delayed gastric emptying induced by glucagon-like peptide-1 receptor agonists and its implications for perioperative risk during anesthesia
  Donghee Kang, Dughyun Choi
  The Korean Journal of Internal Medicine.2026; 41(3): 384.     CrossRef
• Multicomponent Stapling of Glucagon‐Like Peptide‐1 Enables Receptor‐Guided PROTAC Delivery
  Jan L. Venne, Sona Krajcovicova, Graeme Davies, Hannah Bolt, Jefferson Revell, David R. Spring
  Angewandte Chemie International Edition.2026;[Epub]     CrossRef
• Multicomponent Stapling of Glucagon‐Like Peptide‐1 Enables Receptor‐Guided PROTAC Delivery
  Jan L. Venne, Sona Krajcovicova, Graeme Davies, Hannah Bolt, Jefferson Revell, David R. Spring
  Angewandte Chemie.2026;[Epub]     CrossRef
• Computational investigation of single herbal drugs for diabetes and obesity using knowledge graph and network pharmacology
  Priyotosh Sil, Rahul Tiwari, Vasavi Garisetti, Shanmuga Priya Baskaran, Fenita Hephzibah Dhanaseelan, Smita Srivastava, Areejit Samal
  Computational Biology and Chemistry.2026; 124: 109194.     CrossRef
• Do Fasting GLP-1 and GIP Levels Predict the Initial Pharmacological Response to Semaglutide and Tirzepatide?
  Sandro La Vignera, Cristian Fioriglio, Rosita A. Condorelli
  Diagnostics.2026; 16(13): 1979.     CrossRef
• Psychiatric Safety Signals of GLP-1 Receptor Agonists: A FAERS-Based Pharmacovigilance Study with Explainable Machine Learning
  Suhyeon Moon, EunJu Lee, Doyeon Kim, Kyung Hee Choi, Yeo Jin Choi, Sooyoung Shin
  Pharmaceuticals.2026; 19(6): 953.     CrossRef
• The Critical Role of Body Composition Assessment in Advancing Research and Clinical Health Risk Assessment across the Lifespan
  Jonathan P. Bennett, Soo Lim
  Journal of Obesity & Metabolic Syndrome.2025; 34(2): 120.     CrossRef
• Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders
  Marwin A. Farrugia, Enzo Pini, Albert Tran, Nicolas Chevalier, Rodolphe Anty, Philippe Gual
  Current Obesity Reports.2025;[Epub]     CrossRef
• Are GLP-1 receptor agonists and diabetic retinopathy foes or friends?
  Kai Liu, Shu Liu, Dong Wang, Hong Qiao
  Diabetes & Metabolism.2025; 51(6): 101696.     CrossRef
• The multifaceted effects of semaglutide: exploring its broad therapeutic applications
  Mesk Alkhatib, Noor Almasri, Sakhr Alshwayyat, Hebah Almahariq, Bara M. Hammadeh, Zaid Taimeh, Lean Alkhatib, Anas Alshwayat, Nesreen A Saadeh, Mohammed Al-mahdi Al-kurdi
  Future Science OA.2025;[Epub]     CrossRef
• Two decades of diabetes prevention: Sustained benefits, heterogeneous effects, and implications for precision prevention
  Seung‐Hwan Lee
  Journal of Diabetes Investigation.2025; 16(10): 1779.     CrossRef
• Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema for the Treatment of Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis
  Ting Jin, Yange Meng, Luping Ren, Yue Wang
  Journal of Clinical Question.2025;[Epub]     CrossRef
• Beta-Cell Function, Insulin Sensitivity, and Metabolic Characteristics in Young-Onset Type 2 Diabetes Mellitus: Findings from Anam Diabetes Observational Study
  Ji Yoon Kim, Jiyoon Lee, Sin Gon Kim, Nam Hoon Kim
  Diabetes & Metabolism Journal.2025; 49(6): 1287.     CrossRef
• Diabetes and Osteoarthritis: Exploring the Interactions and Therapeutic Implications of Insulin, Metformin, and GLP-1-Based Interventions
  Iryna Halabitska, Liliia Babinets, Valentyn Oksenych, Oleksandr Kamyshnyi
  Biomedicines.2024; 12(8): 1630.     CrossRef
• Why you should not skip tailored exercise interventions when using incretin mimetics for weight loss
  Katharina Gross, Christian Brinkmann
  Frontiers in Endocrinology.2024;[Epub]     CrossRef
• Beyond Glycemic Control: GLP-1 Receptor Agonists and Their Impact on Calcium Homeostasis in Real-World Patients
  Bandar T. Alenezi, Nadra Elfezzani, Rukhsana Uddin, Hinali Patel, Sydney Chester, Ahmed Abdelmaksoud, Mohammad H. Hussein, Sawsan A. Zaitone, Manal S. Fawzy, Hani Aiash, Eman A. Toraih
  Journal of Clinical Medicine.2024; 13(16): 4896.     CrossRef
• Innovative approaches to the treatment of obesity: from pharmacotherapy to nanomedicine
  T. I. Romantsova
  Obesity and metabolism.2024; 21(4): 389.     CrossRef
• Semaglutide effects on cardiovascular outcomes in individuals with overweight or obesity who do not have diabetes: a systematic review
  Anna Klasa, Aleksandra Ewa Sobaś, Kamil Biedka, Oliwia Ziobro, Katarzyna Błaszczyk, Jakub Maciej Bulski, Filip Maj, Karol Sornat, Barbara Pokora, Agata Estreicher
  Medical Science Pulse.2024;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Mitochondrial-derived peptides (Humanin, MOTS-c, and SHLP2) protect pancreatic islet cells and delay the onset and progression of type 2 diabetes mellitus in mice
  Tiyesh Paul, Oly Banerjee, Sangeeta Das, Bithin Kumar Maji, Srikanta Goswami, Sandip Mukherjee
  PharmaNutrition.2026; 35: 100480.     CrossRef
• Sodium-glucose cotransporter-specific substrate αMG stimulates endogenous glucagon secretion and ameliorates obesity-associated metabolic disorders in mice
  Takayoshi Suga, Yoko Tabei, Osamu Kikuchi, Daisuke Kohno, Yuichi Ikeuchi, Masaki Kobayashi, Yuko Nakagawa, Hiroki Tojima, Yuichi Yamazaki, Ken Sato, Satoru Kakizaki, Takashi Nishimura, Yoshio Fujitani, Takumi Takizawa, Toshio Uraoka, Tadahiro Kitamura
  Molecular Metabolism.2026; 105: 102324.     CrossRef
• Association between sleep disorders and alterations in glucose metabolism, insulin, and glucagon in patients with type 2 diabetes
  Zhixue Song, Huashan Zhao, Xiaoxue Yu, Xinguang Sun
  Medicine.2026; 105(7): e47409.     CrossRef
• Antidiabetic Potential of Brewed Arabica Coffee: Modulation of GLUT4, Insulin, and Glucagon in STZ‐Induced Rats
  Yusni Yusni, Hanifah Yusuf, Said Usman, Iflan Nauval, Hasanuddin Hasanuddin, Fahmi Ichwansyah, Nurul Mahmudati, Eric Gumpricht
  Journal of Nutrition and Metabolism.2026;[Epub]     CrossRef
• The Insulin–Urothelial Axis: Evaluating Insulin Resistance as a Convergent Driver of Bladder Cancer Across Diverse Risk Factor Profiles
  Giovanni Tarantino, Vincenzo Citro, Ciro Imbimbo, Felice Crocetto
  International Journal of Molecular Sciences.2026; 27(9): 3919.     CrossRef
• Coordination Chemistry of Diabetes‐Associated Islet Peptide Hormones
  Yonghwan Pi, Hyunwoo Jung, Jiyeon Han
  European Journal of Inorganic Chemistry.2025;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• A narrative review on tirzepatide’s therapeutic potential in glycemic control and cardioprotection
  Mrudula Thiriveedi, Francis Sto. Domingo, Hannah Yates, Sujatha Baddam, Rafik El Beblawy, Bala Nimmana, Siddharth Patel
  Annals of Medicine & Surgery.2026; 88(1): 371.     CrossRef
• PHARMACOLOGICAL TREATMENT FOR OBESITY: MECHANISMS OF ACTION, SAFETY AND THERAPEUTIC EFFICACY
  Raquel Ribeiro Leão dos Santos, Eduarda de Paula Guasti, Fabiane Merigueti Nunes, André Soares Leopoldo, Ana Paula Lima-Leopoldo
  International Journal of Health Management Review.2026; 12(1): e461.     CrossRef
• GLP-1 RECEPTOR AGONISTS IN AESTHETIC MEDICINE: THERAPEUTIC BREAKTHROUGH OR CATALYST FOR UNREALISTIC BODY IDEALS?
  Olga Kowalczyk, Anita Zięba, Michał Domin, Monika Kowalska, Katarzyna Ścibisz, Justyna Całka, Dominika Zdobylak, Karolina Ollik, Kamil Harenza, Mateusz Taranowicz
  International Journal of Innovative Technologies in Social Science.2026;[Epub]     CrossRef
• Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy
  Monika Gupta, Jitendra Shukla
  The Indian Journal of Medical Research.2026; 163: 427.     CrossRef
• Prevention and Management of Recurrent Weight Gain After Bariatric Surgery: Integrating Behavioural, Pharmacological and Procedural Approaches
  Sally Louise Tucker, Samer Humadi
  Obesity Surgery.2026; 36(7): 3883.     CrossRef
• GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists
  Mahroz Abid, Khizer Sohail Sheikh, Muhammad Shahbaz Ahmad, Hongwei Jiang
  Diabetes, Metabolic Syndrome and Obesity.2026; Volume 19: 1.     CrossRef
• The effect of GLP-1RAs and co-agonists on body composition across obesity and type 2 diabetes
  Lifang Sun, Hua Liu, Xuxiang Zhang, Fan Zuo, Yue Kong, Juan Feng, Xin Nian
  European Journal of Medical Research.2026;[Epub]     CrossRef
• Effects of the glucagon-like peptide-1 and glucagon receptor dual agonists on glycemic markers: A systematic review and meta-analysis of randomized controlled trials
  Luis E. Simental-Mendía, Mario Simental-Mendía, Paola Aguillón-Marín, Adriana Sánchez-García
  Journal of Investigative Medicine.2026;[Epub]     CrossRef
• Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials
  Luis E. Simental-Mendía, Laura Jazel Barragán-Zúñiga, Valeria Reyes-Avitia
  High Blood Pressure & Cardiovascular Prevention.2026;[Epub]     CrossRef
• Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis
  Moaz Safwan, Mariam Safwan Bourgleh, Shahad Abdullah Alotaibi, Eman Alotaibi, Abdulsalam Al-Ruqi, Fathiya El Raeya
  Annals of Saudi Medicine.2025; 45(2): 129.     CrossRef
• Glucose-dependent insulinotropic peptide and beyond: co-agonist innovations in the treatment of metabolic diseases
  Chenxu Zhou, Binbin Gong, Xiyu Liu, Guoqiang Hu, Lidan Sun
  European Journal of Pharmacology.2025; 999: 177681.     CrossRef
• Advancing Cardiovascular, Kidney, and Metabolic Medicine: A Narrative Review of Insights and Innovations for the Future
  Kevin Fernando, Derek Connolly, Eimear Darcy, Marc Evans, William Hinchliffe, Patrick Holmes, W. David Strain
  Diabetes Therapy.2025; 16(6): 1155.     CrossRef
• Review Article: GLP‐1 Receptor Agonists and Glucagon/GIP/GLP‐1 Receptor Dual or Triple Agonists—Mechanism of Action and Emerging Therapeutic Landscape in MASLD
  Maryam Zafer, Federica Tavaglione, Manuel Romero‐Gómez, Rohit Loomba
  Alimentary Pharmacology & Therapeutics.2025; 61(12): 1872.     CrossRef
• Retatrutide—A Game Changer in Obesity Pharmacotherapy
  Vasiliki Katsi, Georgios Koutsopoulos, Christos Fragoulis, Kyriakos Dimitriadis, Konstantinos Tsioufis
  Biomolecules.2025; 15(6): 796.     CrossRef
• The role of broad bean albumin 1b on GIP and GLP-1 mediated alterations to glucose metabolism in diabetic mice
  Feifei Han, Lu Jin, Lulu Zhou, Qi Liu, MengLu Ding, Weilin Liu, Jianzhong Han
  npj Science of Food.2025;[Epub]     CrossRef
• Next generation dual GLP-1/GIP, GLP-1/glucagon, and triple GLP-1/GIP/glucagon agonists: a literature review
  Jimmy Wen, Denise Nadora, Alina Truong, Ethan Bernstein, Christiane How-Volkman, Adam Razick, Daniel Razick, Muhammad Karabala, Eldo Frezza
  Nutrition, Metabolism and Cardiovascular Diseases.2025; 35(12): 104213.     CrossRef
• Retatrutide: A novel approach in the treatment of obesity, diabetes mellitus, and MASLD (metabolic dysfunction-associated steatotic liver disease)
  Robert Prosecký, Klaudia Hálová Karoliová
  Klinická farmakologie a farmacie.2025; 39(2): 122.     CrossRef
• Triple Agonist Therapy: A New Frontier in Treating Type 2 Diabetes and Obesity
  Heather P. Whitley
  Clinical Diabetes.2025; 43(3): 439.     CrossRef
• Current and Future Implications of Weight Loss Drugs on Liver Disease
  Arvind Bussetty, Nishali Shah, Toni Marie Chandler, Meghana Ghattu, Keerthana Kesavarapu
  Clinics in Liver Disease.2025; 29(4): 743.     CrossRef
• Are GLP-1 receptor agonists and diabetic retinopathy foes or friends?
  Kai Liu, Shu Liu, Dong Wang, Hong Qiao
  Diabetes & Metabolism.2025; 51(6): 101696.     CrossRef
• Semaglutide and the skin: A brief review of dermatologic implications
  Arisha Salam, Mohammed Salman Hyder
  Cosmoderma.2025; 5: 84.     CrossRef
• Chronic kidney disease in metabolic syndrome
  S. V. Villevalde, N. E. Zvartau
  Russian Journal of Cardiology.2025; 30(1S): 6537.     CrossRef
• Novel Dual and Triple Agonists Targeting GLP-1, GIP, Glucagon, and GDF15 for Type 2 Diabetes and Obesity Management
  Jiudan Zhang, Shriya Sanan, Marta Csanalosi, Chao Zheng, Andreas F H Pfeiffer
  Endocrinology.2025;[Epub]     CrossRef
• MASLD Pharmacotherapy: Current Standards, Emerging Treatments, and Practical Guidance for Indian Physicians
  Ashish Kumar
  Journal of The Association of Physicians of India.2025; 73(7): e45.     CrossRef
• Effect of GLP-1 receptor agonists on body composition
  Akhila Bhandarkar, Sowrabha Bhat, Nitin Kapoor
  Current Opinion in Endocrinology, Diabetes & Obesity.2025; 32(6): 279.     CrossRef
• Innovative Therapeutic Approaches Targeting Obesity: Can Flavonoids Improve the Efficacy of Anti-Obesogenic Drugs?
  Emanuele-Salvatore Scarpa, Stefano Amatori, Giovanni Caprioli, Filippo Maggi, Gianluca Moroncini, Giancarlo Balercia, Gilberta Giacchetti
  International Journal of Molecular Sciences.2025; 26(20): 10142.     CrossRef
• Antidiabetic Agents as Antioxidant and Anti-Inflammatory Therapies in Neurological and Cardiovascular Diseases
  Snehal Raut, Luca Cucullo
  Antioxidants.2025; 14(12): 1490.     CrossRef
• New Mechanisms to Prevent Heart Failure with Preserved Ejection Fraction Using Glucagon-like Peptide-1 Receptor Agonism (GLP-1 RA) in Metabolic Syndrome and in Type 2 Diabetes: A Review
  Jorge E. Jalil, Luigi Gabrielli, María Paz Ocaranza, Paul MacNab, Rodrigo Fernández, Bruno Grassi, Paulina Jofré, Hugo Verdejo, Monica Acevedo, Samuel Cordova, Luis Sanhueza, Douglas Greig
  International Journal of Molecular Sciences.2024; 25(8): 4407.     CrossRef
• New Molecules in Type 2 Diabetes: Advancements, Challenges and Future Directions
  Kyriazoula Chatzianagnostou, Melania Gaggini, Adrian Suman Florentin, Ludovica Simonini, Cristina Vassalle
  International Journal of Molecular Sciences.2024; 25(11): 6218.     CrossRef
• Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, anti-diabetic drugs in heart failure and cognitive impairment: potential mechanisms of the protective effects
  Maria Antonietta Riemma, Elena Mele, Maria Donniacuo, Marialucia Telesca, Gabriella Bellocchio, Giuseppe Castaldo, Francesco Rossi, Antonella De Angelis, Donato Cappetta, Konrad Urbanek, Liberato Berrino
  Frontiers in Pharmacology.2024;[Epub]     CrossRef
• Mechanisms of Glucagon Receptor Agonism and GLP-1/Glucagon/GIP Receptor Triple Agonism for Treatment of Diabetes and Obesity
  Se Hee Min
  The Journal of Korean Diabetes.2024; 25(2): 82.     CrossRef
• Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide
  Wenzhuo Li, Qingtong Zhou, Zhaotong Cong, Qingning Yuan, Wenxin Li, Fenghui Zhao, H. Eric Xu, Li-Hua Zhao, Dehua Yang, Ming-Wei Wang
  Cell Discovery.2024;[Epub]     CrossRef
• Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy
  Michał Nicze, Adrianna Dec, Maciej Borówka, Damian Krzyżak, Aleksandra Bołdys, Łukasz Bułdak, Bogusław Okopień
  International Journal of Molecular Sciences.2024; 25(15): 8202.     CrossRef
• Semaglutide “Ozempic” Face and Implications in Cosmetic Dermatology
  Karen Montecinos, Barbara Kania, David J. Goldberg
  Dermatological Reviews.2024;[Epub]     CrossRef
• GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy
  André J. Scheen
  Drugs.2024; 84(11): 1347.     CrossRef
• Retatrutide
  Nathan Ramsbacher
  Clinical Diabetes.2024; 42(4): 579.     CrossRef
• The power of three: Retatrutide's role in modern obesity and diabetes therapy
  Toufik Abdul-Rahman, Poulami Roy, Fatma Kamal Ahmed, Jann Ludwig Mueller-Gomez, Sarmistha Sarkar, Neil Garg, Victor Oluwafemi Femi-Lawal, Andrew Awuah Wireko, Hala Ibrahim Thaalibi, Muhammad Usman Hashmi, Andrew Sefenu Dzebu, Sewar Basheer Banimusa, Aayus
  European Journal of Pharmacology.2024; 985: 177095.     CrossRef
• Old and new anti-obesity drugs
  Salimeh Dodangeh, Shirin Hasani-Ranjbar
  Journal of Diabetes & Metabolic Disorders.2024;[Epub]     CrossRef
• Innovative approaches to the treatment of obesity: from pharmacotherapy to nanomedicine
  T. I. Romantsova
  Obesity and metabolism.2024; 21(4): 389.     CrossRef

Citations

Citations to this article as recorded by  

• The attenuated incretin effect is associated with glucose intolerance in patients with hepatitis B-related acute-on-chronic liver failure
  Meichuan Li, Han Hu, Yujuan Liu, Xiaohuan Wu, Yin Zhang, Ying Li, Fangwan Yang, Yan Li, Shide Lin
  Frontiers in Physiology.2026;[Epub]     CrossRef
• Do Fasting GLP-1 and GIP Levels Predict the Initial Pharmacological Response to Semaglutide and Tirzepatide?
  Sandro La Vignera, Cristian Fioriglio, Rosita A. Condorelli
  Diagnostics.2026; 16(13): 1979.     CrossRef
• The molecular mechanisms of incretin resistance in Type 2 Diabetes Mellitus (T2DM)
  Rawayh Muslim Albaghlany, Abbas Ali Mansour
  Nutrition & Diabetes.2026;[Epub]     CrossRef
• GHRH in diabetes and metabolism
  Charlotte Steenblock, Stefan R. Bornstein
  Reviews in Endocrine and Metabolic Disorders.2025; 26(3): 413.     CrossRef
• Beta-Cell Function, Insulin Sensitivity, and Metabolic Characteristics in Young-Onset Type 2 Diabetes Mellitus: Findings from Anam Diabetes Observational Study
  Ji Yoon Kim, Jiyoon Lee, Sin Gon Kim, Nam Hoon Kim
  Diabetes & Metabolism Journal.2025; 49(6): 1287.     CrossRef
• Initial Combination Therapy in Type 2 Diabetes
  Ji Yoon Kim, Nam Hoon Kim
  Endocrinology and Metabolism.2024; 39(1): 23.     CrossRef
• Impact of Some Natural and Artificial Sweeteners Consumption on Different Hormonal Levels and Inflammatory Cytokines in Male Rats: In Vivo and In Silico Studies
  Dina Mostafa Mohammed, Mohamed A. Abdelgawad, Mohammed M. Ghoneim, Abdulaziz Alhossan, Rasha Hamed Al-Serwi, Amr Farouk
  ACS Omega.2024; 9(28): 30364.     CrossRef
• Antidiabetic Agents and Bone Quality: A Focus on Glycation End Products and Incretin Pathway Modulations
  Muthanna K. Zaki, Mohammed N. Abed, Fawaz A. Alassaf
  Journal of Bone Metabolism.2024; 31(3): 169.     CrossRef
• Recent Glycemia Is a Major Determinant of β-Cell Function in Type 2 Diabetes Mellitus
  Ji Yoon Kim, Jiyoon Lee, Sin Gon Kim, Nam Hoon Kim
  Diabetes & Metabolism Journal.2024; 48(6): 1135.     CrossRef

Citations

Citations to this article as recorded by  

• Structural and functional magnetic resonance imaging abnormalities and plasma GLP-1 levels in Parkinson's disease with cognitive impairment
  Yunfei Sun, Mengyan Zhang, Xiaoxue Shi, Longyu Wu, Li Wang, Jinhua Zheng, Jianjun Ma, Zonghan She, Xuelin Qi, Yingyun Wang, Qing Xu, Qi Gu, Siyuan Chen, Xue Li
  IBRO Neuroscience Reports.2026; 20: 457.     CrossRef
• New generation anti-obesity drugs and bone health in postmenopausal women
  Jana Tomasová Studýnková
  Vnitřní lékařství.2026; 72(2): 104.     CrossRef
• Regulators of appetite in mammals—old and new players
  Jorge H Fernandes, Jorge Diogo Da Silva, Marta D Costa, Patrícia Maciel
  Endocrine Reviews.2026;[Epub]     CrossRef
• Novel Dual and Triple Agonists Targeting GLP-1, GIP, Glucagon, and GDF15 for Type 2 Diabetes and Obesity Management
  Jiudan Zhang, Shriya Sanan, Marta Csanalosi, Chao Zheng, Andreas F H Pfeiffer
  Endocrinology.2025;[Epub]     CrossRef
• The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update
  Agnieszka Jakubowska, Carel W. le Roux, Adie Viljoen
  Endocrinology and Metabolism.2024; 39(1): 12.     CrossRef
• The Association of Circulating Glucagon-Like Peptide-1 with Cognitive Functions and Biomarkers in Alzheimer’s Disease
  Mengqing Liu, Nenghong Ma, Xiao Yang, Miao Sun, Xiaowen Li, Yuhui Liu, Qing Chang, Changchun Hei, Jian-Hong Wang
  Journal of Alzheimer's Disease.2024; 99(2): 525.     CrossRef
• Energy balance and obesity: the emerging role of glucagon like peptide-1 receptor agonists
  Noémie Beauregard, Kurt McInnis, Gary S. Goldfield, Éric Doucet
  Current Opinion in Clinical Nutrition & Metabolic Care.2024; 27(6): 472.     CrossRef
• Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
  John R. Ussher, Daniel J. Drucker
  Nature Reviews Cardiology.2023; 20(7): 463.     CrossRef
• A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena
  Stephen C Bain, Thinzar Min
  The Lancet.2023; 402(10401): 504.     CrossRef
• Flattening the biological age curve by improving metabolic health: to taurine or not to taurine, that’ s the question
  Kwok M. Ho, Anna Lee, William Wu, Matthew T.V. Chan, Lowell Ling, Jeffrey Lipman, Jason Roberts, Edward Litton, Gavin M. Joynt, Martin Wong
  Journal of Geriatric Cardiology.2023; 20(11): 813.     CrossRef

Citations

Citations to this article as recorded by  

• Tirzepatide and Obesity: A Narrative Review
  Arya Singh, Rahnuma Ahmad, Kona Chowdhury, Mahendra Narwaria, Mainul Haque
  Advances in Human Biology.2026; 16(2): 290.     CrossRef
• Effect of Submaximal-Dose Semaglutide on MASLD Biopsy-Free Scoring Systems in Patients with Obesity
  Boris Focko, Martin Jozef Péč, Zuzana Miertová, Jakub Jurica, Andrej Miert, Lucia Kubíková, Peter Tudík, Norbert Nagy, Patrik Lecký, Ivana Ságová, Tomáš Bolek, Daniel Ján Havaj, Ľubomír Skladaný, Marián Mokáň, Matej Samoš
  Livers.2026; 6(1): 3.     CrossRef
• Glucagon-like peptide-1 and dual/triple receptor agonists in the treatment of metabolic dysfunction-associated steatotic liver disease: advances in mechanistic research
  Xinyi Lu, Li Yang
  Frontiers in Medicine.2026;[Epub]     CrossRef
• Korean red ginseng saponins ameliorate metabolic dysfunction-associated steatohepatitis in mice by inhibiting caspase-11 and NLRP3 inflammasomes
  Eojin Kim, Hee Ryeong Lim, Deok-Hyeong Choi, Young-Su Yi
  Journal of Ginseng Research.2026; : 101075.     CrossRef
• Emerging metabolic hormone therapeutics for metabolic dysfunction-associated steatohepatitis: incretin-based drugs, fibroblast growth factor analogs, and liver-targeting strategies
  Sukwoo Han, Jaehee Shin, Jae Cheon Kim, Dong Hee Na
  Journal of Pharmaceutical Investigation.2026;[Epub]     CrossRef
• Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes
  Brandon Havranek, Rebecca Loh, Beatriz Torre, Rachel Redfield, Dina Halegoua-DeMarzio
  Scientific Reports.2025;[Epub]     CrossRef
• Therapeutic effects and mechanisms of Xinmaitong formula for type 2 diabetes mellitus via GLP-1R signaling
  Weidong Pu, Yang Pan, Kang Yang, Jian Gao, Fen Tian, Jingrui Song, Yubing Huang, Yanmei Li
  Frontiers in Pharmacology.2025;[Epub]     CrossRef
• Glucagon-like peptide-1 receptor agonists improve cholesterol metabolism by inhibiting SREBP-2 via SIRT6-AMPK pathway in HepG2 cells treated with palmitic acid
  Jinmi Lee, Eun-Jung Rhee, Yu-Mi Lim, Seok-Woo Hong, Won-Young Lee
  Cardiovascular Prevention and Pharmacotherapy.2025; 7(3): 61.     CrossRef
• GLP-1/GLP-1RAs: New Options for the Drug Treatment of NAFLD
  Haoran Jiang, Linquan Zang
  Current Pharmaceutical Design.2024; 30(2): 100.     CrossRef
• Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism
  Tong Bu, Ziyan Sun, Yi Pan, Xia Deng, Guoyue Yuan
  Diabetes & Metabolism Journal.2024; 48(3): 354.     CrossRef
• Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
  Inha Jung, Dae-Jeong Koo, Won-Young Lee
  Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
• Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence
  Salvatore Corrao, Chiara Pollicino, Dalila Maggio, Alessandra Torres, Christiano Argano
  Frontiers in Endocrinology.2024;[Epub]     CrossRef
• Effects of the switch from dulaglutide to tirzepatide on glycemic control, body weight, and fatty liver: a retrospective study
  Toshitaka Sawamura, Ren Mizoguchi, Ai Ohmori, Mitsuhiro Kometani, Takashi Yoneda, Shigehiro Karashima
  Journal of Diabetes & Metabolic Disorders.2024; 23(2): 2105.     CrossRef
• FABP1 induces lipogenesis by regulating the processing of SREBP1 in hepatocytes of large yellow croaker (Larimichthys crocea)
  Fan Chen, Tingting Hao, Qiang Chen, Yuning Sun, Yanan Shen, Zengqi Zhao, Jianlong Du, Yueru Li, Kangsen Mai, Qinghui Ai
  The FASEB Journal.2024;[Epub]     CrossRef
• GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
  Riccardo Nevola, Raffaella Epifani, Simona Imbriani, Giovanni Tortorella, Concetta Aprea, Raffaele Galiero, Luca Rinaldi, Raffaele Marfella, Ferdinando Carlo Sasso
  International Journal of Molecular Sciences.2023; 24(2): 1703.     CrossRef
• FAM3A mediates the phenotypic switch of human aortic smooth muscle cells stimulated with oxidised low-density lipoprotein by influencing the PI3K-AKT pathway
  Lei Yang, Baoshun Du, Shitao Zhang, Maode Wang
  In Vitro Cellular & Developmental Biology - Animal.2023; 59(6): 431.     CrossRef
• ATP Secretion and Metabolism in Regulating Pancreatic Beta Cell Functions and Hepatic Glycolipid Metabolism
  Jing Li, Han Yan, Rui Xiang, Weili Yang, Jingjing Ye, Ruili Yin, Jichun Yang, Yujing Chi
  Frontiers in Physiology.2022;[Epub]     CrossRef
• Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
  Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, Shan Liu, Tatsunori Miyata, Qiaoling Song, Qingda Wei, Chenyang Zhao, Chunhua Lin, Jinbo Yang
  Signal Transduction and Targeted Therapy.2022;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Clinical and metabolic profile of adults with obesity attending lifestyle medicine clinics
  Hanan N. AlTaib, Reem AlAqeel, Amr A. Arafat, Faisal Kunnathodi, Abdulmajeed AlShaikh, Haifa F. AlOtaibi, Marwan Salih Al-Nimer
  PLOS One.2026; 21(2): e0342153.     CrossRef
• Anti-obesity medications in adults with congenital heart disease: a comprehensive review and expert clinical recommendations
  Panagiota Mitropoulou, Katja Prokšelj, Andrej Janež, Fernando Riesgo Gil, Suman Verma, Ivana Jurić, Vladimiro Vida, Michael A Gatzoulis, Margarita Brida
  European Heart Journal - Quality of Care and Clinical Outcomes.2026;[Epub]     CrossRef
• The impact of visceral obesity on the outcomes after resection of colorectal cancer: a systematic review and meta-analysis
  Shihao Wang, Yichen Ding, Wanling Lin, Tianrong Ma, Jiaxin Mei, Li Lin, Zhen Li, Weiling He
  Surgery for Obesity and Related Diseases.2026;[Epub]     CrossRef
• Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity
  Andrew Overholser, Eric Czech, Linda Speer, Joel Wilson, Alex Overholser
  Translation: The University of Toledo Journal of Medical Sciences.2025;[Epub]     CrossRef
• Once‐Weekly Semaglutide Versus Once‐Daily Liraglutide for Weight Loss in Adults: A Meta‐Analysis of Randomized Controlled Trials
  Tallal Mushtaq Hashmi, Mushood Ahmed, Ali Haider, Salman Naseem, Uzair Jafar, Munir Hussain, Javed Iqbal, Waqar Ali, Raheel Ahmed
  Clinical and Translational Science.2025;[Epub]     CrossRef
• Mechanisms and treatment of obesity-related hypertension—Part 2: Treatments
  Aneliya Parvanova, Manuela Abbate, Elia Reseghetti, Piero Ruggenenti
  Clinical Kidney Journal.2025;[Epub]     CrossRef
• The efficacy and safety of glucagon-like peptide-1 receptor agonists in non-diabetic adults with overweight/obesity: An umbrella review of systematic reviews and meta-analyses
  Nazanin Zamanian, Hossein Imani, Sepide Talebi, Mehran Rahimlou, Reza Amiri Khosroshahi, Hamed Mohammadi
  European Journal of Pharmacology.2025; 1003: 177966.     CrossRef
• Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP‐1 Receptor Agonists in Adults With Obesity or Overweight: A Meta‐Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration
  Alhussain Khawaji, Abdulaziz A. Jaly, Hanan A. Bakri, Renju Ravi, Ahmed Hattan, Abdullah Khawaji, Wael Najmi, Claire Stocker
  Journal of Obesity.2025;[Epub]     CrossRef
• Modern approaches to obesity management: Is dietary intervention sufficient?
  Jelena Gligorijević, Slavica Stevanović, Veroslava Stanković, Andrijana Zuber, Dušan Avramović
  PONS - medicinski casopis.2025; 22(1): 28.     CrossRef
• Pharmacotherapy for obesity: moving towards efficacy improvement
  Walmir Coutinho, Bruno Halpern
  Diabetology & Metabolic Syndrome.2024;[Epub]     CrossRef
• Physiopathology and Treatment of Obesity and Overweight: A Proposal for a New Anorectic
  Bruno Silvestrini, Mauro Silvestrini, Mayank Choubey
  Journal of Obesity.2024;[Epub]     CrossRef
• Potent synergistic effects of dulaglutide and food restriction in prevention of olanzapine-induced metabolic adverse effects in a rodent model
  Katerina Horska, Jan Kucera, Eva Drazanova, Gabriela Kuzminova, Petra Amchova, Maria Hrickova, Jana Ruda-Kucerova, Silje Skrede
  Biomedicine & Pharmacotherapy.2024; 176: 116763.     CrossRef
• Association between weight loss and cardiovascular outcomes and mortality in Korea: A nationwide cohort study
  So Yoon Kwon, Gyuri Kim, Seohyun Kim, Jae Hyeon Kim
  Diabetes Research and Clinical Practice.2024; 214: 111767.     CrossRef
• Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
  Zhikai Zheng, Yao Zong, Yiyang Ma, Yucheng Tian, Yidan Pang, Changqing Zhang, Junjie Gao
  Signal Transduction and Targeted Therapy.2024;[Epub]     CrossRef
• De la découverte des hormones incrétines aux doubles et triples agonistes GIP / GLP-1 / glucagon
  Franck Phan, Romane Bertrand, Chloé Amouyal, Fabrizio Andreelli
  médecine/sciences.2024; 40(11): 837.     CrossRef
• Side effect profile of pharmacologic therapies for liver fibrosis in nonalcoholic fatty liver disease: a systematic review and network meta-analysis
  Yilin Li, Rong Lei, Honglin Lei, Qin Xiong, Fengjiao Xie, Chengjiao Yao, Peimin Feng
  European Journal of Gastroenterology & Hepatology.2023; 35(1): 1.     CrossRef
• Recommendations for the prevention and management of obesity in the Iraqi population
  Hussein Ali Nwayyir, Esraa Majid Mutasher, Osama Mohammed Alabid, Muthana Abdulrazzaq Jabbar, Wefak Hasan Abdulraheem Al-Kawaz, Haider Ayad Alidrisi, Majid Alabbood, Muhammed Chabek, Munib AlZubaidi, Lujain Anwar Al-khazrajy, Ibtihal Shukri Abd Alhaleem,
  Postgraduate Medicine.2023; 135(5): 425.     CrossRef
• A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
  Fatma Haddad, Ghadeer Dokmak, Maryam Bader, Rafik Karaman
  Life.2023; 13(4): 1012.     CrossRef
• Liraglutide, a glucagon-like peptide-1 analog, in individuals with obesity in clinical practice
  Juyoung Shin, Raeun Kim, Hun-Sung Kim
  Cardiovascular Prevention and Pharmacotherapy.2023; 5(2): 49.     CrossRef
• The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta‐regression analysis of randomized controlled trials
  Pejman Rohani, Nasser Malekpour Alamdari, Seyedeh Elaheh Bagheri, Azita Hekmatdoost, Mohammad Hassan Sohouli
  Frontiers in Endocrinology.2023;[Epub]     CrossRef
• Efficacy and safety of liraglutide for weight management in children and adolescents: a systematic review and meta-analysis of randomized controlled trials
  Hao Gou, Yiman Zhai, Junjun Guo
  European Journal of Pediatrics.2023; 182(11): 5095.     CrossRef
• Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis
  Ping Zhong, Hai Zeng, Miaochun Huang, Wenbin Fu, Zhixia Chen
  Endocrine.2022; 75(3): 718.     CrossRef
• Pharmacological profile of once-weekly injectable semaglutide for chronic weight management
  David C. W. Lau, Rachel L Batterham, Carel W. le Roux
  Expert Review of Clinical Pharmacology.2022; 15(3): 251.     CrossRef
• Pharmacological Management of Obesity: A Century of Expert Opinions in Cecil Textbook of Medicine
  Peter Manu, Cristina-Mihaela Lăcătuşu, Liliana M. Rogozea, Simona Cernea
  American Journal of Therapeutics.2022; 29(4): e410.     CrossRef
• GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?
  Katerina Horska, Jana Ruda-Kucerova, Silje Skrede
  Trends in Endocrinology & Metabolism.2022; 33(9): 628.     CrossRef
• Targeting skeletal muscle mitochondrial health in obesity
  Chantal A. Pileggi, Breana G. Hooks, Ruth McPherson, Robert R.M. Dent, Mary-Ellen Harper
  Clinical Science.2022; 136(14): 1081.     CrossRef
• A Study on Weight Loss Cause as per the Side Effect of Liraglutide
  Jin Yu, Jeongmin Lee, Seung-Hwan Lee, Jae-Hyung Cho, Hun-Sung Kim, Heng Zhou
  Cardiovascular Therapeutics.2022; 2022: 1.     CrossRef

Citations

Citations to this article as recorded by  

• Construction, evaluation, and applications of renal barrier-on-a-chip system
  Tuya Naren, Weikang Lv, Abdellah Aazmi, Yujun Wang, Haoran Yu, Jie Ying Lee, Huixiang Yang, Mengfei Yu, Xiuxiu Jiang, Huayong Yang, Liang Ma
  Bioactive Materials.2026; 59: 421.     CrossRef
• Sodium‐glucose cotransporter 2 inhibitor ameliorates thiazolidinedione‐induced fluid retention through vascular leakage reduction in white adipose tissue
  Ji Yoon Kim, Hye‐Min Jang, Hye‐Jin Lee, Ah Hyeon Lee, Dong‐Hoon Kim, Sin Gon Kim, Nam Hoon Kim
  Diabetes, Obesity and Metabolism.2026; 28(3): 1764.     CrossRef
• Association Between the 2022 AHA/ACC/HFSA Heart Failure Staging and Cardiovascular and Kidney Outcomes in Patients With Diabetes and Kidney Disease: A Post Hoc Analysis of the SCORED Randomized Controlled Trial
  Ayodele Odutayo, Deepak L. Bhatt, Vikas S. Sridhar, Michael Szarek, Christopher P. Cannon, Lawrence A. Leiter, Darren K. McGuire, Julia B. Lewis, Renato D. Lopes, Benjamin M. Scirica, Kausik K. Ray, Michael J. Davies, Phillip Banks, Manon Girard, Subodh V
  Circulation: Heart Failure.2026;[Epub]     CrossRef
• Effects of proANP31–67 in a preclinical model of uninephrectomy and cardiac ischemia/reperfusion injury: cardiac remodeling and tissue biochemical profiling
  Gustavo Jose Justo Silva, Sara Stefani, Reza Parvan, Michael Frisk, Xin Shen, Martina Alunni Cardinali, Mari E. Strand, Karoline Bjarnesdatter Rypdal, Mathis Korseberg Stokke, Håvard Attramadal, Ida G. Lunde, Jan Magnus Aronsen, Kåre-Olav Stensløkken, Wil
  American Journal of Physiology-Cell Physiology.2026; 330(5): C1246.     CrossRef
• Combination treatment for the management of chronic kidney disease and type 2 diabetes: a review and practical guidance
  Mai Mohsen, Tae Won Yi, Labib Faruque, Calvin Ke, Joseph A Cafazzo, Quynh Pham, Vikas S Sridhar, Adeera Levin, Husam Abdel-Qadir, Frederik Persson, Christoph Wanner, Peter Jüni, Javed Butler, Nikolaus Marx, David Z I Cherney, Ayodele Odutayo
  The Journal of Clinical Endocrinology & Metabolism.2026; 111(7): e1726.     CrossRef
• Personalizing Cardio-Kidney-Metabolic Therapy
  Qandeel H. Soomro, David M. Charytan
  Journal of the American Society of Nephrology.2026;[Epub]     CrossRef
• The Role of GLP-1 Receptor Agonists in Diabetic Kidney Disease: Recent Evidence
  Jin Hwa Kim
  The Journal of Korean Diabetes.2025; 26(1): 5.     CrossRef
• Expert Opinion on Fixed Dose Combination of Dapagliflozin Plus Sitagliptin for Unmet Cardiovascular Benefits in Type 2 Diabetes Mellitus
  Soumitra Ray, J Ezhilan, Rajiv Karnik, Ashish Prasad, Rajashree Dhar
  Journal of Diabetology.2024; 15(2): 131.     CrossRef
• The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials
  Mustafa Arici, Bulent Altun, Mustafa Araz, Aysegul Atmaca, Tevfik Demir, Tevfik Ecder, Galip Guz, Dilek Gogas Yavuz, Alaattin Yildiz, Temel Yilmaz
  Frontiers in Medicine.2024;[Epub]     CrossRef
• Relative and Absolute Risks of Adverse Events with Real-World Use of SGLT2 Inhibitors in CKD
  Ayodele Odutayo, Adeera Levin
  Clinical Journal of the American Society of Nephrology.2023; 18(5): 557.     CrossRef
• Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
  Dong-Lim Kim, Seung-Eun Lee, Nan Hee Kim
  Endocrinology and Metabolism.2023; 38(1): 43.     CrossRef
• Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis
  Eun Sil Koh, Gheun-Ho Kim, Sungjin Chung
  Endocrinology and Metabolism.2023; 38(4): 359.     CrossRef
• SGLT2 and DPP4 inhibitors improve Alzheimer’s disease–like pathology and cognitive function through distinct mechanisms in a T2D–AD mouse model
  A Young Sim, Da Hyun Choi, Jong Youl Kim, Eun Ran Kim, A-ra Goh, Yong-ho Lee, Jong Eun Lee
  Biomedicine & Pharmacotherapy.2023; 168: 115755.     CrossRef
• Narrative review investigating the nephroprotective mechanisms of sodium glucose cotransporter type 2 inhibitors in diabetic and nondiabetic patients with chronic kidney disease
  Emma S. Speedtsberg, Martin Tepel
  Frontiers in Endocrinology.2023;[Epub]     CrossRef
• Management of CKD
  Nimrit Goraya, Jennifer D. Moran
  Nephrology Self-Assessment Program.2022; 21(2): 146.     CrossRef
• Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders − New perspectives for combination therapy
  Peter Kolkhof, Amer Joseph, Ulrich Kintscher
  Pharmacological Research.2021; 172: 105859.     CrossRef
• Sodium‐Glucose Cotransporter 2 Inhibitors, All‐Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta‐Analysis and Meta‐Regression
  Ayodele Odutayo, Bruno R. da Costa, Tiago V. Pereira, Vinay Garg, Samir Iskander, Fatimah Roble, Rahim Lalji, Cesar A. Hincapié, Aquila Akingbade, Myanca Rodrigues, Arnav Agarwal, Bishoy Lawendy, Pakeezah Saadat, Jacob A. Udell, Francesco Cosentino, Peter
  Journal of the American Heart Association.2021;[Epub]     CrossRef
• Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus
  Luis D’Marco, María Jesús Puchades, Lorena Gandía, Claudia Forquet, Elena Giménez-Civera, Nayara Panizo, Javier Reque, Isabel Juan-García, Valmore Bermúdez, José Luis Gorriz
  touchREVIEWS in Endocrinology.2021; 17(2): 84.     CrossRef
• Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review
  Jorge I. Fonseca-Correa, Ricardo Correa-Rotter
  Frontiers in Medicine.2021;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study
  Kyung-Soo Kim, Kyung Ah Han, Tae Nyun Kim, Cheol-Young Park, Jung Hwan Park, Sang Yong Kim, Yong Hyun Kim, Kee Ho Song, Eun Seok Kang, Chul Sik Kim, Gwanpyo Koh, Jun Goo Kang, Mi Kyung Kim, Ji Min Han, Nan Hee Kim, Ji Oh Mok, Jae Hyuk Lee, Soo Lim, Sang S
  Diabetes & Metabolism.2023; 49(4): 101440.     CrossRef
• Effects of exercise initiation and smoking cessation after new-onset type 2 diabetes mellitus on risk of mortality and cardiovascular outcomes
  Mee Kyoung Kim, Kyungdo Han, Bongsung Kim, Jinyoung Kim, Hyuk-Sang Kwon
  Scientific Reports.2022;[Epub]     CrossRef
• Combined Effects of Obesity and Dyslipidaemia on the Prevalence of Diabetes Amongst Adults Aged ≥45 Years: Evidence from a Nationally Representative Cross-Sectional Study
  Simin Zhang, Donghan Sun, Xiaoyi Qian, Li Li, Wenwen Wu
  International Journal of Environmental Research and Public Health.2022; 19(13): 8036.     CrossRef
• Low-Density Lipoprotein Cholesterol Level, Statin Use and Myocardial Infarction Risk in Young Adults
  Heekyoung Jeong, Kyungdo Han, Soon Jib Yoo, Mee Kyoung Kim
  Journal of Lipid and Atherosclerosis.2022; 11(3): 288.     CrossRef

Citations

Citations to this article as recorded by  

• Discovery and optimization of novel indolecarboxylic acid derivative as potent glucagon-like peptide‑1 receptor agonists
  Wanting Zhao, Yuqian Yin, Zhuo Shi, Ke Yang, Xinglin Li, Yushe Yang, Tongfei Jing, Zhenghui Kang
  Molecular Diversity.2026; 30(1): 873.     CrossRef
• Innovative Molecules and Delivery Technologies Enabling the Future of GLP-1-based Therapies
  Yining Xu, Daniel J Drucker, Giovanni Traverso, Ana Beloqui
  Endocrine Reviews.2026; 47(1): 1.     CrossRef
• Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
  Jang Won Son, Carel W le Roux, Matthias Blüher, Michael A Nauck, Soo Lim
  Endocrine Reviews.2026; 47(2): 159.     CrossRef
• High Cell Density Fermentation Strategy for High-Level Soluble Expression of Glucagon-like Peptide-1 Analogue in Escherichia coli
  Sushmita R. Kumar, Esha Shukla, Gaurav Pandey
  Fermentation.2026; 12(1): 53.     CrossRef
• Emerging incretin- and multi-agonist-based treatments – the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond
  Emir Muzurović, Niki Katsiki, Špela Volčanšek, Fulvio Plescia, Manfredi Rizzo, Christos S. Mantzoros
  Metabolism.2026; 177: 156494.     CrossRef
• Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes
  Urna Kansakar, Stanislovas S. Jankauskas, Shivangi Pande, Pasquale Mone, Fahimeh Varzideh, Gaetano Santulli
  International Journal of Molecular Sciences.2026; 27(3): 1409.     CrossRef
• Novel Small Molecule GLP-1R Agonists Based on 1H-Benzo[d]imidazole-5-Carboxylic Acid Scaffold
  Elena V. Tolkacheva, Tagir L. Salakhov, Alexandr Yu. Saliev, Natalia D. Lebedeva, Alisa M. Krasnodubets, Eugene Y. Smirnov, Sergey A. Silonov, Konstantin V. Balakin, Vladimir V. Chernyshov, Roman A. Ivanov
  Molecules.2026; 31(7): 1129.     CrossRef
• Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders
  Yun Kyung Cho, Chang Hee Jung
  Clinical and Molecular Hepatology.2026; 32(2): 464.     CrossRef
• Comparative Positioning of Orforglipron Among Selected GLP-1 Receptor Agonist Benchmarks: A Narrative Review
  José Castro-Gamboa, Jeaustin Mora-Jiménez, Sebastián Arguedas-Chacón, Esteban Zavaleta-Monestel
  Cureus.2026;[Epub]     CrossRef
• Research progress and future prospects of small-molecule glucagon-like peptide-1 receptor agonists (GLP-1RAs)
  Yinfang Tu, Haoyong Yu
  Metabolism and Target Organ Damage.2025;[Epub]     CrossRef
• Recommendations for the Management of Diabetes During Ramadan Applying the Principles of the ADA/ EASD Consensus: Update 2025
  Mahmoud Ibrahim, Ebtesam M. Ba‐Essa, Asma Ahmed, Ehtasham Ahmad, Firas A. Annabi, Hanene Chaabane, Dario Tuccinardi, Melanie J. Davies, Francesco De Domenico, Robert H. Eckel, Nancy Elbarbary, Pamela Houeiss, Silvia Manfrini, Shabeen Naz Masood, Omar Moba
  Diabetes/Metabolism Research and Reviews.2025;[Epub]     CrossRef
• Insights into the structural dynamics of the secretin family (class B1) G protein-coupled receptors
  Ting Liu, Narisa Ria Naidoo, Eugene Agyemang, Rajan Lamichhane
  Journal of Biological Chemistry.2025; 301(8): 110466.     CrossRef
• First‐in‐human study of HDM1002, a GLP‐1 receptor agonist: Safety, tolerability, pharmacokinetics and pharmacodynamics of escalating single oral doses in healthy volunteers
  Junliang Pu, Yurui Huang, Lei Wan, Mingxue Zhu, Huili Wei, Hong Gao, Liping Zhong, Chengyong Tang, Junfang Xu
  Diabetes, Obesity and Metabolism.2025; 27(10): 5622.     CrossRef
• Development of a Manufacturing Process for a Key (S)-5-(2,2-Dimethyltetrahydro-2H-pyran-4-yl)-1H-indole Intermediate for Orforglipron. Part I. Selection of an Evans Auxiliary-Assisted Asymmetric 1,4-Addition Route
  Qiang Yang, Alison Campbell Brewer, Sarah J. Ryan, Derek R. Starkey, Radhe K. Vaid, Ping Huang, Mo Jia, Peng Liu, Lixuan Liang, Lingxing Meng, Manabu Wadamoto, Satoshi Tsuchiya, Fumiki Kawagishi, Akemi Mizutani, Minoru Yamawaki
  Organic Process Research & Development.2025; 29(8): 1994.     CrossRef
• Are GLP-1 receptor agonists and diabetic retinopathy foes or friends?
  Kai Liu, Shu Liu, Dong Wang, Hong Qiao
  Diabetes & Metabolism.2025; 51(6): 101696.     CrossRef
• Recent advances and trends in oral absorption enhancements of GLP-1 receptor agonist formulations
  Do-Hyub Kim, Joo-Eun Kim
  Journal of Pharmaceutical Investigation.2025;[Epub]     CrossRef
• Semaglutide - properties, action and chromatographic analysis
  Barbara Wasilewska, Anna Petruczynik
  Journal of Diabetes & Metabolic Disorders.2025;[Epub]     CrossRef
• Small-Molecule GLP-1 Receptor Agonists: A Promising Pharmacological Approach
  Oana Cristina Șeremet, Ciprian Pușcașu, Corina Andrei, Georgiana Nițulescu, Cristina Elena Zbârcea, Octavian Tudorel Olaru
  Medicina.2025; 61(11): 1902.     CrossRef
• Sulfobetaine modification of poly (D, L-lactide-co-glycolic acid) nanoparticles enhances mucus permeability and improves bioavailability of orally delivered liraglutide
  Zhenyu Zhao, Ruihuan Ding, Yumei Wang, Ranran Yuan, Houqian Zhang, Tianyang Li, Wei Zheng, Entao Chen, Aiping Wang, Yanan Shi
  Journal of Drug Delivery Science and Technology.2024; 93: 105437.     CrossRef
• Physiology and pharmacology of glucagon-like peptide-1 receptor
  D. V. Kurkin, D. A. Bakulin, E. I. Morkovin, V. I. Petrov, A. V. Strygin, K. N. Koryanova, Yu. V. Gorbunova, Yu. A. Kolosov, O. V. Ivanova, E. V. Pavlova, M. A. Dzhavakhyan, A. V. Zaborovsky, V. B. Saparova, I. E. Makarenko, R. I. Drai, A. N. Chumachenko
  Pharmacy & Pharmacology.2024; 11(4): 347.     CrossRef
• G protein-coupled receptors driven intestinal glucagon-like peptide-1 reprogramming for obesity: Hope or hype?
  Mohan Patil, Ilaria Casari, Leon N. Warne, Marco Falasca
  Biomedicine & Pharmacotherapy.2024; 172: 116245.     CrossRef
• Glucagon-like peptide-1 analogs: Miracle drugs are blooming?
  Binbin Gong, Zhihong Yao, Chenxu Zhou, Wenxi Wang, Lidan Sun, Jing Han
  European Journal of Medicinal Chemistry.2024; 269: 116342.     CrossRef
• The Discovery and Development of Glucagon-Like Peptide-1 Receptor Agonists
  Haowen Fang, Bing Niu, Qin Chen
  Current Medicinal Chemistry.2024; 31(20): 2921.     CrossRef
• Binding sites and design strategies for small molecule GLP-1R agonists
  Haibo Zhang, Tianxiao Wu, Yong Wu, Yuran Peng, Xian Wei, Tao Lu, Yu Jiao
  European Journal of Medicinal Chemistry.2024; 275: 116632.     CrossRef
• Advances in small-molecule insulin secretagogues for diabetes treatment
  Jingqian Su, Jingran Xu, Shan Hu, Hui Ye, Lian Xie, Songying Ouyang
  Biomedicine & Pharmacotherapy.2024; 178: 117179.     CrossRef
• Peptide GLP-1 receptor agonists: From injection to oral delivery strategies
  Zhiqiang Ke, Qianqian Ma, Xiaonan Ye, Yanlin Wang, Yan Jin, Xinyuan Zhao, Zhengding Su
  Biochemical Pharmacology.2024; 229: 116471.     CrossRef
• Design and Evaluation of 3-Phenyloxetane Derivative Agonists of the Glucagon-Like Peptide-1 Receptor
  Zhimin Zhang, Hao Pan, Liubin Guo, Cancan Cai, Tingni Chen, Zhiping Zhang, Xu Yang, Haowen Zheng, Chunhua Jiang, Zhiyong Wang, Yacheng Yang, Zhe Wang, Xiaohua Zhang, Yuchen Zhang, Dongzhou Liu
  Journal of Medicinal Chemistry.2024; 67(17): 14820.     CrossRef
• Toxicology profile of a novel GLP-1 receptor biased agonist-SAL0112 in nonhuman primates
  Jingchao Sun, Ying Xiao, Xuefeng Hu, Shu Chen, Jing Huang, Zhiqiang Ren, Binbin Luo, Rongzhi Jiang, Hongmei Zhang, Xiaolei Shen
  Toxicology and Applied Pharmacology.2024; 492: 117125.     CrossRef
• Discovery of Non-Peptide GLP-1 Positive Allosteric Modulators from Natural Products: Virtual Screening, Molecular Dynamics, ADMET Profiling, Repurposing, and Chemical Scaffolds Identification
  Mohamed S. Gomaa, Mansour S. Alturki, Nada Tawfeeq, Dania A. Hussein, Faheem H. Pottoo, Abdulaziz H. Al Khzem, Mohammad Sarafroz, Samar Abubshait
  Pharmaceutics.2024; 16(12): 1607.     CrossRef
• Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition
  Yaochen Xie, Qian Zhou, Qiaojun He, Xiaoyi Wang, Jincheng Wang
  Acta Pharmaceutica Sinica B.2023; 13(6): 2383.     CrossRef
• Advances in GLP-1 receptor agonists for the treatment of type 2 diabetes
  Shurui Hong, J. Xiao, Y. He
  BIO Web of Conferences.2023; 61: 01006.     CrossRef
• Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials
  Paschalis Karakasis, Dimitrios Patoulias, Konstantinos Pamporis, Panagiotis Stachteas, Konstantinos I. Bougioukas, Aleksandra Klisic, Nikolaos Fragakis, Manfredi Rizzo
  Metabolism.2023; 149: 155710.     CrossRef
• A review of glucoregulatory hormones potentially applicable to the treatment of Alzheimer’s disease: mechanism and brain delivery
  Reeju Amatya, Kyoung Ah Min, Meong Cheol Shin
  Journal of Pharmaceutical Investigation.2022; 52(2): 195.     CrossRef
• Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022
  Harold E. Bays, Angela Fitch, Sandra Christensen, Karli Burridge, Justin Tondt
  Obesity Pillars.2022; 2: 100018.     CrossRef
• Structural basis of peptidomimetic agonism revealed by small-molecule GLP-1R agonists Boc5 and WB4-24
  Zhaotong Cong, Qingtong Zhou, Yang Li, Li-Nan Chen, Zi-Chen Zhang, Anyi Liang, Qing Liu, Xiaoyan Wu, Antao Dai, Tian Xia, Wei Wu, Yan Zhang, Dehua Yang, Ming-Wei Wang
  Proceedings of the National Academy of Sciences.2022;[Epub]     CrossRef
• Improved Split TEV GPCR β-arrestin-2 Recruitment Assays via Systematic Analysis of Signal Peptide and β-arrestin Binding Motif Variants
  Yuxin Wu, Isabelle von Hauff, Niels Jensen, Moritz Rossner, Michael Wehr
  Biosensors.2022; 13(1): 48.     CrossRef
• GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
  Xin Zhao, Minghe Wang, Zhitong Wen, Zhihong Lu, Lijuan Cui, Chao Fu, Huan Xue, Yunfeng Liu, Yi Zhang
  Frontiers in Endocrinology.2021;[Epub]     CrossRef
• Recent developments in GLP‐1RA therapy: A review of the latest evidence of efficacy and safety and differences within the class
  Evie K. Bain, Stephen C. Bain
  Diabetes, Obesity and Metabolism.2021; 23(S3): 30.     CrossRef

Citations

Citations to this article as recorded by  

• Engineered Elastin‐Like Polypeptides: Intelligent Self‐Assembling Platforms for Biomedical Application
  Yang Yuan, Chen Zeng, Zichun Chen, Zhuoga Ciren, Qinran Yu, Chuanbo Wang, Hui Mao, Gang Li, Weizhi Chen, Xiqun Jiang
  Small Structures.2026;[Epub]     CrossRef
• Direct or Indirect Action? Mechanisms of the Antiatherosclerotic Effects of Glucagon‐Like Peptide‐1 Receptor Agonists
  Michał Zawadzki, Monika Karczewska-Kupczewska, Arquimedes Gasparotto Junior
  Cardiovascular Therapeutics.2026;[Epub]     CrossRef
• Metabolic state determines the brain and direct islet effects of liraglutide on enhanced insulin secretion
  Chiara Saponaro, Monica Imbernon, Isaline Louvet, Eleonora Deligia, Shiqian Chen, Iona Davies, Ana Acosta-Montalvo, Maria Moreno-Lopez, Eve Wemelle, Lakshmi Kothegala, Begoña Porteiro, Florent Auger, Lorea Zubiaga, Nathalie Dellalau, Julien Thevenet, Mark
  Diabetologia.2026;[Epub]     CrossRef
• GLP-1 receptor agonism reduces PTSD-like anxiety and alters amygdala–hippocampal activity patterns in a Chemogenetic mouse model
  Kubra Akillioglu, Seda Kose Korkmaz, Meltem Donmez Kutlu, Tugce Sapmaz Ercakallı, Leman Sencar
  Progress in Neuro-Psychopharmacology and Biological Psychiatry.2026; 148: 111804.     CrossRef
• Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
  Zara Siu Wa Chui, Yaqian Xue, Xiaoping Wu, Aimin Xu
  Pharmacological Reviews.2026; : 100150.     CrossRef
• Clonal Hematopoiesis of Indeterminate Potential and Atrial Fibrillation: Insights into Pathophysiology and Clinical Implications
  Paschalis Karakasis, Panagiotis Theofilis, Eleftheria Lefkou, Antonios P. Antoniadis, Dimitrios Patoulias, Panagiotis Korantzopoulos, Nikolaos Fragakis
  International Journal of Molecular Sciences.2025; 26(6): 2739.     CrossRef
• Therapeutic effects and mechanistic insights of YiQiHuangDou decoction on high-fat diet-induced obesity-related Glomerulopathy (ORG) in mice
  Xiaoxiao Liu, Longfei Zhang, Mingze Xu, Ning Li, Canfeng Bian, Linlin Hu, Wenlong Ma, Dawei Chen, Tianzhu Guan, Lixia Xiao
  Journal of Functional Foods.2025; 127: 106728.     CrossRef
• Targeting Diabetic Atherosclerosis: The Role of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Nonsteroidal Mineralocorticoid Receptor Antagonists in Vascular Protection and Disease Modulation
  Merita Rroji, Nereida Spahia, Andreja Figurek, Goce Spasovski
  Biomedicines.2025; 13(3): 728.     CrossRef
• Atrial Cardiomyopathy in Atrial Fibrillation: Mechanistic Pathways and Emerging Treatment Concepts
  Paschalis Karakasis, Panagiotis Theofilis, Panayotis K. Vlachakis, Nikolaos Ktenopoulos, Dimitrios Patoulias, Antonios P. Antoniadis, Nikolaos Fragakis
  Journal of Clinical Medicine.2025; 14(9): 3250.     CrossRef
• Imo-induced changes in gut hormones and glucose metabolism: A key to improving insulin sensitivity in type 2 diabetes
  Sobia Naseem, Muhammad Rizwan
  Diabetes Research and Clinical Practice.2025; 226: 112285.     CrossRef
• Atrial Fibrillation in Diabetes: Pathogenesis and Targeted Rhythm Control Strategies
  Konstantinos Grigoriou, Paschalis Karakasis, Konstantinos Pamporis, Panagiotis Theofilis, Dimitrios Patoulias, Efstratios Karagiannidis, Barbara Fyntanidou, Antonios P. Antoniadis, Nikolaos Fragakis
  Current Issues in Molecular Biology.2025; 47(7): 559.     CrossRef
• Research progress on the role of FGF21 in insulin resistance
  Haixin Zhang, Rongyu Zhu, Quanhao Sun, Likun Du
  Frontiers in Endocrinology.2025;[Epub]     CrossRef
• Comprehensive phytochemical mapping and biomedical evaluation of Lawsonia inermis L: a potential natural treatment for diabetic foot ulcers with wound healing and antimicrobial effects
  Safaa M. Kotb, Mai M. Farid, Ahmed A. Al-Karmalawy, Magdy A.H. Zahran, Briksam S. Mohamed, Abdelnaser A. Gadallah, Bishoy El-Aarag
  Fitoterapia.2025; 187: 106939.     CrossRef
• Arrhythmia-Induced Cardiomyopathy in Atrial Fibrillation: Pathogenesis, Diagnosis, and Treatment
  Paschalis Karakasis, Panagiotis Theofilis, Panayotis K. Vlachakis, Anastasios Apostolos, Nikolaos Ktenopoulos, Konstantinos Grigoriou, Dimitrios Patoulias, Antonios P. Antoniadis, Nikolaos Fragakis
  Life.2025; 15(11): 1675.     CrossRef
• Current status and future perspectives of FGF21 analogues in clinical trials
  Zara Siu Wa Chui, Qing Shen, Aimin Xu
  Trends in Endocrinology & Metabolism.2024; 35(5): 371.     CrossRef
• Hepatokines and MASLD: The GLP1-Ras-FGF21-Fetuin-A Crosstalk as a Therapeutic Target
  Ilaria Milani, Michela Codini, Gloria Guarisco, Marianna Chinucci, Chiara Gaita, Frida Leonetti, Danila Capoccia
  International Journal of Molecular Sciences.2024; 25(19): 10795.     CrossRef
• Atrial Fibrosis in Atrial Fibrillation: Mechanistic Insights, Diagnostic Challenges, and Emerging Therapeutic Targets
  Paschalis Karakasis, Panagiotis Theofilis, Panayotis K. Vlachakis, Panagiotis Korantzopoulos, Dimitrios Patoulias, Antonios P. Antoniadis, Nikolaos Fragakis
  International Journal of Molecular Sciences.2024; 26(1): 209.     CrossRef
• Design and pharmaceutical evaluation of bifunctional fusion protein of FGF21 and GLP-1 in the treatment of nonalcoholic steatohepatitis
  Xianlong Ye, Yingli Chen, Jianying Qi, Shenglong Zhu, Yuanyuan Wu, Jingjing Xiong, Fei Hu, Zhimou Guo, Xinmiao Liang
  European Journal of Pharmacology.2023; 952: 175811.     CrossRef
• Use of FGF21 analogs for the treatment of metabolic disorders: a systematic review and meta-analysis
  Maria Paula Carbonetti, Fernanda Almeida-Oliveira, David Majerowicz
  Archives of Endocrinology and Metabolism.2023;[Epub]     CrossRef
• Exploring the potential mechanism of Simiao Yongan decoction in the treatment of diabetic peripheral vascular disease based on network pharmacology and molecular docking technology
  Fang Cao, Yongkang Zhang, Yuan Zong, Xia Feng, Junlin Deng, Yuzhen Wang, Yemin Cao
  Medicine.2023; 102(52): e36762.     CrossRef
• The Healing Capability of Clove Flower Extract (CFE) in Streptozotocin-Induced (STZ-Induced) Diabetic Rat Wounds Infected with Multidrug Resistant Bacteria
  Rewaa Ali, Tarek Khamis, Gamal Enan, Gamal El-Didamony, Basel Sitohy, Gamal Abdel-Fattah
  Molecules.2022; 27(7): 2270.     CrossRef
• Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs
  Eleftheria Galatou, Elena Mourelatou, Sophia Hatziantoniou, Ioannis S. Vizirianakis
  Antioxidants.2022; 11(6): 1060.     CrossRef
• Unlocking the Therapeutic Potential of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination for the Pathogenesis of Atherosclerosis in Type 2 Diabetes
  Jang Won Son
  Endocrinology and Metabolism.2021; 36(1): 57.     CrossRef
• Effects of fasting on skeletal muscles and body fat of adult and old C57BL/6J mice
  Mindaugas Kvedaras, Petras Minderis, Leonardo Cesanelli, Agne Cekanauskaite, Aivaras Ratkevicius
  Experimental Gerontology.2021; 152: 111474.     CrossRef
• The Role of Fibroblast Growth Factor 21 in Diabetic Cardiovascular Complications and Related Epigenetic Mechanisms
  Mengjie Xiao, Yufeng Tang, Shudong Wang, Jie Wang, Jie Wang, Yuanfang Guo, Jingjing Zhang, Junlian Gu
  Frontiers in Endocrinology.2021;[Epub]     CrossRef
• Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
  Xinyue Li, Xiaojuan Wu, Yumei Jia, Jing Fu, Lin Zhang, Tao Jiang, Jia Liu, Guang Wang, Claudia Cardoso
  Journal of Diabetes Research.2021; 2021: 1.     CrossRef
• Differential importance of endothelial and hematopoietic cell GLP-1Rs for cardiometabolic versus hepatic actions of semaglutide
  Brent A. McLean, Chi Kin Wong, Kiran Deep Kaur, Randy J. Seeley, Daniel J. Drucker
  JCI Insight.2021;[Epub]     CrossRef

Weight loss is an important goal in the management of several chronic conditions, including type 2 diabetes mellitus, and pharmacological therapies that aid weight loss are appealing. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) are novel glucose-lowering therapies that have been shown to induce clinically significant reductions in body weight. However, this weight loss may not be attributed solely to fat mass (FM). Given the importance of skeletal muscle and lean body mass (LBM) on cardio-metabolic health and physical function, we reviewed the available literature reporting the effects of GLP-1RAs and SGLT2is on body composition. Results demonstrate that, in most circumstances, the weight loss associated with both therapies predominantly comprises a reduction in FM, although significant heterogeneity exists between studies. In over half of the studies identified, the proportion of LBM reduction ranged between 20% and 50% of total weight lost, which is consistent with diet-induced weight loss and bariatric surgery. No clear differences existed between GLP-1RAs and SGLT2is. Consequently, the loss of LBM and skeletal muscle associated with weight loss induced by GLP-1RAs and SGLT2is warrants attention. Strategies to preserve skeletal muscle and improve physical function, for example through structured exercise, are of great importance.

Citations

Citations to this article as recorded by  

• GPR75: A Newly Identified Receptor for Targeted Intervention in the Treatment of Obesity and Metabolic Syndrome
  Michael L. Fragner, Manish A. Parikh, Kaedrea A. Jackson, Michal Laniado Schwartzman, William H. Frishman, Stephen J. Peterson
  Cardiology in Review.2026; 34(4): 364.     CrossRef
• Narrative Review of Perioperative Glucagon-like Peptide-1 (GLP-1) Agonists in Spine Surgery
  James W. Connelly, Rajkishen Narayanan, Teeto Ezeonu, Parth Kothari, Nicholas Spina, William Ryan Spiker, Brandon Lawrence, Darrel S. Brodke, Gregory D. Schroeder, Brian A. Karamian
  Clinical Spine Surgery.2026; 39(2): 47.     CrossRef
• Mechanisms of insulin resistance in elderly sarcopenia patients and their bidirectional relationship
  Haiyan Du, Yuqing Qu, Zhouyang Huai, Shumin Wang
  Geriatric Nursing.2026; 69: 103907.     CrossRef
• Relevance and Safe Utilization of Amino Acids in Supplements for Human Nutrition: Lessons from Clinical and Preclinical Studies
  François Blachier
  Nutrients.2026; 18(2): 296.     CrossRef
• Semaglutide augments vascular proliferation and cardiac performance in a large animal model of ischemic cardiomyopathy
  Kelsey C. Muir, Christopher Stone, Dwight D. Harris, Meghamsh Kanuparthy, Mark Broadwin, Jad Hamze, Jun Feng, Frank W. Sellke
  American Journal of Physiology-Heart and Circulatory Physiology.2026; 330(3): H651.     CrossRef
• Body composition changes after 6 and 12 months of dietary weight loss: insights from the DIETFITS trial
  Sun H Kim, Ji Hye Heo, Kristen Cunanan, Christopher D Gardner
  Journal of the Endocrine Society.2026;[Epub]     CrossRef
• Advancing sarcopenia assessment with wearable and app-based technology: a scoping review
  Ayush Mehra, Justo Perez, Jessica L. Krok-Schoen, Roberto M. Benzo, Colleen K. Spees, Shang-Jui Wang, Steven K. Clinton, Stefan A. Czerwinski, Brett S. Nickerson
  The Journal of nutrition, health and aging.2026; 30(5): 100824.     CrossRef
• Obesity and Weight Management in HIV: Epidemiology, Complications, and Emerging Treatments
  Luke Pryke, John R. Koethe, Samuel Bailin
  Current HIV/AIDS Reports.2026;[Epub]     CrossRef
• Humans with function-disrupting variants in the myostatin gene (MSTN) have increased skeletal muscle mass and strength, and less adiposity
  Joseph L. Herman, Peter Dornbos, Karl Landheer, Benjamin J. Geraghty, Marc A. Egerman, Duc Phan, Mary Germino, Jason W. Mastaitis, Johnathon R. Walls, Luca A. Lotta, Gonçalo Abecasis, Aris Baras, Judith Y. Altarejos, Mark W. Sleeman, Olle Melander, Tea Sh
  Nature Communications.2026;[Epub]     CrossRef
• Type 2 diabetes mellitus
  Melanie J. Davies, Soo Lim, Tommy Slater, Jonathan Goldney, Athena Philis-Tsimikas, Denise R. Franco, Roberta Lamptey, Thomas Yates, Tsvetalina Tankova, Ildiko Lingvay
  Nature Reviews Disease Primers.2026;[Epub]     CrossRef
• Mitochondrial Adaptations in Skeletal Muscle Following Incretin‐Based Therapies: In Vitro
  Victoria Old, Melanie Davies, Matthew Denniff, Pratik Choudhary, Nicholas Eastley, Robert U. Ashford, Emma Watson
  Journal of Cachexia, Sarcopenia and Muscle.2026;[Epub]     CrossRef
• Prehabilitation in cardiac surgery: a state-of-the-art review
  Ben Gibbison, Maria Pufulete, Rebecca Maier, Enoch Akowuah
  Heart.2026; : heartjnl-2025-326769.     CrossRef
• Glucagon‐Like Peptide‐1 Receptor Agonism and Muscle Health: Vascular and Myocellular Effects on Glucose and Protein Metabolism
  Christos S. Katsanos, Zhenqi Liu, Philip J. Atherton
  Comprehensive Physiology.2026;[Epub]     CrossRef
• The onco-bariatric paradigm: a tri-phasic metabolic obesity framework for synergizing glucagon-like peptide-1 receptor agonists and metabolic bariatric surgery
  Dong Jin Park, Yoonhong Kim, Dongjae Jeon, Young Suk Park, Kyung Won Seo, Ki Hyun Kim
  Kosin Medical Journal.2026; 41(1): 3.     CrossRef
• Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition
  John A. Batsis, Alessandro Gavras, Danae C. Gross, C. Ray Cheever, Bruna R. Da Silva, Luiz Fernando Meira Filho, Emily P. Jones, Dakota Batchek, Simone Khandpekar, Rohan Patel, Bilal Awkal, Annamarie Pape, Marianne Bahna, Mauro Zamboni, Carla M. Prado
  Annals of Internal Medicine.2026;[Epub]     CrossRef
• Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Complications Following Thoracic and/or Lumbar Spinal Fusion for Degenerative Spine Disease
  Arman Kishan, Harmon S. Khela, Nicolas L. Carayannopoulos, Manjot Singh, Lara Cohen, Zvipo Chisango, Kyriakos Chatzis, Peter S. Tretiakov, Shaleen Vira, Pawel P. Jankowski, Andrew J. Schoenfeld, Peter G. Passias, Alan H. Daniels
  Spine.2026; 51(9): E218.     CrossRef
• GLP-1 Receptor Agonist-Associated Weight Loss and Aesthetic Breast Surgery: A Narrative Review and Experience-Based Recommendations for Plastic and Reconstructive Surgeons
  Maurice Y Nahabedian, Anand K Deva, Deeba Ahmed, Paolo Fanzio, Jason Hammer
  Aesthetic Surgery Journal Open Forum.2026;[Epub]     CrossRef
• Biased agonists for the treatment of type 2 diabetes and obesity: a novel pharmacological paradigm edging closer to clinical reality?
  Ibrahim E. Hashem, Baha H. Abuajameia, Saghir Akhtar
  Journal of Drug Targeting.2026; : 1.     CrossRef
• LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial
  Ameenah A Alawadhi, Dherar Alroudhan, Dalal J Alsaeed, Bashayer W Almarshad, Dalal H Alshehabi, Badreya A Allahou, Anant Mashankar, Ebaa Al Ozairi, Stuart Gray
  BMJ Open.2026; 16(4): e116911.     CrossRef
• Impact of GLP-1 receptor agonists on cardiovascular risk reduction in patients with obesity without type 2 diabetes mellitus: a systematic review
  Paquita del Rocío Quizhpe Donoso, Raffaele Francesco Zirufo Briones, Carmen Paola Montes Castro, Daniela Lorena Barros Narváez, Steven Ayala Velasco, Sara Noelia Cabrera Jimenez
  International Journal of Research in Medical Sciences.2026; 14(5): 2051.     CrossRef
• Safety of SGLT2 inhibitors for patients with type 2 diabetes: where are we now?
  André J. Scheen
  Expert Opinion on Drug Safety.2026; : 1.     CrossRef
• Advantages of Skeletal Muscle Preservation in Settings of Weight Loss
  David J. Glass
  Aging Cell.2026;[Epub]     CrossRef
• Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials
  Naseem Eisa, Omar Barood
  Diabetes, Obesity and Metabolism.2026; 28(6): 4818.     CrossRef
• Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society
  Dariush Mozaffarian, Monica Agarwal, Monica Aggarwal, Lydia Alexander, Caroline M Apovian, Shagun Bindlish, Jonathan Bonnet, W Scott Butsch, Sandra Christensen, Eugenia Gianos, Mahima Gulati, Alka Gupta, Debbie Horn, Ryan M Kane, Jasdeep Saluja, Deepa San
  Obesity Pillars.2026; 18: 100269.     CrossRef
• Gut-Derived FGF15 Modulates Lean Mass, Bone, and Bile Acid Responses to Weight Loss
  Nadejda Bozadjieva-Kramer, Garrett McMahon, Ziru Li, Jordan Wean, Jae Hoon Shin, Andriy Myronovych, Robert W. O’Rourke, Ormond A. MacDougald, Randy J. Seeley
  Diabetes.2026; 75(6): 938.     CrossRef
• The Role of Combining Exercise with Pharmacologic Management of Chronic Kidney disease: From Sodium-Glucose Co-Transporter-2 and Glucagon-Like Peptide-1 to Broader Therapeutic Strategies
  Thomas J. Wilkinson, Greg Biddle, Emily James
  Nephron.2026; : 1.     CrossRef
• Radiological assessment of body composition changes and complications in an era of incretin-based therapies: A narrative review
  Jonah Moyal, Benjamin Rehany
  University of Toronto Medical Journal.2026;[Epub]     CrossRef
• Preoperative Weight Loss Intervention With Glucagon-Like Peptides 1 Receptor Agonists Is Associated With Lower Complication Rates Following Primary Total Knee Arthroplasty Than Preoperative Bariatric Surgery
  George Bcharah, Austin E. Wininger, Zaid Elsabbagh, Collin L. Braithwaite, Paul R. Van Schuyver, Mark J. Spangehl, Henry D. Clarke, Joshua S. Bingham
  Arthroplasty Today.2026; 39: 102033.     CrossRef
• GLP-1 Agonist Use Is Not Associated With a Reduction of Paraspinal Muscle Quality in Diabetic Patients With Low Back Pain: A Retrospective Cohort Study
  Arman T. Zadeh, Erika Chiapparelli, Krizia Amoroso, Ali E. Guven, Jiaqi Zhu, Paul Kohli, Bruno Verna, Anna-Maria Mielke, Jennifer Shue, Marco D. Burkhard, Andrew A. Sama, Federico P. Girardi, Frank P. Cammisa, Alexander P. Hughes
  HSS Journal®: The Musculoskeletal Journal of Hospital for Special Surgery.2026;[Epub]     CrossRef
• Beyond diabetes and obesity: GLP-1 receptor agonists as multifunctional therapeutics across the steatotic liver disease spectrum
  Sundararajan Mahalingam, Kusum K. Kharbanda, Carol A. Casey, Karuna Rasineni
  Frontiers in Pharmacology.2026;[Epub]     CrossRef
• Associations Between Weight Loss Prior to Knee and Hip Arthroplasty and Peri‐ and Post‐Operative Outcomes: A Systematic Review and Meta‐Analysis
  Moneet Gill, Tim Lindsay, Daniel Kevin Llanera, Tricia M.‐M. Tan, Alex Liddle, Chioma Izzi‐Engbeaya
  Obesity Reviews.2026;[Epub]     CrossRef
• Impact of GLP-1/GIP Therapy and Nutrition Counseling on Body Composition
  Peter Gillespie, Kathryn Hoffman, Candace Smith
  The Journal of Nutrition.2026; : 101618.     CrossRef
• Body composition changes in patients on GLP-1 receptor agonists undergoing an intensive cardiac rehabilitation program
  Ian Jennings, Kristine Ly, Mariam Marooki, Marissa Dzotsi, Gavin McLaren, Raphael E Cuomo, Shady Abohashem, Pam R Taub
  European Journal of Preventive Cardiology.2026;[Epub]     CrossRef
• Effects of Semaglutide on Body Composition and GFR
  Hiddo J.L. Heerspink, Maria Soler, Jelle M. Beernink, Niels Jongs, Secundino Cigarran, Josep M. Cruzado, Maria Jesús Puchades, Marina López-Martínez, Ellen Apperloo, Femke Waanders, Gozewijn D. Laverman, Annemarie van der Aart-van der Beek, André P. van B
  Clinical Journal of the American Society of Nephrology.2026;[Epub]     CrossRef
• Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial
  Richard E. Pratley, Douglas Scott Denham, Rupal Trivedi, Elaine Watkins, Lisa Connery, Jennifer Barnes, Dongzi Yu, Janet Hong, Christopher Simard, Kimberly Umans, Lan Liu, Giridhar S. Tirucherai, Jing L. Marantz
  Nature Medicine.2026;[Epub]     CrossRef
• The Effects of Glucagon‐Like Peptide‐1 Receptor Agonists and Sodium‐Glucose Co‐Transporter‐2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials
  Rishi Jobanputra, Jack A. Sargeant, Tatiana Plekhanova, Emily James, Abdullah Almaqhawi, David R. Webb, Melanie J. Davies, Thomas Yates
  Diabetes/Metabolism Research and Reviews.2026;[Epub]     CrossRef
• Invited State of the Art Review for MCP Rethinking Obesity Beyond Body Mass Index: A Review of Body Composition and Chronic Disease Risk
  Jason R. Jaggers, Madison Kindred, Ryan Porter, Xuemei Sui, Carl J. Lavie, Vivek K. Prasad
  Mayo Clinic Proceedings.2026;[Epub]     CrossRef
• Strategies for Optimizing Heart Failure Care in the Older Adult: A Scientific Statement From the American Heart Association
  Sabra C. Lewsey, Trejeeve Martyn, Vanessa Blumer, Nicholas K. Brownell, Quin E. Denfeld, Shannon M. Dunlay, Parag Goyal, Shannon Halloway, Daniel Matlock, Orly Vardeny, Harriette G.C. Van Spall
  Circulation.2026;[Epub]     CrossRef
• Effects of caloric restriction with different doses of exercise on fat loss in people living with type 2 diabetes: A secondary analysis of the DOSE-EX randomized clinical trial
  Mark P.P. Lyngbæk, Grit E. Legaard, Nina S. Nielsen, Cody Durrer, Thomas P. Almdal, Morten Asp Vonsild Lund, Benedikte Liebetrau, Caroline Ewertsen, Carsten Lauridsen, Thomas P.J. Solomon, Kristian Karstoft, Bente K. Pedersen, Mathias Ried-Larsen
  Journal of Sport and Health Science.2025; 14: 100999.     CrossRef
• Worldwide burden of antidiabetic drug-induced sarcopenia: An international pharmacovigilance study
  Jaehyun Kong, Seoyoung Park, Tae Hyeon Kim, Jae E. Lee, Hanseul Cho, Jiyeon Oh, Sooji Lee, Hyesu Jo, Hayeon Lee, Kyeongmin Lee, Jaeyu Park, Louis Jacob, Damiano Pizzol, Sang Youl Rhee, Sunyoung Kim, Dong Keon Yon
  Archives of Gerontology and Geriatrics.2025; 129: 105656.     CrossRef
• Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
  Albert Do, Frhaan Zahrawi, Wajahat Z. Mehal
  Nature Reviews Drug Discovery.2025; 24(3): 171.     CrossRef
• Medically Tailored Meals in Heart Failure: A Systematic Review of the Literature, 2013-2023
  NATHALIE MCINTOSH, HAYLEY BILLINGSLEY, SCOTT L. HUMMEL, WHITNEY L. MILLS
  Journal of Cardiac Failure.2025; 31(6): 939.     CrossRef
• Medical Weight Management Considerations in Plastic Surgery
  Alisha B. Paranzino, Brittany Vieira, Caroline M. Apovian, Shailesh Agarwal
  Plastic & Reconstructive Surgery.2025; 155(1): 207.     CrossRef
• GLP1Ra‐based therapies and DXA‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials
  Kristen M. Beavers, Tiffany M. Cortes, Colleen M. Foy, Lauren Dinkla, Fernando Reyes San Martin, Jamy D. Ard, Monica C. Serra, Daniel P. Beavers
  Obesity.2025; 33(2): 225.     CrossRef
• Sodium-dependent glucose transporter 2 inhibitors improve heart function in patients with type 2 diabetes and heart failure
  Yi-Fei Zhang, Yu-Xiang Liu, Wu-Xiao Yang
  World Journal of Cardiology.2025;[Epub]     CrossRef
• The Effects of Glucagon‐Like Peptide‐1 Receptor Agonists on Mitochondrial Function Within Skeletal Muscle: A Systematic Review
  Victoria J. Old, Melanie J. Davies, Dimitris Papamargaritis, Pratik Choudhary, Emma L. Watson
  Journal of Cachexia, Sarcopenia and Muscle.2025;[Epub]     CrossRef
• Pharmacologic Management of Heart Failure with Preserved Ejection Fraction (HFpEF) in Older Adults
  Ashkan Hashemi, Min Ji Kwak, Parag Goyal
  Drugs & Aging.2025; 42(2): 95.     CrossRef
• Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes
  Areesha Moiz, Kristian B. Filion, Helia Toutounchi, Michael A. Tsoukas, Oriana H.Y. Yu, Tricia M. Peters, Mark J. Eisenberg
  Annals of Internal Medicine.2025; 178(2): 199.     CrossRef
• Hypoglycemic drugs and sarcopenia
  Yu. A. Dolgikh, S. V. Bulgakova, D. P. Kurmaev, E. V. Treneva, O. V. Kosareva, P. Ya. Merzlova, L. A. Sharonova, A. S. Bulgakov
  Experimental and Clinical Gastroenterology.2025; (8): 216.     CrossRef
• Resistance Exercise in Treating Heart Failure with Preserved Ejection Fraction (HFpEF) and Obesity: Targeting Skeletal Muscle Abnormalities and Ectopic Adipose Depots
  Daniel J. McDonough
  Physiologia.2025; 5(1): 10.     CrossRef
• Are strategies to increase muscle mass and strength as effective in people with type 2 diabetes?
  Amina A. Al-Awadi, Stuart R. Gray, Ebaa Al-Ozairi
  Reviews in Endocrine and Metabolic Disorders.2025; 26(5): 857.     CrossRef
• Challenges, current innovations, and opportunities for managing type 2 diabetes in frail older adults: a position paper of the European Geriatric Medicine Society (EuGMS)—Special Interest Group in Diabetes
  Virginia Boccardi, Gülistan Bahat, Cafer Balci, Isabelle Bourdel-Marchasson, Antoine Christiaens, Lorenzo Maria Donini, Sibel Cavdar, Stefania Maggi, Serdar Özkök, Tajana Pavic, Stany Perkisas, Stefano Volpato, Muhammad Shoaib Zaidi, Andrej Zeyfang, Alan
  European Geriatric Medicine.2025; 16(4): 1231.     CrossRef
• Exploring the Potential Effect of GLP1R Agonism on Common Aging-Related Diseases via Glucose Reduction: A Mendelian Randomization Study
  Wei Jiang, Kaixi Ding, Maoyi Yang, Zhipeng Hu, Rensong Yue, Lewis A Lipsitz
  The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences.2025;[Epub]     CrossRef
• Metabolic dysfunction-associated steatotic liver disease in adults
  Daniel Q. Huang, Vincent W. S. Wong, Mary E. Rinella, Jerome Boursier, Jeffrey V. Lazarus, Hannele Yki-Järvinen, Rohit Loomba
  Nature Reviews Disease Primers.2025;[Epub]     CrossRef
• Body composition changes during weight reduction with tirzepatide in the SURMOUNT‐1 study of adults with obesity or overweight
  Michelle Look, Julia P. Dunn, Robert F. Kushner, Dachuang Cao, Charles Harris, Theresa Hunter Gibble, Adam Stefanski, Ryan Griffin
  Diabetes, Obesity and Metabolism.2025; 27(5): 2720.     CrossRef
• Longitudinal association of SGLT2 inhibitors and GLP-1RAs on falls in persons with type 2 diabetes
  Yasuhiro Suzuki, Hiroaki Suzuki, Kazushi Maruo, Takaaki Matsuda, Yuki Murayama, Yoko Sugano, Yoshinori Osaki, Hitoshi Iwasaki, Motohiro Sekiya, Yasushi Hada, Hitoshi Shimano
  Scientific Reports.2025;[Epub]     CrossRef
• Non-invasive vestibular nerve stimulation (VeNS) reduces visceral adipose tissue: results of a randomised controlled trial
  Erik Viirre, Julie Sittlington, David Wing, Ruth Price, Caomhan Logue, Daniel Moreno, Jeff Ledford-Mills, Cynthia Knott, Carel W. le Roux, David Grieve, Sinead Watson, Jason McKeown, Paul D. McGeoch
  Scientific Reports.2025;[Epub]     CrossRef
• Role of GLP‑1 receptor agonists in sepsis and their therapeutic potential in sepsis‑induced muscle atrophy (Review)
  Xuan Zhao, Yukun Liu, Dongfang Wang, Tonghan Li, Zhikai Xu, Zhanfei Li, Xiangjun Bai, Yuchang Wang
  International Journal of Molecular Medicine.2025; 55(5): 1.     CrossRef
• Effect of liraglutide biosimilar vs. reference liraglutide on weight reduction in T2DM patients with obesity: post hoc analysis of phase III trial
  Sujoy Ghosh, Bipin Sethi, Sanjay Kalra, Manash P. Baruah, Abhishek Mane, Sanjay Choudhari, Anup Petare, Mayur Jadhav, Saiprasad Patil, Hanmant Barkate
  Cardiovascular Diabetology – Endocrinology Reports.2025;[Epub]     CrossRef
• Effectiveness of tele‐guidance for physiotherapy in older patients with type 2 diabetes: A randomized controlled trial
  Hiroaki Kataoka, Takuo Nomura, Hiroyuki Oka, Yukio Ikeda
  Journal of Diabetes Investigation.2025; 16(7): 1284.     CrossRef
• How do glucagon‐like Peptide‐1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: A systematic review and meta‐analysis
  Oluwaseun Anyiam, Arash Ardavani, Rushdina Sofia Abdul Rashid, Avinash Panesar, Iskandar Idris
  Obesity Reviews.2025;[Epub]     CrossRef
• Changes in body composition and handgrip strength during dapagliflozin administration in patients with chronic kidney disease
  Takahiro Yajima, Kaoru Noda, Kumiko Yajima
  Clinical Kidney Journal.2025;[Epub]     CrossRef
• Exercise for Postmenopausal Bone Health – Can We Raise the Bar?
  Shejil Kumar, Cassandra Smith, Roderick J. Clifton-Bligh, Belinda R. Beck, Christian M. Girgis
  Current Osteoporosis Reports.2025;[Epub]     CrossRef
• Mechanosensitive Channels Mediate Pancreatic β Cells Reactive Oxygen Species Formation and Downregulation of Essential Genes During Therapeutic Ultrasound Treatment
  Mallory Brayer, Vesna Zderic, Aleksandar Jeremic
  Journal of Ultrasound in Medicine.2025; 44(9): 1577.     CrossRef
• Navigating Sarcopenia Risks in GLP-1RA Therapy for Advanced Heart Failure
  Winston Wang, Danielle Green, Ramzi Ibrahim, Mahmoud Abdelnabi, Hoang Nhat Pham, Beani Forst, Mohamed Allam, Patrick Sarkis, George Bcharah, Juan Farina, Chadi Ayoub, Dan Sorajja, Reza Arsanjani
  Biomedicines.2025; 13(5): 1108.     CrossRef
• Aerobic, resistance, and specialized exercise training in heart failure with preserved ejection fraction: A state-of-the-art review
  Saeid Mirzai, Uttsav Sandesara, Mark J. Haykowsky, Peter H. Brubaker, Dalane W. Kitzman, Anthony E. Peters
  Heart Failure Reviews.2025; 30(5): 1015.     CrossRef
• The Effects of GLP-1 Agonists on Musculoskeletal Health and Orthopedic Care
  Andrew Gatto, Kevin Liu, Nesa Milan, Stephanie Wong
  Current Reviews in Musculoskeletal Medicine.2025; 18(10): 469.     CrossRef
• GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates
  Jason W. Mastaitis, Daniel Gomez, José G. Raya, Diana Li, Soo Min, Michael Stec, Sandra Kleiner, Toya McWilliams, Judith Y. Altarejos, Andrew J. Murphy, George D. Yancopoulos, Mark W. Sleeman
  Nature Communications.2025;[Epub]     CrossRef
• Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus
  Christopher S. Walker, Jacqueline F. Aitken, Greeshma Vazhoor Amarsingh, Shaoping Zhang, Garth J. S. Cooper
  Nature Reviews Endocrinology.2025; 21(8): 482.     CrossRef
• Obesity medications in patients with recurrent weight gain or suboptimal clinical response following bariatric surgery: a meta-analysis
  Mahdieh Golzarand, Karamollah Toolabi, Parvin Mirmiran
  International Journal of Obesity.2025; 49(9): 1676.     CrossRef
• Exploring the disconnect: mechanisms underpinning the absence of physical function improvement with SGLT2 inhibitors
  Cian Sutcliffe, Jack A. Sargeant, Thomas Yates, Melanie J. Davies, Luke A. Baker
  Frontiers in Systems Biology.2025;[Epub]     CrossRef
• Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society
  Dariush Mozaffarian, Monica Agarwal, Monica Aggarwal, Lydia Alexander, Caroline M Apovian, Shagun Bindlish, Jonathan Bonnet, W Scott Butsch, Sandra Christensen, Eugenia Gianos, Mahima Gulati, Alka Gupta, Debbie Horn, Ryan M Kane, Jasdeep Saluja, Deepa San
  The American Journal of Clinical Nutrition.2025; 122(1): 344.     CrossRef
• Nutritional priorities to support GLP‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society
  Dariush Mozaffarian, Monica Agarwal, Monica Aggarwal, Lydia Alexander, Caroline M. Apovian, Shagun Bindlish, Jonathan Bonnet, W. Scott Butsch, Sandra Christensen, Eugenia Gianos, Mahima Gulati, Alka Gupta, Debbie Horn, Ryan M. Kane, Jasdeep Saluja, Deepa
  Obesity.2025; 33(8): 1475.     CrossRef
• Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society
  Dariush Mozaffarian, Monica Agarwal, Monica Aggarwal, Lydia Alexander, Caroline M. Apovian, Shagun Bindlish, Jonathan Bonnet, W. Scott Butsch, Sandra Christensen, Eugenia Gianos, Mahima Gulati, Alka Gupta, Debbie Horn, Ryan M. Kane, Jasdeep Saluja, Deepa
  American Journal of Lifestyle Medicine.2025;[Epub]     CrossRef
• Targeting intramyocellular lipids to improve aging muscle function
  David W. Russ, Ravikumar Manickam, Srinivas M. Tipparaju
  Lipids in Health and Disease.2025;[Epub]     CrossRef
• Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society
  Dariush Mozaffarian, Monica Agarwal, Monica Aggarwal, Lydia Alexander, Caroline M. Apovian, Shagun Bindlish, Jonathan Bonnet, W. Scott Butsch, Sandra Christensen, Eugenia Gianos, Mahima Gulati, Alka Gupta, Debbie Horn, Ryan M. Kane, Jasdeep Saluja, Deepa
  Obesity Pillars.2025; 15: 100181.     CrossRef
• Glucagon-Like Peptide-1 Receptor Agonist Medications Alter Outcomes of Spine Surgery
  Joshua M. Wiener, Parshva A. Sanghvi, Katelyn Vlastaris, Thomas Mroz, Jonathan Belding, David C. Kaelber, Thomas Olson, Kevin P. Francis, John S. Adams, Nicholas Bernthal, William L. Sheppard
  Spine.2025; 50(13): 871.     CrossRef
• Ultra-processed food consumption is associated with knee osteoarthritis: Data from the Osteoarthritis Initiative
  Zehra Akkaya, Wynton M. Sims, John A. Lynch, Maximilian T. Löffler, Felix Gassert, Michael Nevitt, Charles E. McCulloch, Nancy E. Lane, Valentina Pedoia, Katharina Ziegeler, Thomas M. Link, Gabby B. Joseph
  Osteoarthritis and Cartilage.2025; 33(9): 1130.     CrossRef
• Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: A retrospective observational study
  W. Scott Butsch, Suela Sulo, Andrew T. Chang, Jeeyun A. Kim, Kirk W. Kerr, Dominique R. Williams, Refaat Hegazi, Thadchaigeni Panchalingam, Scott Goates, Steven B. Heymsfield
  Obesity Pillars.2025; 15: 100186.     CrossRef
• Lifestyle Interventions for Treatment and Remission of Type 2 Diabetes and Prediabetes in Adults: A Clinical Practice Guideline From the American College of Lifestyle Medicine
  Richard M. Rosenfeld, Meagan L. Grega, Micaela C. Karlsen, Abd Moain Abu Dabrh, R. Nisha Aurora, Jonathan P. Bonnet, Lori Donnell, Stephanie L. Fitzpatrick, Beth Frates, Elizabeth A. Joy, Jane F. Kapustin, Dawn R. Noe, Gunadhar Panigrahi, Arun Ram, Lianna
  American Journal of Lifestyle Medicine.2025;[Epub]     CrossRef
• Serum uric acid reduction through SGLT2 inhibitors: evidence from a systematic review and meta-analysis
  Shiwen Yang, Qiaozhi Hu, Kexin Liu, Binjie Xiao, Bofei Zhang, Na Su
  Frontiers in Pharmacology.2025;[Epub]     CrossRef
• GLP-1 receptor agonists, body composition, skeletal muscle and risk of sarcopaenia: from promising findings in animal models to debated concern in human studies
  André J. Scheen
  Diabetes & Metabolism.2025; 51(5): 101681.     CrossRef
• Incretin Receptor Agonism, Fat-free Mass, and Cardiorespiratory Fitness: A Narrative Review
  Zhenqi Liu, Nathan R Weeldreyer, Siddhartha S Angadi
  The Journal of Clinical Endocrinology & Metabolism.2025; 110(10): 2709.     CrossRef
• Redefining obesity: beyond body mass index
  Javed Butler, Francesco Fioretti, Melanie J Davies
  European Heart Journal.2025; 46(38): 3758.     CrossRef
• Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects
  Jessica Chadwick, Colin Berry, Meredith A. Carpenter, Geeta Gulati, Siri Lagethon Heck, Michael A. Hinterberg, Rury R. Holman, Matthew M.Y. Lee, Torbjørn Omland, Clare Paterson, Mark C. Petrie, Naveed Sattar, Svati H. Shah, Sama Shrestha, Harald Sourij, E
  The Journal of Clinical Pharmacology.2025; 65(11): 1460.     CrossRef
• Emerging evidence and potential avenues to achieve durable outcomes in patients with obesity: the confluence of nutrition, and Microbiome on body composition
  Dra. M. Isabel T. D. Correia, Nitin Kapoor, Emma Chávez-Manzanera, Luís Henrique Wolff Gowdak, Amira Al Kharusi, Felipe F. Casanueva, Bruno Halpern, Gary Frost, Raed Aldahash
  Reviews in Endocrine and Metabolic Disorders.2025; 26(5): 745.     CrossRef
• Pattern of Antidiabetic Drug Prescription in Older Persons With Type 2 Diabetes: Results From the German DPV Registry
  Andrej Zeyfang, Stefan Gölz, Federica Iraci, Christian Wagner, Christian Scheer, Thomas Kubiak, Latife Bozkurt, Martin Heni, Reinhard W. Holl
  Journal of the American Medical Directors Association.2025; 26(8): 105724.     CrossRef
• GLP-1 Receptor Agonists in Spine Surgery: Current Evidence and Future Directions
  Luis M. Salazar, Samuel Alfonsi, Vincent P. Federico, Arash Sayari
  Contemporary Spine Surgery.2025; 26(8): 1.     CrossRef
• The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions
  Areesha Moiz, Kristian B. Filion, Michael A. Tsoukas, Oriana H.Y. Yu, Tricia M. Peters, Mark J. Eisenberg
  eClinicalMedicine.2025; 86: 103363.     CrossRef
• The Potential of SARMs and Antimyostatin Agents in Addressing Lean Body Mass Loss From GLP‐1 Agonists: A Literature Review
  Jimmy Wen, Ubaid Ansari, Mouhamad Shehabat, Zaid Ansari, Burhaan Syed, Adam Razick, Daniel Razick, Muzammil Akhtar, Eldo Frezza
  Journal of Diabetes.2025;[Epub]     CrossRef
• Harnessing Facebook to Investigate Real-World Mentions of Adverse Events of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications: Observational Study of Facebook Posts From 2022 to 2024
  Amrutha S Alibilli, Vidur Jain, Heran Mane, Xiaohe Yue, Alexandria Ratzki-Leewing, Junaid S Merchant, Shaniece Criss, Quynh C Nguyen, Rozalina G McCoy, Thu T Nguyen
  JMIR Infodemiology.2025; 5: e73619.     CrossRef
• Effects of Blood-Glucose Lowering Therapies on Body Composition and Muscle Outcomes in Type 2 Diabetes: A Narrative Review
  Ioana Bujdei-Tebeică, Doina Andrada Mihai, Anca Mihaela Pantea-Stoian, Simona Diana Ștefan, Claudiu Stoicescu, Cristian Serafinceanu
  Medicina.2025; 61(8): 1399.     CrossRef
• Discovery of pan-EphB tyrosine kinase inhibitor for metabolic syndrome sparing EphB3 signaling in mice
  Syed Tareq, Heba A. Ewida, Sumaih Zoubi, Harrison Benson, Dhavalkumar Patel, Hanin Diab, Souvik Patra, Daniela Redrovan, Ehsan Nozohouri, Taysa Berivan Bassani, Alisson Campos Cardoso, Kofi Frimpong-Manson, Lida Khodavirdilou, Md Tareq Aziz, Jenny L. Wilk
  Pharmacological Research.2025; 219: 107900.     CrossRef
• Mortality Risk of Sarcopenia and Malnutrition in Older Patients with Type 2 Diabetes Mellitus
  Shinta Yamamoto, Yoshitaka Hashimoto, Fuyuko Takahashi, Ryosuke Sakai, Yuto Saijo, Chihiro Munekawa, Hanako Nakajima, Noriyuki Kitagawa, Rieko Nakatani, Takafumi Osaka, Hiroshi Okada, Naoko Nakanishi, Saori Majima, Emi Ushigome, Masahide Hamaguchi, Michia
  Nutrients.2025; 17(16): 2622.     CrossRef
• Glucagon-like peptide-1 receptor agonists and muscle mass effects
  Alexandr Ceasovschih, Andreea Asaftei, Maria Giovanna Lupo, Stanislav Kotlyarov, Hana Bartušková, Anastasia Balta, Victorita Sorodoc, Laurentiu Sorodoc, Maciej Banach
  Pharmacological Research.2025; 220: 107927.     CrossRef
• Cardiometabolic and renal benefits of sodium–glucose cotransporter 2 inhibitors
  Yong-ho Lee, Soo Lim, Melanie J. Davies
  Nature Reviews Endocrinology.2025; 21(12): 783.     CrossRef
• The Pharmacist's Role in the Use of Incretin‐Based Therapies for Weight Management: An Opinion of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy
  Sara Lingow, Nicholas Carris, Jennifer Clements, Lindsay Courtney, Abby Lennon, Christina H. Sherrill, Elizabeth Van Dril
  JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY.2025; 8(10): 1078.     CrossRef
• KYLO-0603, a novel liver-targeting, thyroid hormone receptor-β agonist for the inhibition of MASH progression
  Xueqin lu, Shengjun Wang, Yanchun Du, Bixian Xie, Qingyan Chen, Jinzhen Lin, Bailing Chen, Kunyuan Cui, Hanbing Li,
  PLOS One.2025; 20(9): e0331768.     CrossRef
• GLP-1 receptor agonists and sarcopenia: Weight loss at a cost? A brief narrative review
  Dimitrios Pantazopoulos, Evanthia Gouveri, Dimitrios Papazoglou, Nikolaos Papanas
  Diabetes Research and Clinical Practice.2025; 229: 112924.     CrossRef
• Frailty and Effects of Semaglutide in Obesity-Related HFpEF
  Ambarish Pandey, Dalane W. Kitzman, Khaja M. Chinnakondepalli, Shachi Patel, Barry A. Borlaug, Javed Butler, Melanie J. Davies, Sanjiv J. Shah, Subodh Verma, Cecilia Rönnbäck, Anne Domdey, Karoline Liisberg, Morten Schou, Eduardo Perna, Fozia Z. Ahmed, Mi
  JACC: Heart Failure.2025; 13(10): 102610.     CrossRef
• Cannabis improves metabolic dysfunction and macrophage signatures in obese mice
  Brandon N. VanderVeen, Thomas D. Cardaci, Christian A. Unger, Mitchell M. NeSmith, Jeffrey C. Freeman, Arianna V. Bastian, Kasie Roark, Mansi Upadhyay, Andrew G. Levy, Brooke M. Bullard, Sierra J. McDonald, Kandy T. Velázquez, Reilly T. Enos, Jason L. Kub
  American Journal of Physiology-Cell Physiology.2025; 329(4): C1316.     CrossRef
• Thermogenic Targets for Obesity Management in the Era of Incretin-Based Therapies
  Sahar Soliman, Rebecca Andrews-Dickert, Petra Rocic, Mihail Mitov
  Pharmaceuticals.2025; 18(10): 1519.     CrossRef
• Agonistes du récepteur du GLP-1 et sarcopénie : question émergente ou véritable enjeu clinique ?
  Serge Halimi
  Médecine des Maladies Métaboliques.2025; 19(8): 593.     CrossRef
• Glucagon-like peptide-1 receptor agonists and muscle health: potential role in sarcopenia prevention and treatment
  Ainhoa González-Luis, Vicente Llinares-Arvelo, Carlos E Martínez-Alberto, Carolina Hernández-Carballo, Carmen Mora-Fernández, Juan F Navarro-González, Javier Donate-Correa
  European Journal of Endocrinology.2025; 193(5): R31.     CrossRef
• Effects of Semaglutide in Obesity-Related Heart Failure with Preserved Ejection Fraction Across the Age Spectrum: Findings from the STEP-HFpEF Programme
  Ambarish Pandey, Michael Moroney, Subodh Verma, Barry A. Borlaug, Javed Butler, Melanie J. Davies, Dalane W. Kitzman, Sanjiv J. Shah, Mark C. Petrie, Cecilia Rönnbäck, Anne Domdey, Søren Rasmussen, Khaja M. Chinnakondepalli, Shachi Patel, Mikhail N. Kosib
  European Journal of Heart Failure.2025; 27(11): 2537.     CrossRef
• Clinician Guidance on the Benefits of Healthy Nutrition and Increased Physical Activity for People With Type 2 Diabetes Following Glucagon-Like Peptide 1 Receptor Agonist Initiation
  Pamela Kushner, Carlos Campos, Aaron King, Davida F. Kruger, Javier Morales
  Clinical Diabetes.2025; 43(5): 681.     CrossRef
• Preserving the Metabolic Engine: Muscle as the Therapeutic Target for Cardiovascular Prevention in Obesity Pharmacotherapy
  Fabian Sanchis-Gomar, Ian J. Neeland, Pilar Ruiz-Lozano, Osama Alnahar, Fatima Rodriguez
  Current Cardiology Reports.2025;[Epub]     CrossRef
• Sarcopenia and obesity: Two sides of the same coin. Incretin technologies in addressing the problem
  T. Yu. Demidova, K. A. Tolmacheva, S. A. Prilepa
  FOCUS. Endocrinology.2025; 6(4): 43.     CrossRef
• Liraglutide Protects Against Diastolic Dysfunction and Improves Ventricular Protein Translation
  Cody Rutledge, Angela Enriquez, Kevin Redding, Mabel Lopez, Steven Mullett, Stacy L. Gelhaus, Michael Jurczak, Eric Goetzman, Brett A. Kaufman
  Cardiovascular Drugs and Therapy.2024; 38(6): 1289.     CrossRef
• Drug‐related sarcopenia as a secondary sarcopenia
  Masafumi Kuzuya
  Geriatrics & Gerontology International.2024; 24(2): 195.     CrossRef
• Exercise induces tissue-specific adaptations to enhance cardiometabolic health
  Stephen P. Ashcroft, Ben Stocks, Brendan Egan, Juleen R. Zierath
  Cell Metabolism.2024; 36(2): 278.     CrossRef
• Once-weekly semaglutide administered after laparoscopic sleeve gastrectomy: Effects on body weight, glycemic control, and measured nutritional metrics in Japanese patients having both obesity and type 2 diabetes
  Rieko Kanai, Sachiho Kinoshita, Izumi Kanbe, Mariko Sameda, Shuhei Yamaoka, Osamu Horikawa, Yasuhiro Watanabe, Ichiro Tatsuno, Kohji Shirai, Takashi Oshiro, Atsuhito Saiki
  Obesity Pillars.2024; 9: 100098.     CrossRef
• Twenty‐four‐hour physical behaviour profiles across type 2 diabetes mellitus subtypes
  Joseph Henson, Aikaterina Tziannou, Alex V. Rowlands, Charlotte L. Edwardson, Andrew P. Hall, Melanie J. Davies, Thomas Yates
  Diabetes, Obesity and Metabolism.2024; 26(4): 1355.     CrossRef
• The Current Landscape of Pharmacotherapies for Sarcopenia
  Gulistan Bahat, Serdar Ozkok
  Drugs & Aging.2024; 41(2): 83.     CrossRef
• Malnutrition and Sarcopenia as Reasons for Caution with GLP-1 Receptor Agonist Use in HFpEF
  ELISSA DRIGGIN, PARAG GOYAL
  Journal of Cardiac Failure.2024; 30(4): 610.     CrossRef
• Is the GLP-1 receptor agonist, semaglutide, a good option for weight loss in persons with HIV?
  Daniel Lee, Jacqueline Capeau
  AIDS.2024; 38(4): 603.     CrossRef
• Efficacy and safety of tirzepatide, GLP‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis
  Xin‐Hui Pan, Bryan Tan, Yip Han Chin, Ethan Cheng Zhe Lee, Gwyneth Kong, Bryan Chong, Martin Kueh, Chin Meng Khoo, Anurag Mehta, Priyanka Majety, Gowtham R. Grandhi, Georgios K. Dimitriadis, Roger Foo, Nicholas W. S. Chew, Carel W. Le Roux, Mamas A. Mamas
  Obesity.2024; 32(5): 840.     CrossRef
• Glucagon-Like Peptide-1 Receptor Agonists and Sodium Glucose Cotransporter-2 Inhibitors and Cardiorespiratory Fitness Interaction
  David Ni, Peter Kokkinos, Eric S Nylen
  Military Medicine.2024; 189(11-12): 2369.     CrossRef
• Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes
  Robert M. Gutgesell, Rubén Nogueiras, Matthias H. Tschöp, Timo D. Müller
  Diabetes Therapy.2024; 15(5): 1069.     CrossRef
• The effects of myosteatosis on skeletal muscle function in older adults
  Kathleen Dondero, Ben Friedman, Julie Rekant, Rian Landers‐Ramos, Odessa Addison
  Physiological Reports.2024;[Epub]     CrossRef
• Preservation of healthy lean body mass and function during weight loss
  T. J. Wilkinson, D. Papamargaritis, J. A. King, J. A. Sargeant, C. Sutcliffe, L. A. Baker, S. Taheri, T. Yates, M. J. Davies
  Clinical Obesity.2024;[Epub]     CrossRef
• The novel adrenergic agonist ATR-127 targets skeletal muscle and brown adipose tissue to tackle diabesity and steatohepatitis
  Emanuela Talamonti, Jelena Davegardh, Anastasia Kalinovich, Sten M.M. van Beek, Nodi Dehvari, Carina Halleskog, Hamza M. Bokhari, Dana S. Hutchinson, Seungmin Ham, Laura J. Humphrys, Nicola C. Dijon, Aikaterini Motso, Anna Sandstrom, Evelyn Zacharewicz, I
  Molecular Metabolism.2024; 85: 101931.     CrossRef
• Core Trainee Prize Winner: Weight loss drugs: their role and potential future in orthopaedic surgery
  Tom Doyle
  Bone & Joint 360.2024; 13(3): 12.     CrossRef
• Challenges and opportunities in the management of type 2 diabetes in patients with lower extremity peripheral artery disease: a tailored diagnosis and treatment review
  Guillaume Mahé, Victor Aboyans, Emmanuel Cosson, Kamel Mohammedi, Gabrielle Sarlon-Bartoli, Damien Lanéelle, Tristan Mirault, Patrice Darmon
  Cardiovascular Diabetology.2024;[Epub]     CrossRef
• Changes in lean body mass with glucagon‐like peptide‐1‐based therapies and mitigation strategies
  Ian J. Neeland, Jennifer Linge, Andreas L. Birkenfeld
  Diabetes, Obesity and Metabolism.2024; 26(S4): 16.     CrossRef
• Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice
  Paola Pantanetti, Giovanni Cangelosi, Sara Alberti, Sandra Di Marco, Grazia Michetti, Gianluca Cerasoli, Marco Di Giacinti, Silvia Coacci, Nadia Francucci, Fabio Petrelli, Giuseppe Ambrosio, Roberto Grinta
  Frontiers in Endocrinology.2024;[Epub]     CrossRef
• Decoding the Implications of Glucagon-like Peptide-1 Receptor Agonists on Accelerated Facial and Skin Aging
  Zainab Ridha, Sabrina Guillen Fabi, Raheel Zubair, Steven H Dayan
  Aesthetic Surgery Journal.2024; 44(11): NP809.     CrossRef
• Second Generation Anti-Obesity Medications
  Sri Nikhita Chimatapu, Steven D. Mittelman, Vibha Singhal
  Current Pediatrics Reports.2024; 12(4): 138.     CrossRef
• Metabolic effects of very-low calorie diet, Semaglutide, or combination of the two, in individuals with type 2 diabetes mellitus
  Oluwaseun Anyiam, Bethan Phillips, Katie Quinn, Daniel Wilkinson, Kenneth Smith, Philip Atherton, Iskandar Idris
  Clinical Nutrition.2024; 43(8): 1907.     CrossRef
• Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs
  Sandra Christensen, Katie Robinson, Sara Thomas, Dominique R. Williams
  Obesity Pillars.2024; 11: 100121.     CrossRef
• Gut-muscle communication links FGF19 levels to the loss of lean muscle mass following rapid weight loss
  Jordan Wean, Salisha Baranwal, Nicole Miller, Jae Hoon Shin, Robert W. O'Rourke, Charles F. Burant, Randy J. Seeley, Amy E. Rothberg, Nadejda Bozadjieva-Kramer
  Diabetes & Metabolism.2024; 50(5): 101570.     CrossRef
• The Effects of Imeglimin on Muscle Strength in Patients with Type 2 Diabetes: A Prospective Cohort Study
  Takeshi Oyanagi, Shin Kawanabe, Hidekazu Tsukiyama, Ami Nishine, Yuta Nakamura, Tomoko Nakagawa, Mayuko Kanou, Juri Kubota, Shingo Tsunemi, Kenichi Yokota, Masakatsu Sone
  Diabetes Therapy.2024; 15(11): 2323.     CrossRef
• Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes
  Lidiya Kukova, Kashif M. Munir, Ahmed Sayeed, Stephen N. Davis
  Expert Opinion on Drug Metabolism & Toxicology.2024; 20(10): 939.     CrossRef
• Sarcopenia
  Avan A. Sayer, Rachel Cooper, Hidenori Arai, Peggy M. Cawthon, Marie-Josiane Ntsama Essomba, Roger A. Fielding, Miranda D. Grounds, Miles D. Witham, Alfonso J. Cruz-Jentoft
  Nature Reviews Disease Primers.2024;[Epub]     CrossRef
• Glucagon‐like peptide‐1 receptor agonist‐based agents and weight loss composition: Filling the gaps
  Robert L. Dubin, Steven B. Heymsfield, Eric Ravussin, Frank L. Greenway
  Diabetes, Obesity and Metabolism.2024; 26(12): 5503.     CrossRef
• Geriatric Pharmacotherapy Case Series: Medications for Diabetes—A Focus on Secondary Stroke Prevention
  Sabrina Warren, Shayla McKee, Erin Yakiwchuk
  The Senior Care Pharmacist.2024; 39(10): 350.     CrossRef
• Effectiveness and Side Effect Incidence in a Real-World Digital Weight-Loss Service Using Compounded Semaglutide: A Retrospective Comparative Study
  Louis Talay, Matt Vickers
  Obesities.2024; 4(4): 399.     CrossRef
• Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?
  Jennifer Linge, Andreas L. Birkenfeld, Ian J. Neeland
  Circulation.2024; 150(16): 1288.     CrossRef
• Sculpting Success: The Importance of Diet and Physical Activity to Support Skeletal Muscle Health during Weight Loss with New Generation Anti-Obesity Medications
  Gregory J Grosicki, Nikhil V Dhurandhar, Jessica L Unick, Shawn M Arent, J Graham Thomas, Holly Lofton, Madelyn C Shepherd, Jessica Kiel, Christopher Coleman, Satya S Jonnalagadda
  Current Developments in Nutrition.2024; 8(11): 104486.     CrossRef
• Malnutrition in patients with obesity: An overview perspective
  Cagney Cristancho, Kris M. Mogensen, Malcolm K. Robinson
  Nutrition in Clinical Practice.2024; 39(6): 1300.     CrossRef
• Changes in 24-Hour Urine Chemistry in Patients with Nephrolithiasis during Weight Loss with Glucagon-Like Peptide 1–Based Therapies
  Karen Feghali, Xilong Li, Naim M. Maalouf
  Kidney360.2024; 5(11): 1706.     CrossRef
• Nutritional Supplementation to Preserve Healthy Lean Mass and Function During Periods of Pharmacological and Nonpharmacological‐Induced Weight Loss: Protocol for a Systematic Review and Meta‐Analysis
  Emily James, Ryan J. Kelsey, Jack A. Sargeant, Joe Henson, Tom Yates, Thomas J. Wilkinson
  Health Science Reports.2024;[Epub]     CrossRef
• Semaglutide Improves Myocardial Perfusion and Performance in a Large Animal Model of Coronary Artery Disease
  Christopher R. Stone, Dwight D. Harris, Mark Broadwin, Meghamsh Kanuparthy, Ju-Woo Nho, Keertana Yalamanchili, Jad Hamze, M. Ruhul Abid, Frank W. Sellke
  Arteriosclerosis, Thrombosis, and Vascular Biology.2024;[Epub]     CrossRef
• Spotlight on the Mechanism of Action of Semaglutide
  Ilias Papakonstantinou, Konstantinos Tsioufis, Vasiliki Katsi
  Current Issues in Molecular Biology.2024; 46(12): 14514.     CrossRef
• Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Body Composition and Fluid Status in Cardiovascular Rehabilitation Patients with Coronary Artery Disease and Heart Failure
  José C. De La Flor, Blanca Coto Morales, Elena Basabe, María Rey Hernandez, Rocío Zamora González-Mariño, Celia Rodríguez Tudero, Irwing Benites Flores, Carlos Espinoza, Michael Cieza Terrones, Secundino Cigarrán Guldris, Jesús Hernández Vaquero
  Medicina.2024; 60(12): 2096.     CrossRef
• Malnutrition in real-world patients hospitalized for heart failure with preserved ejection fraction and its potential impact on generalizability of EMPEROR-Preserved trial
  Shinsuke Takeuchi, Takashi Kohno, Ayumi Goda, Yasuyuki Shiraishi, Mike Saji, Yuji Nagatomo, Toshikazu D. Tanaka, Makoto Takei, Shintaro Nakano, Kyoko Soejima, Shun Kohsaka, Tsutomu Yoshikawa
  International Journal of Cardiology.2023; 370: 263.     CrossRef
• Marked weight loss on liraglutide 3.0 mg: Real‐life experience of a Swiss cohort with obesity
  Sara Santini, Nathalie Vionnet, Jérôme Pasquier, Elena Gonzalez‐Rodriguez, Montserrat Fraga, Nelly Pitteloud, Lucie Favre
  Obesity.2023; 31(1): 74.     CrossRef
• Early type 2 diabetes treatment intensification with glucagon‐like peptide‐1 receptor agonists in primary care: An Australian perspective on guidelines and the global evidence
  Roy Rasalam, Sarah Abdo, Gary Deed, Richard O'Brien, Jane Overland
  Diabetes, Obesity and Metabolism.2023; 25(4): 901.     CrossRef
• The effects of weight‐lowering pharmacotherapies on physical activity, function and fitness: A systematic review and meta‐analysis of randomized controlled trials
  Rishi Jobanputra, Jack A. Sargeant, Abdullah Almaqhawi, Ehtasham Ahmad, Franciskos Arsenyadis, David R. Webb, Louisa Y. Herring, Kamlesh Khunti, Melanie J. Davies, Thomas Yates
  Obesity Reviews.2023;[Epub]     CrossRef
• Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial
  Rasmus M. Sandsdal, Christian R. Juhl, Simon B. K. Jensen, Julie R. Lundgren, Charlotte Janus, Martin B. Blond, Mads Rosenkilde, Adrian F. Bogh, Lasse Gliemann, Jens-Erik B. Jensen, Charalambos Antoniades, Bente M. Stallknecht, Jens J. Holst, Sten Madsbad
  Cardiovascular Diabetology.2023;[Epub]     CrossRef
• Impact of novel glucose‐lowering therapies on physical function in people with type 2 diabetes: A systematic review and meta‐analysis of randomised placebo‐controlled trials
  Ehtasham Ahmad, Franciskos Arsenyadis, Abdullah Almaqhawi, Mary Barker, Rishi Jobanputra, Jack A. Sargeant, David R. Webb, Thomas Yates, Melanie J. Davies
  Diabetic Medicine.2023;[Epub]     CrossRef
• Cancer cachexia as a blueprint for treating obesity
  Nikolai P. Jaschke, Tilman D. Rachner
  Trends in Endocrinology & Metabolism.2023; 34(7): 395.     CrossRef
• The sun is rising on a new era of pharmacotherapy for obesity: some words of caution
  Peter N. Benotti, Bruce R. Bistrian
  Surgery for Obesity and Related Diseases.2023; 19(9): 1075.     CrossRef
• Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
  Sha Zhang, Zhan Qi, Yidong Wang, Danfei Song, Deqiu Zhu
  Frontiers in Endocrinology.2023;[Epub]     CrossRef
• Cysteine‐lowering treatment with mesna against obesity: Proof of concept and results from a human phase I, dose‐finding study
  Kathrine J. Vinknes, Thomas Olsen, Hasse Khiabani Zaré, Nasser E. Bastani, Emma Stolt, Anja F. Dahl, Roger D. Cox, Helga Refsum, Kjetil Retterstøl, Anders Åsberg, Amany Elshorbagy
  Diabetes, Obesity and Metabolism.2023; 25(11): 3161.     CrossRef
• Repurposing Drugs for Diabetes Mellitus as Potential Pharmacological Treatments for Sarcopenia – A Narrative Review
  Miles D. Witham, Antoneta Granic, Ewan Pearson, Sian M. Robinson, Avan A. Sayer
  Drugs & Aging.2023; 40(8): 703.     CrossRef
• Introduction to the dietary management of obesity in adults
  Vivian Lee
  Clinical Medicine.2023; 23(4): 304.     CrossRef
• Efficacy and safety of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, 52‐week clinical trial (EMPA‐ELDERLY)
  Daisuke Yabe, Kosuke Shiki, Gosuke Homma, Thomas Meinicke, Yuji Ogura, Yutaka Seino
  Diabetes, Obesity and Metabolism.2023; 25(12): 3538.     CrossRef
• Independent Link Between Use of Mineralocorticoid Receptor Antagonists and Muscle Wasting in Heart Failure Patients Not Receiving Renin-Angiotensin System Inhibitors
  Ryo Numazawa, Satoshi Katano, Toshiyuki Yano, Ryohei Nagaoka, Katsuhiko Ohori, Hidemichi Kouzu, Suguru Honma, Yusuke Fujisawa, Kotaro Yamano, Arata Osanami, Masayuki Koyama, Akiyoshi Hashimoto, Masato Furuhashi
  Circulation Journal.2023; 88(1): 10.     CrossRef
• Sodium-glucose co-transporter 2 inhibitors and Sarcopenia: A controversy that must be solved
  Baris Afsar, Rengin Elsurer Afsar
  Clinical Nutrition.2023; 42(12): 2338.     CrossRef
• Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study
  Sara Volpe, Giuseppe Lisco, Margherita Fanelli, Davide Racaniello, Valentina Colaianni, Valentina Lavarra, Domenico Triggiani, Lucilla Crudele, Vincenzo Triggiani, Carlo Sabbà, Giovanni De Pergola, Giuseppina Piazzolla
  Frontiers in Endocrinology.2023;[Epub]     CrossRef
• The Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Body Composition in Type 2 Diabetes Mellitus: A Narrative Review
  Soodeh Jahangiri, Mojtaba Malek, Sanjay Kalra, Mohammad E. Khamseh
  Diabetes Therapy.2023; 14(12): 2015.     CrossRef
• Relationship between sodium–glucose cotransporter-2 inhibitors and muscle atrophy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
  Chengdong Xia, Yufeng Han, Chunhui Yin, Ruyue Geng, Zhenfei Liu, Yongle Du, Mingkun Yu
  Frontiers in Endocrinology.2023;[Epub]     CrossRef
• The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities
  Thomas A. Wadden, Ariana M. Chao, Molly Moore, Jena S. Tronieri, Adam Gilden, Anastassia Amaro, Sharon Leonard, John M. Jakicic
  Current Obesity Reports.2023; 12(4): 453.     CrossRef
• Sarcopenia and Diabetes: A Detrimental Liaison of Advancing Age
  Giuseppe Lisco, Olga Eugenia Disoteo, Anna De Tullio, Vincenzo De Geronimo, Vito Angelo Giagulli, Fabio Monzani, Emilio Jirillo, Renato Cozzi, Edoardo Guastamacchia, Giovanni De Pergola, Vincenzo Triggiani
  Nutrients.2023; 16(1): 63.     CrossRef
• Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis
  Sabine Kahl, Jennifer Pützer, Michael Roden
  Seminars in Liver Disease.2022; 42(01): 048.     CrossRef
• Effect of Empagliflozin Versus Placebo on Body Fluid Balance in Patients With Acute Myocardial Infarction and Type 2 Diabetes Mellitus: Subgroup Analysis of the EMBODY Trial
  Yu Hoshika, Yoshiaki Kubota, Kosuke Mozawa, Shuhei Tara, Yukichi Tokita, Kenji Yodogawa, Yu-Ki Iwasaki, Takeshi Yamamoto, Hitoshi Takano, Yayoi Tsukada, Kuniya Asai, Masaaki Miyamoto, Yasushi Miyauchi, Eitaro Kodani, Mitsunori Maruyama, Jun Tanabe, Wataru
  Journal of Cardiac Failure.2022; 28(1): 56.     CrossRef
• Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats
  Shohei Yamada, Yuji Ogura, Kazuho Inoue, Jun Tanabe, Takeshi Sugaya, Keiichi Ohata, Yoshio Nagai, Yasunori Natsuki, Seiko Hoshino, Shiika Watanabe, Daisuke Ichikawa, Kenjiro Kimura, Yugo Shibagaki, Atsuko Kamijo-Ikemori
  Molecular and Cellular Endocrinology.2022; 539: 111472.     CrossRef
• Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt/-catenin signaling pathway
  Olfa Khalifa, Neyla S. AL-Akl, Khaoula Errafii, Abdelilah Arredouani
  Scientific Reports.2022;[Epub]     CrossRef
• Body composition changes at 12 months following different surgical weight loss interventions in adults with obesity: A systematic review and meta‐analysis of randomized control trials
  Amy Sylivris, Jakub Mesinovic, David Scott, Paul Jansons
  Obesity Reviews.2022;[Epub]     CrossRef
• Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study
  Kohei Kaku, Kazuhiro Yamamoto, Yumiko Fukushima, Hristo Lliev, Atsutaka Yasui
  Expert Opinion on Drug Safety.2022; 21(10): 1315.     CrossRef
• Safety and effectiveness of empagliflozin according to body mass index in Japanese patients with type 2 diabetes: a subgroup analysis of a 3-year post-marketing surveillance study
  Kohei Kaku, Kazuhiro Yamamoto, Yumiko Fukushima, Seiko Mizuno, Daisuke Nitta
  Expert Opinion on Drug Safety.2022; 21(11): 1411.     CrossRef
• Le risque de dénutrition chez le sujet âgé diabétique : une limite à l’utilisation des « nouvelles » classes thérapeutiques ?
  Lyse Bordier, Jean Doucet, Bernard Bauduceau
  Médecine des Maladies Métaboliques.2022; 16(5): 422.     CrossRef
• Emerging evidence of the relationship between fat-free mass and ghrelin, glucagon-like peptide-1, and peptide-YY
  Austin J. Graybeal, Jada L. Willis, Elisa Morales-Marroquin, Grant M. Tinsley, Sarah E. Messiah, Meena Shah
  Nutrition.2022; 103-104: 111815.     CrossRef
• The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study
  Yoshinori Ozeki, Takayuki Masaki, Akari Kamata, Shotaro Miyamoto, Yuichi Yoshida, Mitsuhiro Okamoto, Koro Gotoh, Hirotaka Shibata
  Medicines.2022; 9(9): 47.     CrossRef
• Distribution of lean mass and mortality risk in patients with type 2 diabetes
  Li Ding, Yuxin Fan, Jingting Qiao, Jing He, Ruodan Wang, Qing He, Jingqiu Cui, Zhongshu Ma, Fangqiu Zheng, Hua Gao, Chenlin Dai, Hongyan Wei, Jun Li, Yuming Cao, Gang Hu, Ming Liu
  Primary Care Diabetes.2022; 16(6): 824.     CrossRef
• Cardio-sarcopenia: A syndrome of concern in aging
  De Rong Loh, Ru-San Tan, Wee Shiong Lim, Angela S. Koh
  Frontiers in Medicine.2022;[Epub]     CrossRef
• Type 2 diabetes
  Ehtasham Ahmad, Soo Lim, Roberta Lamptey, David R Webb, Melanie J Davies
  The Lancet.2022; 400(10365): 1803.     CrossRef
• Elevated circulating level of β-aminoisobutyric acid (BAIBA) in heart failure patients with type 2 diabetes receiving sodium-glucose cotransporter 2 inhibitors
  Satoshi Katano, Toshiyuki Yano, Hidemichi Kouzu, Ryohei Nagaoka, Ryo Numazawa, Kotaro Yamano, Yusuke Fujisawa, Katsuhiko Ohori, Nobutaka Nagano, Takefumi Fujito, Ryo Nishikawa, Wataru Ohwada, Masaki Katayose, Tatsuya Sato, Atsushi Kuno, Masato Furuhashi
  Cardiovascular Diabetology.2022;[Epub]     CrossRef
• An overview of anamorelin as a treatment option for cancer-associated anorexia and cachexia
  Guilherme Wesley Peixoto Da Fonseca, Stephan von Haehling
  Expert Opinion on Pharmacotherapy.2021; 22(7): 889.     CrossRef
• Liraglutide Does Not Adversely Impact Fat‐Free Mass Loss
  Andrew Grannell, William P. Martin, Babak Dehestani, Werd Al‐Najim, John C. Murphy, Carel W. le Roux
  Obesity.2021; 29(3): 529.     CrossRef
• Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium–glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabet
  Daisuke Yabe, Kosuke Shiki, Keiko Suzaki, Thomas Meinicke, Yutaro Kotobuki, Kenichiro Nishida, Douglas Clark, Atsutaka Yasui, Yutaka Seino
  BMJ Open.2021; 11(4): e045844.     CrossRef
• Cancer Risk in Normal Weight Individuals with Metabolic Obesity: A Narrative Review
  Bethina Liu, Hugh E. Giffney, Rhonda S. Arthur, Thomas E. Rohan, Andrew J. Dannenberg
  Cancer Prevention Research.2021; 14(5): 509.     CrossRef
• Comprehensive analysis of LncRNAs expression profiles in an in vitro model of steatosis treated with Exendin-4
  Khaoula Errafii, Neyla S. Al-Akl, Olfa Khalifa, Abdelilah Arredouani
  Journal of Translational Medicine.2021;[Epub]     CrossRef
• Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus
  Vaneza Lira W. Wolf, Ikaro Breder, Luiz Sérgio F. de Carvalho, Alexandre A. S. Soares, Riobaldo M. Cintra, Joaquim Barreto, Daniel B. Munhoz, Sheila T. Kimura-Medorima, Wilson Nadruz, Gil Guerra-Júnior, Thiago Quinaglia, Elza Muscelli, Andrei C. Sposito
  Nutrition & Diabetes.2021;[Epub]     CrossRef
• Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors
  Marc Evans, Angharad R. Morgan, Zaheer Yousef, Gethin Ellis, Umesh Dashora, Dipesh C. Patel, Pam Brown, Wasim Hanif, Johnathan N. Townend, Naresh Kanumilli, Jim Moore, John P. H. Wilding, Stephen C. Bain
  Drugs.2021; 81(11): 1243.     CrossRef
• Glucose-lowering Drugs and Hospitalization for Heart Failure: A Systematic Review and Additive-effects Network Meta-analysis With More Than 500 000 Patient-years
  Riobaldo M Cintra, Ana Claudia Nogueira, Isabella Bonilha, Beatriz M Luchiari, Otavio R Coelho-Filho, Otavio R Coelho, Pedro Schwartzmann, Elza Muscellie, Wilson Nadruz, Luiz Sergio F Carvalho, Andrei C Sposito
  The Journal of Clinical Endocrinology & Metabolism.2021; 106(10): 3060.     CrossRef
• Physical activity and exercise in the management of type 2 diabetes: where to start?
  Deirdre Harrington, Joe Henson
  Practical Diabetes.2021; 38(5): 35.     CrossRef
• Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes
  
  New England Journal of Medicine.2021; 385(22): 2105.     CrossRef
• Effects of Antidiabetic Drugs on Muscle Mass in Type 2 Diabetes Mellitus
  Satoshi Ida, Ryutaro Kaneko, Kanako Imataka, Kaoru Okubo, Yoshitaka Shirakura, Kentaro Azuma, Ryoko Fujiwara, Kazuya Murata
  Current Diabetes Reviews.2021; 17(3): 293.     CrossRef
• Relationship between serum bilirubin concentration and sarcopenia in patients with type 2 diabetes: a cross-sectional study
  Chuan Wang, Chen Jin, Xiaofei Yin, Jidong Liu, Jinbo Liu
  Journal of International Medical Research.2021;[Epub]     CrossRef
• Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study
  Hirotatsu Nakaguchi, Yoshinobu Kondo, Mayu Kyohara, Hiromi Konishi, Koji Oiwa, Yasuo Terauchi
  Journal of Diabetes Investigation.2020; 11(6): 1542.     CrossRef
• Sodium Glucose Co-Transporter 2 Inhibition Does Not Favorably Modify the Physiological Responses to Dietary Counselling in Diabetes-Free, Sedentary Overweight and Obese Adult Humans
  Shane P.P. Ryan, Alissa A. Newman, Jessie R. Wilburn, Lauren D. Rhoades, S. Raj J. Trikha, Ellen C. Godwin, Hayden M. Schoenberg, Micah L. Battson, Taylor R. Ewell, Gary J. Luckasen, Laurie M. Biela, Christopher L. Melby, Christopher Bell
  Nutrients.2020; 12(2): 510.     CrossRef
• GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report
  Eva W. Iepsen, Christian T. Have, Simon Veedfald, Sten Madsbad, Jens J. Holst, Niels Grarup, Oluf Pedersen, Ivan Brandslund, Jens-Christian Holm, Torben Hansen, Signe S. Torekov
  Cell Reports Medicine.2020; 1(1): 100006.     CrossRef
• Glucagon‐like peptide 1 infusions overcome anabolic resistance to feeding in older human muscle
  Haitham Abdulla, Bethan E. Phillips, Daniel J. Wilkinson, Marie Limb, Tereza Jandova, Joseph J. Bass, Debbie Rankin, Jessica Cegielski, Mariwan Sayda, Hannah Crossland, John P. Williams, Kenneth Smith, Iskandar Idris, Philip J. Atherton
  Aging Cell.2020;[Epub]     CrossRef

The morbidity and mortality associated with diabetic complications impose a huge socioeconomic burden worldwide. Therefore, the ultimate goal of managing diabetes mellitus (DM) is to lower the risk of macrovascular complications and highly morbid microvascular complications such as diabetic nephropathy (DN) and diabetic retinopathy (DR). Potential benefits of incretin-based therapies such as glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors on the diabetic macrovascular complications have been recently suggested, owing to their pleiotropic effects on multiple organ systems. However, studies primarily investigating the role of these therapies in diabetic microvascular complications are rare. Nevertheless, preclinical and limited clinical data suggest the potential protective effect of incretin-based agents against DN and DR via their anti-inflammatory, antioxidative, and antiapoptotic properties. Evidence also suggests that these incretin-dependent and independent beneficial effects are not necessarily associated with the glucose-lowering properties of GLP-1 RAs and DPP-4 inhibitors. Hence, in this review, we revisit the preclinical and clinical evidence of incretin-based therapy for DR and DN, the two most common, morbid complications in individuals with DM. In addition, the review discusses a few recent studies raising concerns of aggravating DR with the use of incretin-based therapies.

Citations

Citations to this article as recorded by  

• Risk of Sight-Threatening Diabetic Retinopathy with Glucagon-Like Peptide-1 Receptor Agonist Use in Routine Clinical Practice
  Andrew J. Barkmeier, Yihong Deng, Kavya Sindhu Swarna, Jeph Herrin, Eric C. Polley, Guillermo E. Umpierrez, Rodolfo J. Galindo, Joseph S. Ross, Mindy M. Mickelson, Rozalina G. McCoy
  Ophthalmology Retina.2026; 10(2): 142.     CrossRef
• Redox-Driven Blood–Nerve Barrier Dysfunction in Diabetic Peripheral Neuropathy: Mechanisms and Therapeutic Opportunities
  Wei-Hsiu Huang, Chih-Shung Wong
  Antioxidants.2026; 15(6): 670.     CrossRef
• Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related Macular Degeneration
  Reut Shor, Andrew Mihalache, Atefeh Noori, Renana Shor, Radha P. Kohly, Marko M. Popovic, Rajeev H. Muni
  JAMA Ophthalmology.2025; 143(7): 587.     CrossRef
• Efficacy and Safety of the Utilization of Dipeptidyl Peptidase IV Inhibitors in Diabetic Patients with Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials
  Moeber Mahzari, Muhannad Alqirnas, Moustafa Alhamadh, Faisal Alrasheed, Abdulrahman Alhabeeb, Wedad Al Madani, Hussain Aldera
  Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 1425.     CrossRef
• Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy
  Andrew J. Barkmeier, Jeph Herrin, Kavya Sindhu Swarna, Yihong Deng, Eric C. Polley, Guillermo E. Umpierrez, Rodolfo J. Galindo, Joseph S. Ross, Mindy M. Mickelson, Rozalina G. McCoy
  Ophthalmology Retina.2024; 8(10): 943.     CrossRef
• Incretin-based therapy: a new horizon in diabetes management
  Malek Zarei, Navideh Sahebi Vaighan, Mohammad Hadi Farjoo, Soosan Talebi, Mohammad Zarei
  Journal of Diabetes & Metabolic Disorders.2024; 23(2): 1665.     CrossRef
• Anti-Inflammatory Effects of GLP-1R Activation in the Retina
  Alessandra Puddu, Davide Maggi
  International Journal of Molecular Sciences.2022; 23(20): 12428.     CrossRef
• Diabetes and Its Complications: Therapies Available, Anticipated and Aspired
  Anu Grover, Komal Sharma, Suresh Gautam, Srishti Gautam, Monica Gulati, Sachin Kumar Singh
  Current Diabetes Reviews.2021; 17(4): 397.     CrossRef
• SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
  Christopher El Mouhayyar, Ruba Riachy, Abir Bou Khalil, Asaad Eid, Sami Azar
  International Journal of Endocrinology.2020; 2020: 1.     CrossRef
• Novel therapeutic agents for the treatment of diabetic kidney disease
  Rachel E. Hartman, P.S.S. Rao, Mariann D. Churchwell, Susan J. Lewis
  Expert Opinion on Investigational Drugs.2020; 29(11): 1277.     CrossRef
• Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors
  Minyoung Lee, Jiyu Sun, Minkyung Han, Yongin Cho, Ji-Yeon Lee, Chung Mo Nam, Eun Seok Kang
  Diabetes Care.2019; 42(11): 2057.     CrossRef
• Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
  Jae Hyun Bae, Sunhee Kim, Eun-Gee Park, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim
  Endocrinology and Metabolism.2019; 34(1): 80.     CrossRef
• Serum adipocytokines are associated with microalbuminuria in patients with type 1 diabetes and incipient chronic complications
  Tomislav Bulum, Marijana Vučić Lovrenčić, Martina Tomić, Sandra Vučković-Rebrina, Vinko Roso, Branko Kolarić, Vladimir Vuksan, Lea Duvnjak
  Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2019; 13(1): 496.     CrossRef
• Protective Effects of Incretin Against Age-Related Diseases
  Di Zhang, Mingzhu Ma, Yueze Liu
  Current Drug Delivery.2019; 16(9): 793.     CrossRef
• Dipeptidyl Peptidase-4 Inhibitors and Inflammation: Dpp-4 Inhibitors Improve Mean Pleatelet Volume and Gamma Glutamyl Transferase Level
  Deniz Avcı
  Journal of Biosciences and Medicines.2019; 07(02): 42.     CrossRef
• The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin
  Annayya R. Aroor, Camila Manrique-Acevedo, Vincent G. DeMarco
  Cardiovascular Diabetology.2018;[Epub]     CrossRef

It is well known that both insulin resistance and decreased insulin secretory capacity are important factors in the pathogenesis of type 2 diabetes mellitus (T2DM). In addition to genetic factors, obesity and lipotoxicity can increase the risk of T2DM. Glucagon-like peptide 1 (GLP-1) receptor agonists are novel antidiabetic drugs with multiple effects. They can stimulate glucose-dependent insulin secretion, inhibit postprandial glucagon release, delay gastric emptying, and induce pancreatic β-cell proliferation. They can also reduce the weight of patients with T2DM and relieve lipotoxicity at the cellular level. Many intracellular targets of GLP-1 have been found, but more remain to be identified. Elucidating these targets could be a basis for developing new potential drugs. My colleagues and I have investigated new targets of GLP-1, with a particular focus on pancreatic β-cell lines and hepatic cell lines. Herein, I summarize the recent work from my laboratory, with profound gratitude for receiving the prestigious 2016 Namgok Award.

Citations

Citations to this article as recorded by  

• Glucagon-Like Peptide-1 Receptor Agonists Reduce Liver Stiffness in a Pediatric Metabolic Dysfunction-Associated Liver Disease Cohort and Normalize Disease-Associated Core Gene Expression in an Experimental Model
  Ella Findling, Terrence Bissoondial, Prakash Narayan
  Cureus.2026;[Epub]     CrossRef
• Potential Role of Phytochemicals as Glucagon-like Peptide 1 Receptor (GLP-1R) Agonists in the Treatment of Diabetes Mellitus
  Julianah Ore Abiola, Ayoola Abidemi Oluyemi, Olajumoke Tolulope Idowu, Oluwatoyin Mary Oyinloye, Chukwudi Sunday Ubah, Olutunmise Victoria Owolabi, Oluwatobi T. Somade, Sunday Amos Onikanni, Basiru Olaitan Ajiboye, Foluso Oluwagbemiga Osunsanmi, Oyekanmi
  Pharmaceuticals.2024; 17(6): 736.     CrossRef
• Venom Peptides, Polyphenols and Alkaloids: Are They the Next Antidiabetics That Will Preserve β-Cell Mass and Function in Type 2 Diabetes?
  Michele Lodato, Valérie Plaisance, Valérie Pawlowski, Maxime Kwapich, Alexandre Barras, Emeline Buissart, Stéphane Dalle, Sabine Szunerits, Jérôme Vicogne, Rabah Boukherroub, Amar Abderrahmani
  Cells.2023; 12(6): 940.     CrossRef
• Diabetes, Incretin Therapy and Thoracic Aortic Aneurysm – What Does the Evidence Show?
  Camilla Krizhanovskii , Anders Franco-Cereceda
  Current Vascular Pharmacology.2019; 17(5): 432.     CrossRef
• Toll-like receptor 4 is necessary for glucose-dependent glucagon-like peptide-1 secretion in male mice
  Lijuan Wang, Xiandong Zhan, Zhenhui Wang, Jing Ma, Xiaotong Chang, Xiaobo Zhu
  Biochemical and Biophysical Research Communications.2019; 510(1): 104.     CrossRef

Citations

Citations to this article as recorded by  

• Evaluation of circulating glypican 4 as a novel biomarker in disease – A comprehensive review
  A. Muendlein, A. Leiherer, H. Drexel
  Journal of Molecular Medicine.2025; 103(4): 355.     CrossRef
• How Reliable are Commercially Available Glypican4 ELISA Kits?
  Joseph P. Buhl, Antje Garten, Jürgen Kratzsch, Wieland Kiess, Melanie Penke
  Experimental and Clinical Endocrinology & Diabetes.2022; 130(02): 110.     CrossRef
• Serum glypican-4 is associated with the 10-year clinical outcome of patients with peripheral artery disease
  Axel Muendlein, Christine Heinzle, Andreas Leiherer, Kathrin Geiger, Eva Maria Brandtner, Stella Gaenger, Peter Fraunberger, Christoph H. Saely, Heinz Drexel
  International Journal of Cardiology.2022; 369: 54.     CrossRef
• Berberine activates the β-catenin/TCF4 signaling pathway by down-regulating miR-106b to promote GLP-1 production by intestinal L cells
  Jiao Wang, Li-Rui Wei, Yan-Ling Liu, Cheng-Zhi Ding, Feng Guo, Jiao Wang, Qian Qin, Feng-Jiao Huang, Ying Xin, Sheng-Nan Ma, Qiu-Ran Zhai, Shou-Jun Wang, Gui-Jun Qin
  European Journal of Pharmacology.2021; 911: 174482.     CrossRef
• Increased Glypican-4 Levels Are Associated with Obesity in Adolescents
  Huseyin Dag, Nevin Cetin Dag, Okan Dikker
  Iranian Journal of Pediatrics.2019;[Epub]     CrossRef
• Serum glypican 4 level in obese children and its relation to degree of obesity
  Chutima Leelalertlauw, Manassawee Korwutthikulrangsri, Pat Mahachoklertwattana, Suwannee Chanprasertyothin, Patcharin Khlairit, Sarunyu Pongratanakul, Preamrudee Poomthavorn
  Clinical Endocrinology.2017; 87(6): 689.     CrossRef
• Articles inEndocrinology and Metabolismin 2016
  Won-Young Lee
  Endocrinology and Metabolism.2017; 32(1): 62.     CrossRef
• Efficacy and Safety of Single‐ or Double‐Drug Antidiabetic Regimens in the Treatment of Type 2 Diabetes Mellitus: A Network Meta‐Analysis
  Xi‐Ling Yang, Mi‐Ma Duo‐Ji, Zi‐Wen Long
  Journal of Cellular Biochemistry.2017; 118(12): 4536.     CrossRef

Glucagon-like peptide-1 (GLP-1) is a member of the proglucagon incretin family, and GLP-1 receptor agonists (RAs) have been introduced as a new class of antidiabetic medications in the past decade. The benefits of GLP-1 RAs are derived from their pleiotropic effects, which include glucose-dependent insulin secretion, suppressed glucagon secretion, and reduced appetite. Moreover, GLP-1 RAs also exert beneficial roles on multiple organ systems in which the GLP-1 receptors exist, including the cardiovascular system. Cardiovascular effects of GLP-1 RAs have been of great interest since the burden from cardiovascular diseases (CVD) has been unbearably increasing in a diabetic population worldwide, despite strict glycemic control and advanced therapeutic techniques to treat CVD. Preclinical studies have already demonstrated the beneficial effects of GLP-1 on myocardium and vascular endothelium, and many clinical studies evaluating changes in surrogate markers of CVD have suggested potential benefits from the use of GLP-1 RAs. Data from numerous clinical trials primarily evaluating the antihyperglycemic effects of multiple GLP-1 RAs have also revealed that changes in most CVD risk markers reported as secondary outcomes have been in favor of GLP-1 RAs treatment. However, to date, there is only one randomized clinical trial of GLP-1 RAs (the ELIXA study) evaluating major cardiovascular events as their primary outcomes, and in this study, a neutral cardiovascular effect of lixisenatide was observed in high-risk diabetic subjects. Therefore, the results of ongoing CVD outcome trials with the use of GLP-1 RAs should be awaited to elucidate the translation of benefits previously seen in CVD risk marker studies into large clinical trials with primary cardiovascular outcomes.

Citations

Citations to this article as recorded by  

• Walking Further with GLP-1RAs: Lessons from the STRIDE Trial
  Dimitrios Pantazopoulos, Stella Papachristou, Prashanth R J Vas, Nikolaos Papanas
  The International Journal of Lower Extremity Wounds.2026; 25(1): 5.     CrossRef
• Injectable thermosensitive hydrogel-based sustained delivery system for anti-diabetic peptides in type 2 diabetes mellitus therapy: A review
  Lam Quoc Vu, I.-Hui Chiu, Cuong Thai Hoa Hoang, Nhung Thi Quynh Bui, Muhammad Suhail, Pao-Chu Wu
  Biomedicine & Pharmacotherapy.2026; 198: 119249.     CrossRef
• Glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and advanced CKD: kidney and cardiovascular outcomes in a real-world setting
  Ching-Chung Hsiao, Mon-Ting Chen, Chieh-Yu Liu, Chih-Yu Chan, Yu-Wei Fang, Hung-Hsiang Liou, Ming-Hsien Tsai
  Clinical Kidney Journal.2025;[Epub]     CrossRef
• The Potential Effect of Dapagliflozin and Liraglutide in Attenuating Cardio-Renal Injuries in Diabetic Rats
  Adel Albanna, Doa’a Ibrahim, Amani Shamsher, Mojahed Al-Shawia, Abdulsalam Halboup
  Journal of Experimental Pharmacology.2025; Volume 17: 467.     CrossRef
• Genetically proxied glucagon-like peptide-1 receptor agonist is associated with risk of tubulo-interstitial nephritis: A network Mendelian randomization study
  Xu-Chun Xu, Fang-Zhong Huang, Jun Ying, Ting-Ting Zhang, Hua-Ying Huang
  Medicine.2025; 104(38): e44742.     CrossRef
• Can glucagon-like peptide-1 receptor agonists induce asthma? An analysis of the FAERS database
  Mario Cazzola, Maria Gabriella Matera, Luigino Calzetta, Davide Lauro, Paola Rogliani
  Journal of Asthma.2024; 61(12): 1638.     CrossRef
• Unveiling the Potential Role of Glucagon-Like Peptide-1 (Glp-1) Receptor Agonists in Offering Protection of the Cardiovascular, Renal, and Neural Systems: An Updated Narrative Review
  Divya Rajagopal, Sulthan Al Rashid, Monisha Prasad, Mohammad Fareed
  Cureus.2024;[Epub]     CrossRef
• A Comprehensive Review of the Role of GLP-1 Agonists in Weight Management and Their Effect on Metabolic Parameters Such as Blood Glucose, Cholesterol, and Blood Pressure
  Ushna Gul, Thandar Aung, Mehwish Martin, Daanyal N Farrukh, Pari C Shah, Zeenia S Lovely, Esaúl Marroquín León, Mohamed Alansaari, Shriya Maini, Muddasir Mohammed Fariduddin, Ashraf Ullah, Zahra Nazir
  Cureus.2024;[Epub]     CrossRef
• Cardioprotective Actions of a Glucagon‐like Peptide‐1 Receptor Agonist on Hearts Donated After Circulatory Death
  Sachiko Kadowaki, M. Ahsan Siraj, Weiden Chen, Jian Wang, Marlee Parker, Anita Nagy, Chun‐Po Steve Fan, Kyle Runeckles, Jing Li, Junko Kobayashi, Christoph Haller, Mansoor Husain, Osami Honjo
  Journal of the American Heart Association.2023;[Epub]     CrossRef
• The role of dipeptidyl peptidase-IV in abdominal aortic aneurysm pathogenesis: A systematic review
  Elisha Ngetich, Pierfrancesco Lapolla, Anirudh Chandrashekar, Ashok Handa, Regent Lee
  Vascular Medicine.2022; 27(1): 77.     CrossRef
• Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors
  Jasna Klen, Vita Dolžan
  International Journal of Molecular Sciences.2022; 23(7): 3451.     CrossRef
• Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials
  Jing Qin, Li Song
  BMC Endocrine Disorders.2022;[Epub]     CrossRef
• Role of G-protein coupled receptor (GPCRs)/(GPR-120) as an agonists in diabetic wound healing
  Jagat Pal Yadav, Dinesh Kumar Patel, Prateek Pathak, Maria Grishina
  Obesity Medicine.2022; 36: 100466.     CrossRef
• Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms
  Bruno Vergès, Victor Aboyans, Denis Angoulvant, Pierre Boutouyrie, Bertrand Cariou, Fabien Hyafil, Kamel Mohammedi, Pierre Amarenco
  Cardiovascular Diabetology.2022;[Epub]     CrossRef
• Changing Fields-Diabetes Medications Invading the Cardiovascular Space
  Lauren D. Breite, Mackenzie Steck, Brandon Tate Cutshall, Samarth P. Shah, Brandon E. Cave
  Current Problems in Cardiology.2021; 46(3): 100736.     CrossRef
• PEGDA/HA mineralized hydrogel loaded with Exendin4 promotes bone regeneration in rat models with bone defects by inducing osteogenesis
  Wei Liu, Xiaowei Jing, Zhiwen Xu, Chong Teng
  Journal of Biomaterials Applications.2021; 35(10): 1337.     CrossRef
• Metabolite G-Protein Coupled Receptors in Cardio-Metabolic Diseases
  Derek Strassheim, Timothy Sullivan, David C. Irwin, Evgenia Gerasimovskaya, Tim Lahm, Dwight J. Klemm, Edward C. Dempsey, Kurt R. Stenmark, Vijaya Karoor
  Cells.2021; 10(12): 3347.     CrossRef
• PPG neurons in the nucleus of the solitary tract modulate heart rate but do not mediate GLP-1 receptor agonist-induced tachycardia in mice
  Marie K. Holt, Daniel R. Cook, Daniel I. Brierley, James E. Richards, Frank Reimann, Alexander V. Gourine, Nephtali Marina, Stefan Trapp
  Molecular Metabolism.2020; 39: 101024.     CrossRef
• A glycosylated Fc‐fused glucagon‐like peptide‐1 receptor agonist exhibits equivalent glucose lowering to but fewer gastrointestinal side effects than dulaglutide
  In Bok An, Mi Sun Byun, Sang In Yang, Yuri Choi, Jung Won Woo, Hak Chul Jang, Young Chul Sung
  Diabetes, Obesity and Metabolism.2020; 22(8): 1455.     CrossRef
• Glucagon-Like Peptide-1 Receptor Agonists in Adult Patients With Type 2 Diabetes: Review of Cardiovascular Outcome Trials
  Elodie M. Varin, Brent A. McLean, Julie A. Lovshin
  Canadian Journal of Diabetes.2020; 44(1): 68.     CrossRef
• Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors
  Alexandros Sachinidis, Dragana Nikolic, Anca Pantea Stoian, Nikolaos Papanas, Omer Tarar, Ali A. Rizvi, Manfredi Rizzo
  Metabolism.2020; 111: 154343.     CrossRef
• GLP-1 receptor agonist liraglutide protects cardiomyocytes from IL-1β-induced metabolic disturbance and mitochondrial dysfunction
  Lili Zhang, Jiali Tian, Sujuan Diao, Guowei Zhang, Mochao Xiao, Dong Chang
  Chemico-Biological Interactions.2020; 332: 109252.     CrossRef
• Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity
  Alina Yu. Babenko, Daria A. Savitskaya, Yulia A. Kononova, Aleksandra Yu. Trofimova, Anna V. Simanenkova, Elena Yu. Vasilyeva, Evgeny V. Shlyakhto
  Journal of Diabetes Research.2019; 2019: 1.     CrossRef
• Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity
  Ekaterina V. Tikhonenko, Alina Y. Babenko, Evgeny V. Shlyakhto
  Obesity and metabolism.2019; 15(4): 22.     CrossRef
• Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials
  Yu Mi Kang, Yun Kyung Cho, Jiwoo Lee, Seung Eun Lee, Woo Je Lee, Joong-Yeol Park, Ye-Jee Kim, Chang Hee Jung, Michael A. Nauck
  Diabetes & Metabolism Journal.2019; 43(4): 410.     CrossRef
• Diabetes, Incretin Therapy and Thoracic Aortic Aneurysm – What Does the Evidence Show?
  Camilla Krizhanovskii , Anders Franco-Cereceda
  Current Vascular Pharmacology.2019; 17(5): 432.     CrossRef
• Dipeptidyl Peptidase-4 Inhibitors and Inflammation: Dpp-4 Inhibitors Improve Mean Pleatelet Volume and Gamma Glutamyl Transferase Level
  Deniz Avcı
  Journal of Biosciences and Medicines.2019; 07(02): 42.     CrossRef
• Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
  Gül Bahtiyar, Jean Pujals-Kury, Alan Sacerdote
  Current Diabetes Reports.2018;[Epub]     CrossRef
• Efficacy From Strange Sources
  Lawrence J. Lesko
  Clinical Pharmacology & Therapeutics.2018; 103(2): 253.     CrossRef
• Exogenous SERP1 attenuates restenosis by restoring GLP-1 receptor activity in diabetic rats following vascular injury
  Lishuai Feng, Jianbo Wang, Xu Ma
  Biomedicine & Pharmacotherapy.2018; 103: 290.     CrossRef
• Exenatide exhibits anti‐inflammatory properties and modulates endothelial response to tumor necrosis factor α‐mediated activation
  Wojciech Garczorz, Enrique Gallego‐Colon, Agnieszka Kosowska, Agnieszka Kłych‐Ratuszny, Michał Woźniak, Wiesław Marcol, K.J. Niesner, Tomasz Francuz
  Cardiovascular Therapeutics.2018;[Epub]     CrossRef
• Molecular and clinical roles of incretin-based drugs in patients with heart failure
  Bassant Orabi, Rasha Kaddoura, Amr S. Omar, Cornelia Carr, Abdulaziz Alkhulaifi
  Heart Failure Reviews.2018; 23(3): 363.     CrossRef
• The effects of Exendin-4 on bone marrow-derived mesenchymal cells
  Paola Luciani, Benedetta Fibbi, Benedetta Mazzanti, Cristiana Deledda, Lara Ballerini, Alessandra Aldinucci, Susanna Benvenuti, Riccardo Saccardi, Alessandro Peri
  Endocrine.2018; 60(3): 423.     CrossRef
• Real-world clinical experience of Xultophy in the management of patients with type 2 diabetes in a secondary care clinic
  David M. Williams, Natasha Shrikrishnapalasuriyar, Waheeba Syed, Win L. Yin, Richard Chudleigh, Stephen C. Bain, David E. Price, Jeffrey W. Stephens
  Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2018; 12(6): 1079.     CrossRef
• Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome
  Maja Ðanić, Bojan Stanimirov, Nebojša Pavlović, Svetlana Goločorbin-Kon, Hani Al-Salami, Karmen Stankov, Momir Mikov
  Frontiers in Pharmacology.2018;[Epub]     CrossRef
• Cardiovascular Outcome Trials of Diabetes and Obesity Drugs: Implications for Conditional Approval and Early Phase Clinical Development
  Andrew J. Krentz, Gerardo Rodriguez-Araujo
  Pharmaceutical Medicine.2017; 31(6): 399.     CrossRef
• Articles inEndocrinology and Metabolismin 2016
  Won-Young Lee
  Endocrinology and Metabolism.2017; 32(1): 62.     CrossRef
• GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?
  Rafael Simó, Cristina Hernández
  Diabetes.2017; 66(6): 1453.     CrossRef
• GLP-1 receptor agonists and heart failure in diabetes
  André J. Scheen
  Diabetes & Metabolism.2017; 43: 2S13.     CrossRef
• Effects of Incretin-Based Therapies on Diabetic Microvascular Complications
  Yu Mi Kang, Chang Hee Jung
  Endocrinology and Metabolism.2017; 32(3): 316.     CrossRef
• Historique des études cardiovasculaires : de l’UGDP… aux dernières études
  A.-J. Scheen
  Médecine des Maladies Métaboliques.2017; 11: 2S15.     CrossRef
• Cardiovascular safety and benefits of GLP-1 receptor agonists
  Niels B. Dalsgaard, Andreas Brønden, Tina Vilsbøll, Filip K. Knop
  Expert Opinion on Drug Safety.2017; 16(3): 351.     CrossRef

Citations

Citations to this article as recorded by  

• Glucose‐Dependent Insulinotropic Polypeptide and Glucagon After Weight Loss Induced by Diet or Bariatric Surgery
  Amanda Finn, Yenni Cedillo, Marthe Aukan, Barbara Gower, Catia Martins
  Obesity.2025; 33(12): 2277.     CrossRef
• Mendelian randomization analyses suggest a causal role for circulating GIP and IL-1RA levels in homeostatic model assessment-derived measures of β-cell function and insulin sensitivity in Africans without type 2 diabetes
  Karlijn A. C. Meeks, Amy R. Bentley, Themistocles L. Assimes, Nora Franceschini, Adebowale A. Adeyemo, Charles N. Rotimi, Ayo P. Doumatey
  Genome Medicine.2023;[Epub]     CrossRef
• Glucose- and Bile Acid-Stimulated Secretion of Gut Hormones in the Isolated Perfused Intestine Is Not Impaired in Diet-Induced Obese Mice
  Jenna E. Hunt, Jens J. Holst, Sara L. Jepsen
  Frontiers in Endocrinology.2022;[Epub]     CrossRef
• Combined treatment with a gastric inhibitory polypeptide receptor antagonist and a peptidyl peptidase-4 inhibitor improves metabolic abnormalities in diabetic mice
  Fei Yang, Shan Dang, Hongjun LV, Bingyin Shi
  Journal of International Medical Research.2021;[Epub]     CrossRef
• Elevated levels of fasting serum GIP may be protective factors for diabetic retinopathy in type 2 diabetes mellitus
  LingHong Huang, JingXiong Zhou, Bo Liang, HuiBin Huang, LiangYi Li
  International Journal of Diabetes in Developing Countries.2021; 41(4): 543.     CrossRef
• Enteroendocrine K and L cells in healthy and type 2 diabetic individuals
  Tina Jorsal, Nicolai A. Rhee, Jens Pedersen, Camilla D. Wahlgren, Brynjulf Mortensen, Sara L. Jepsen, Jacob Jelsing, Louise S. Dalbøge, Peter Vilmann, Hazem Hassan, Jakob W. Hendel, Steen S. Poulsen, Jens J. Holst, Tina Vilsbøll, Filip K. Knop
  Diabetologia.2018; 61(2): 284.     CrossRef
• Articles inEndocrinology and Metabolismin 2016
  Won-Young Lee
  Endocrinology and Metabolism.2017; 32(1): 62.     CrossRef

Glucagon-like peptide-1 (GLP-1) is a gut-derived incretin hormone that increases glucose-stimulated insulin secretion in pancreatic β-cells. Since mitochondrial function is crucial to insulin secretion, we hypothesized that GLP-1 may increase mitochondrial biogenesis in pancreatic β-cells. We treated INS-1 rat insulinoma cells with GLP-1 or exendin-4 for 48 hours and measured mitochondrial mass and function. Both GLP-1 and exendin-4 increased mitochondrial mass by approximately 20%. The mitochondria/cytosol ratio was increased from 7.60±3.12% to 10.53±2.70% by exendin-4. In addition, GLP-1 increased the mitochondrial membrane potential and oxygen consumption. Proliferator-activated receptor-gamma coactivator 1α expression was increased approximately 2-fold by GLP-1 treatment. In conclusion, the present study presents evidence for a new mechanism of action by which GLP-1 improves pancreatic β-cell function via enhanced mitochondrial mass and performance.

Citations

Citations to this article as recorded by  

• The Bioenergetic Architecture of Metabolic Regulation: From Gut–Brain Signalling to Next-Generation Peptide Pharmacology
  Miriana Rega, Francesco Maria Petraglia, Luisa D’Ursi, Michela Buonocore, Diego Criscuolo, Angelo Santoro
  Clinical Bioenergetics.2026; 2(1): 5.     CrossRef
• Molecular Mechanisms and Clinical Evidence Supporting the Four Pillars of Therapy in Diabetic Kidney Disease: Emerging Therapeutic Perspectives
  Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, Hisayuki Katsuyama
  International Journal of Molecular Sciences.2026; 27(6): 2757.     CrossRef
• GLP-1 receptor and Mitochondria-ER Contact Sites: an emerging mechanism of metabolic regulation
  Pablo Cruz, Andrea Puebla-Huerta, Mayarling F. Troncoso, Eduardo Silva-Pavez, Yessia Hidalgo-Fadic, Ulises Ahumada-Castro
  Frontiers in Physiology.2026;[Epub]     CrossRef
• GLP-1R R131Q links long-range conformational remodeling to cellular stress phenotypes
  Takashi Kato, Noriko Inomata, Keiko Serizawa, Yoshinori Matsuo, Misato Oguchi, Satoshi Kuranami, Yoshitaka Sakurai, Tomohisa Aoyama, Ken Suzuki, Nobuhiro Shojima, Toshimasa Yamauchi
  Journal of Molecular Graphics and Modelling.2026; 146: 109445.     CrossRef
• Mitochondria and the Repurposing of Diabetes Drugs for Off-Label Health Benefits
  Joyce Mei Xin Yip, Grace Shu Hui Chiang, Ian Chong Jin Lee, Rachel Lehming-Teo, Kexin Dai, Lokeysh Dongol, Laureen Yi-Ting Wang, Denise Teo, Geok Teng Seah, Norbert Lehming
  International Journal of Molecular Sciences.2025; 26(1): 364.     CrossRef
• Therapies Using Anti-diabetics to Prevent and Manage Progression of Parkinson's Disease
  Monalisa Rout, Shakti Ketan Prusty, Durga Madhab Kar
  Current Drug Therapy.2025; 20(3): 298.     CrossRef
• Molecular mapping and functional validation of GLP-1R cholesterol binding sites in pancreatic beta cells
  Affiong Ika Oqua, Kin Chao, Liliane El Eid, Lisa Casteller, Billy P Baxter, Alba Miguéns-Gómez, Sebastian Barg, Ben Jones, Jorge Bernardino de la Serna, Sarah L Rouse, Alejandra Tomas
  eLife.2025;[Epub]     CrossRef
• Efficacy and safety of glucagon-like peptide 1 agonists for Parkinson's disease: a systematic review and meta-analysis
  Luis O. S. Nogueira, Roberto A. S. V. Mazetto, Maria L. R. Defante, Vânio L. J. Antunes, Ocílio Ribeiro Gonçalves, Angela Maria Sandini Corso, Marcus V. Della Coletta, Dayany Leonel Boone, Walderico Silva Machado Filho, Vanderci Borges, Henrique Ballalai
  Arquivos de Neuro-Psiquiatria.2025; 83(04): 001.     CrossRef
• Deuterium trafficking, mitochondrial dysfunction, copper homeostasis, and neurodegenerative disease
  Stephanie Seneff, Anthony M. Kyriakopoulos
  Frontiers in Molecular Biosciences.2025;[Epub]     CrossRef
• Mitochondrial heteroplasmy-phenotype correlation and response to glucose lowering therapy in subjects with m.3243A>G mutations
  N Ng, B Sanchez-Lechuga, CJ McCarrick, C Mangan, M Burke, J.A. Ioana, C Gavin, R O’Byrne, JJ O’Byrne, MM Byrne
  Diabetes & Metabolism.2025; 51(5): 101678.     CrossRef
• β-Cell Mitochondrial Dysfunction: Underlying Mechanisms and Potential Therapeutic Strategies
  Radwan Darwish, Yasmine Alcibahy, Ghena Abu-Sharia, Alexandra E. Butler
  Cells.2025; 14(23): 1861.     CrossRef
• New fraternine analogues: Evaluation of the antiparkinsonian effect in the model of Parkinson's disease
  Andréia Biolchi Mayer, Henrique de Oliveira Amaral, Danilo Gustavo R. de Oliveira, Gabriel Avohay Alves Campos, Priscilla Galante Ribeiro, Solange Cristina Rego Fernandes, Adolfo Carlos Barros de Souza, Raffael Júnio Araújo de Castro, Anamélia Lorenzetti
  Neuropeptides.2024; 103: 102390.     CrossRef
• Prospects of antidiabetic drugs in the treatment of neurodegenerative disease
  Lidan Hu, Wenmin Wang, Xiangjun Chen, Guannan Bai, Liangjian Ma, Xin Yang, Qiang Shu, Xuekun Li
  Brain‐X.2024;[Epub]     CrossRef
• Attenuating mitochondrial dysfunction and morphological disruption with PT320 delays dopamine degeneration in MitoPark mice
  Vicki Wang, Kuan-Yin Tseng, Tung-Tai Kuo, Eagle Yi-Kung Huang, Kuo-Lun Lan, Zi-Rong Chen, Kuo-Hsing Ma, Nigel H. Greig, Jin Jung, Ho-II Choi, Lars Olson, Barry J. Hoffer, Yuan-Hao Chen
  Journal of Biomedical Science.2024;[Epub]     CrossRef
• Targeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidence
  Rae J. Herman, Heath D. Schmidt
  Physiology & Behavior.2024; 281: 114565.     CrossRef
• Unlocking longevity with GLP-1: A key to turn back the clock?
  Vivek P. Chavda, Pankti C. Balar, Dixa A. Vaghela, Payal Dodiya
  Maturitas.2024; 186: 108028.     CrossRef
• A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Bioactive Peptides
  Kuldeep Singh, Jeetendra Kumar Gupta, Shivendra Kumar, Urvashi Soni
  Current Protein & Peptide Science.2024; 25(7): 507.     CrossRef
• Targeting organ-specific mitochondrial dysfunction to improve biological aging
  Corina T. Madreiter-Sokolowski, Ursula Hiden, Jelena Krstic, Katrin Panzitt, Martin Wagner, Christian Enzinger, Michael Khalil, Mahmoud Abdellatif, Ernst Malle, Tobias Madl, Elena Osto, Markus Schosserer, Christoph J. Binder, Andrea Olschewski
  Pharmacology & Therapeutics.2024; 262: 108710.     CrossRef
• Liraglutide demonstrates a therapeutic effect on mitochondrial dysfunction in human SGBS adipocytes in vitro
  Maija Vaittinen, Mariana Ilha, Elena Herbers, Anita Wagner, Kirsi A. Virtanen, Kirsi H. Pietiläinen, Eija Pirinen, Jussi Pihlajamäki
  Diabetes Research and Clinical Practice.2023; 199: 110635.     CrossRef
• The cardioprotective effect of human glucagon‐like peptide‐1 receptor agonist (semaglutide) on cisplatin‐induced cardiotoxicity in rats: Targeting mitochondrial functions, dynamics, biogenesis, and redox status pathways
  Marwa Mohamed Atef, Yasser Mostafa Hafez, Omnia Safwat El‐Deeb, Eman H. Basha, Radwa Ismail, Hanan Alshenawy, Rasha Osama El‐Esawy, Amira Kamel Eltokhy
  Cell Biochemistry and Function.2023; 41(4): 450.     CrossRef
• Targeting mitochondrial quality control for diabetic cardiomyopathy: Therapeutic potential of hypoglycemic drugs
  Yutong Zhou, Wendong Suo, Xinai Zhang, Jiaojiao Liang, Weizhe Zhao, Yue Wang, Hong Li, Qing Ni
  Biomedicine & Pharmacotherapy.2023; 168: 115669.     CrossRef
• Soft X-ray tomography to map and quantify organelle interactions at the mesoscale
  Valentina Loconte, Jitin Singla, Angdi Li, Jian-Hua Chen, Axel Ekman, Gerry McDermott, Andrej Sali, Mark Le Gros, Kate L. White, Carolyn A. Larabell
  Structure.2022; 30(4): 510.     CrossRef
• Comparisons of pleiotropic effects of SGLT2 inhibition and GLP-1 agonism on cardiac glucose intolerance in heart dysfunction
  Belma Turan, Aysegul Durak, Yusuf Olgar, Erkan Tuncay
  Molecular and Cellular Biochemistry.2022; 477(11): 2609.     CrossRef
• Modulation of Reactive Oxygen Species Homeostasis as a Pleiotropic Effect of Commonly Used Drugs
  Carolin Thomas, Lia Wurzer, Ernst Malle, Michael Ristow, Corina T. Madreiter-Sokolowski
  Frontiers in Aging.2022;[Epub]     CrossRef
• Anti-cancer effects of sitagliptin, vildagliptin, and exendin-4 on triple-negative breast cancer cells via mitochondrial modulation
  POOJA JAISWAL, VERSHA TRIPATHI, ANSHUL ASSAIYA, DHARMENDRA KASHYAP, RAHUL DUBEY, ANAMIKA SINGH, JANESH KUMAR, HEM CHANDRA JHA, RAJESH SHARMA, AMIT KUMAR DIXIT, HAMENDRA SINGH PARMAR
  BIOCELL.2022; 46(12): 2645.     CrossRef
• Effect of liraglutide on neural and peripheral markers of metabolic function during antipsychotic treatment in rats
  Ilijana Babic, Dominic Sellers, Paul L Else, Jessica Nealon, Ashleigh L Osborne, Nagesh Pai, Katrina Weston-Green
  Journal of Psychopharmacology.2021; 35(3): 284.     CrossRef
• Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson’s Disease
  Vicki Wang, Tung-Tai Kuo, Eagle Yi-Kung Huang, Kuo-Hsing Ma, Yu-Ching Chou, Zhao-Yang Fu, Li-Wen Lai, Jin Jung, Hoi-II Choi, Doo-Sup Choi, Yazhou Li, Lars Olson, Nigel H. Greig, Barry J. Hoffer, Yuan-Hao Chen
  ACS Pharmacology & Translational Science.2021; 4(2): 858.     CrossRef
• Antioxidative Potentials of Incretin‐Based Medications: A Review of Molecular Mechanisms
  Habib Yaribeygi, Mina Maleki, Thozhukat Sathyapalan, Tannaz Jamialahmadi, Amirhossein Sahebkar, Marina Sokovi
  Oxidative Medicine and Cellular Longevity.2021;[Epub]     CrossRef
• Vernicia fordii (Hemsl.) Airy Shaw extract stimulates insulin secretion in pancreatic β-cells and improves insulin sensitivity in diabetic mice
  Jimin Hyun, Mi Hyeon Park, Yo Han Lee, Youngeun Lee, Su Ji Jeong, Sun Sil Choi, Keon Woo Khim, Hye Jin Eom, Jin-Hoe Hur, Chan Young Park, Jae-Ick Kim, Jiyoung Park, Hyung Won Ryu, Hyun-Jun Jang, Sei-Ryang Oh, Jang Hyun Choi
  Journal of Ethnopharmacology.2021; 278: 114238.     CrossRef
• Connecting the dots between mitochondrial dysfunction and Parkinson’s disorder: focus mitochondria-targeting therapeutic paradigm in mitigating the disease severity
  Ishnoor Kaur, Tapan Behl, Aayush Sehgal, Sukhbir Singh, Neelam Sharma, Lotfi Aleya, Simona Bungau
  Environmental Science and Pollution Research.2021; 28(28): 37060.     CrossRef
• Neuromodulatory effects of anti-diabetes medications: A mechanistic review
  Habib Yaribeygi, Milad Ashrafizadeh, Neil C. Henney, Thozhukat Sathyapalan, Tannaz Jamialahmadi, Amirhossein Sahebkar
  Pharmacological Research.2020; 152: 104611.     CrossRef
• Antidiabetic Agents for Treatment of Parkinson’s Disease: A Meta-Analysis
  Shu-Yi Wang, Shey-Lin Wu, Ta-Cheng Chen, Chieh-Sen Chuang
  International Journal of Environmental Research and Public Health.2020; 17(13): 4805.     CrossRef
• Visualizing subcellular rearrangements in intact β cells using soft x-ray tomography
  Kate L. White, Jitin Singla, Valentina Loconte, Jian-Hua Chen, Axel Ekman, Liping Sun, Xianjun Zhang, John Paul Francis, Angdi Li, Wen Lin, Kaylee Tseng, Gerry McDermott, Frank Alber, Andrej Sali, Carolyn Larabell, Raymond C. Stevens
  Science Advances.2020;[Epub]     CrossRef
• Nutrient Sensor mTOR and OGT: Orchestrators of Organelle Homeostasis in Pancreatic β-Cells
  Nicholas Esch, Seokwon Jo, Mackenzie Moore, Emilyn U. Alejandro, Yingke Xu
  Journal of Diabetes Research.2020; 2020: 1.     CrossRef
• Metabolic dynamics of human Sertoli cells are differentially modulated by physiological and pharmacological concentrations of GLP-1
  Ana D. Martins, Mariana P. Monteiro, Branca M. Silva, Alberto Barros, Mário Sousa, Rui A. Carvalho, Pedro F. Oliveira, Marco G. Alves
  Toxicology and Applied Pharmacology.2019; 362: 1.     CrossRef
• Sarcopenia in Chronic Kidney Disease: Factors, Mechanisms, and Therapeutic Interventions
  Hiroshi Watanabe, Yuki Enoki, Toru Maruyama
  Biological and Pharmaceutical Bulletin.2019; 42(9): 1437.     CrossRef
• Recent Advances in Drug Repurposing for Parkinson’s Disease
  Xin Chen, Giuseppe Gumina, Kristopher G. Virga
  Current Medicinal Chemistry.2019; 26(28): 5340.     CrossRef
• Mitochondrial dysfunction in diabetes and the regulatory roles of antidiabetic agents on the mitochondrial function
  Habib Yaribeygi, Stephen L. Atkin, Amirhossein Sahebkar
  Journal of Cellular Physiology.2019; 234(6): 8402.     CrossRef
• Liraglutide protects against glucolipotoxicity‐induced RIN‐m5F β‐cell apoptosis through restoration of PDX1 expression
  Edy Kornelius, Hsin‐Hua Li, Chiung‐Huei Peng, Yi‐Sun Yang, Wei‐Jen Chen, Yan‐Zin Chang, Yi‐Chiao Bai, Stanley Liu, Chien‐Ning Huang, Chih‐Li Lin
  Journal of Cellular and Molecular Medicine.2019; 23(1): 619.     CrossRef
• The osteogenic effect of liraglutide involves enhanced mitochondrial biogenesis in osteoblasts
  Subhashis Pal, Shailendra K. Maurya, Sourav Chattopadhyay, Shyamsundar Pal China, Konica Porwal, Chirag Kulkarni, Sabyasachi Sanyal, Rohit A. Sinha, Naibedya Chattopadhyay
  Biochemical Pharmacology.2019; 164: 34.     CrossRef
• Novel Treatment Opportunities Against Cognitive Impairment in Parkinson’s Disease with an Emphasis on Diabetes-Related Pathways
  Holly Green, Panagiota Tsitsi, Ioanna Markaki, Dag Aarsland, Per Svenningsson
  CNS Drugs.2019; 33(2): 143.     CrossRef
• Mitral cells and the glucagon‐like peptide 1 receptor: The sweet smell of success?
  Enrico Bagnoli, Una FitzGerald
  European Journal of Neuroscience.2019; 49(4): 422.     CrossRef
• Targeting the DPP-4-GLP-1 pathway improves exercise tolerance in heart failure patients: a systematic review and meta-analysis
  Chengcong Chen, Ying Huang, Yongmei Zeng, Xiyan Lu, Guoqing Dong
  BMC Cardiovascular Disorders.2019;[Epub]     CrossRef
• Acute exposure to 3‑deoxyglucosone at high glucose levels impairs insulin secretion from β‑cells by downregulating the sweet taste receptor signaling pathway
  Xiudao Song, Guoqiang Liang, Min Shi, Liang Zhou, Fei Wang, Lurong Zhang, Fei Huang, Guorong Jiang
  Molecular Medicine Reports.2019;[Epub]     CrossRef
• Translational approaches to restoring mitochondrial function in Parkinson's disease
  Heather Mortiboys, Ruby Macdonald, Thomas Payne, Matilde Sassani, Thomas Jenkins, Oliver Bandmann
  FEBS Letters.2018; 592(5): 776.     CrossRef
• Neuroprotective exendin-4 enhances hypothermia therapy in a model of hypoxic-ischaemic encephalopathy
  Eridan Rocha-Ferreira, Laura Poupon, Aura Zelco, Anna-Lena Leverin, Syam Nair, Andrea Jonsdotter, Ylva Carlsson, Claire Thornton, Henrik Hagberg, Ahad A Rahim
  Brain.2018; 141(10): 2925.     CrossRef
• Current perspective of mitochondrial biology in Parkinson's disease
  Navneet Ammal Kaidery, Bobby Thomas
  Neurochemistry International.2018; 117: 91.     CrossRef
• Humanin promotes mitochondrial biogenesis in pancreatic MIN6 β-cells
  Qingqing Qin, Jieqiong Jin, Fang He, Yongqin Zheng, Tingting Li, Yun Zhang, Jundong He
  Biochemical and Biophysical Research Communications.2018; 497(1): 292.     CrossRef
• Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
  Dilan Athauda, Kate Maclagan, Simon S Skene, Martha Bajwa-Joseph, Dawn Letchford, Kashfia Chowdhury, Steve Hibbert, Natalia Budnik, Luca Zampedri, John Dickson, Yazhou Li, Iciar Aviles-Olmos, Thomas T Warner, Patricia Limousin, Andrew J Lees, Nigel H Grei
  The Lancet.2017; 390(10103): 1664.     CrossRef
• Alogliptin, a Dipeptidyl Peptidase‐4 Inhibitor, Alleviates Atrial Remodeling and Improves Mitochondrial Function and Biogenesis in Diabetic Rabbits
  Xiaowei Zhang, Zhiwei Zhang, Yungang Zhao, Ning Jiang, Jiuchun Qiu, Yajuan Yang, Jian Li, Xue Liang, Xinghua Wang, Gary Tse, Guangping Li, Tong Liu
  Journal of the American Heart Association.2017;[Epub]     CrossRef
• Potential therapeutic interventions for chronic kidney disease‐associated sarcopenia via indoxyl sulfate‐induced mitochondrial dysfunction
  Yuki Enoki, Hiroshi Watanabe, Riho Arake, Rui Fujimura, Kana Ishiodori, Tadashi Imafuku, Kento Nishida, Ryusei Sugimoto, Saori Nagao, Shigeyuki Miyamura, Yu Ishima, Motoko Tanaka, Kazutaka Matsushita, Hirotaka Komaba, Masafumi Fukagawa, Masaki Otagiri, To
  Journal of Cachexia, Sarcopenia and Muscle.2017; 8(5): 735.     CrossRef
• The pancreas: Bandmaster of glucose homeostasis
  Nathalie Jouvet, Jennifer L. Estall
  Experimental Cell Research.2017; 360(1): 19.     CrossRef
• The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action
  Dilan Athauda, Thomas Foltynie
  Drug Discovery Today.2016; 21(5): 802.     CrossRef
• Effects of addition of a dipeptidyl peptidase IV inhibitor to metformin on sirolimus-induced diabetes mellitus
  Long Jin, Sun Woo Lim, Jian Jin, Byung Ha Chung, Chul Woo Yang
  Translational Research.2016; 174: 122.     CrossRef
• Pharmacological Modulators of Endoplasmic Reticulum Stress in Metabolic Diseases
  Tae Jung, Kyung Choi
  International Journal of Molecular Sciences.2016; 17(2): 192.     CrossRef

Citations

Citations to this article as recorded by  

• Modulation of Bone Turnover Markers with Dipeptidyl Deptidase-4: Interplay in Bone Health
  Faraha Ahmed, Syed Sufian Ahmad, Abul Kalam Najmi, Mohammad Ahmed Khan
  Current Drug Therapy.2026; 21(1): 63.     CrossRef
• The crucial role of beta-catenin in the osteoprotective effect of semaglutide in an ovariectomized rat model of osteoporosis
  Mohannad Hakam Hamed Abo-Elenin, Rehab Kamel, Shahira Nofal, Amany Ali Eissa Ahmed
  Naunyn-Schmiedeberg's Archives of Pharmacology.2025; 398(3): 2677.     CrossRef
• Glucagon-like peptide-1: a new potential regulator for mesenchymal stem cells in the treatment of type 2 diabetes mellitus and its complication
  Zi’an Shao, Xiaoguang Zhang, Junrong Cai, Feng Lu
  Stem Cell Research & Therapy.2025;[Epub]     CrossRef
• The Effects of GLP-1 Agonists on Musculoskeletal Health and Orthopedic Care
  Andrew Gatto, Kevin Liu, Nesa Milan, Stephanie Wong
  Current Reviews in Musculoskeletal Medicine.2025; 18(10): 469.     CrossRef
• GLP-1RA in JBMMSCs promoted osteogenic differentiation via modulating CREB and BRD4 signaling mediated proliferation and stemness
  Huiming Liu, Yawei Tian, Xiaoxue Bao, Yukun Li
  Scientific Reports.2025;[Epub]     CrossRef
• Effect of gut hormones on bone metabolism and their possible mechanisms in the treatment of osteoporosis
  Hongyu Liu, Huimin Xiao, Sufen Lin, Huan Zhou, Yizhao Cheng, Baocheng Xie, Daohua Xu
  Frontiers in Pharmacology.2024;[Epub]     CrossRef
• Glucagon-like peptide-1 receptor promotes osteoblast differentiation of dental pulp stem cells and bone formation in a zebrafish scale regeneration model
  Shafei Zhai, Changkui Liu, Selvaraj Vimalraj, Raghunandhakumar Subramanian, Shahabe Saquib abullais, Suraj Arora, Sekaran Saravanan
  Peptides.2023; 163: 170974.     CrossRef
• The associations of gut microbiota, endocrine system and bone metabolism
  Ye Tu, Xinyi Kuang, Ling Zhang, Xin Xu
  Frontiers in Microbiology.2023;[Epub]     CrossRef
• Effect of Liraglutide on Osteoporosis in a Rat Model of Type 2 Diabetes Mellitus: A Histological, Immunohistochemical, and Biochemical Study
  Maha Abdelhamid Fathy, Amal Anbaig, Raja Aljafil, Sherein F El-Sayed, Hanim Magdy Abdelnour, Mona Mostafa Ahmed, Eman M A Abdelghany, Sulaiman Mohammed Alnasser, Shaimaa Mohamed Abdelfattah Hassan, Amany Mohamed Shalaby
  Microscopy and Microanalysis.2023; 29(6): 2053.     CrossRef
• Metabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands
  Neil Tanday, Peter R. Flatt, Nigel Irwin
  British Journal of Pharmacology.2022; 179(4): 526.     CrossRef
• Exendin‐4 enhances osteogenic differentiation of adipose tissue mesenchymal stem cells through the receptor activator of nuclear factor‐kappa B and osteoprotegerin signaling pathway
  Sarah A. Habib, Mohamed M. Kamal, Shohda A. El‐Maraghy, Mahmoud A. Senousy
  Journal of Cellular Biochemistry.2022; 123(5): 906.     CrossRef
• Risk of fracture caused by anti-diabetic drugs in individuals with type 2 diabetes: A network meta-analysis
  Wen-Hsuan Tsai, Siang-Ke Kong, Chu-Lin Lin, Kai-Hsuan Cheng, Yi-Ting Cheng, Ming-Nan Chien, Chun-Chuan Lee, Ming-Chieh Tsai
  Diabetes Research and Clinical Practice.2022; 192: 110082.     CrossRef
• Comprehensive Analysis of Novel Genes and Pathways Associated with Osteogenic Differentiation of Adipose Stem Cells
  Qiuni Gao, Xiaorong Ma, Zuoliang Qi, Jianxin Shi
  Disease Markers.2022; 2022: 1.     CrossRef
• Novel Insights into the Roles and Mechanisms of GLP-1 Receptor Agonists against Aging-Related Diseases
  Wei Peng, Rui Zhou, Ze-Fang Sun, Jia-Wei Long, Yong-Qiang Gong
  Aging and disease.2022; 13(2): 468.     CrossRef
• Correlation of Osteoporosis in Patients With Newly Diagnosed Type 2 Diabetes: A Retrospective Study in Chinese Population
  Yuhua Wen, Huijuan Li, Xiaoya Zhang, Peipei Liu, Jing Ma, Liya Zhang, Keqin Zhang, Lige Song
  Frontiers in Endocrinology.2021;[Epub]     CrossRef
• Effects of Incretin-Related Diabetes Drugs on Bone Formation and Bone Resorption
  Hideki Kitaura, Saika Ogawa, Fumitoshi Ohori, Takahiro Noguchi, Aseel Marahleh, Yasuhiko Nara, Adya Pramusita, Ria Kinjo, Jinghan Ma, Kayoko Kanou, Itaru Mizoguchi
  International Journal of Molecular Sciences.2021; 22(12): 6578.     CrossRef
• Liraglutide regulates bone destruction and exhibits anti-inflammatory effects in periodontitis in vitro and in vivo
  Yunxia Zhang, Xuemin Yuan, Yuyan Wu, Minyu Pei, Man Yang, Xuanye Wu, Yunqing Pang, Jing Wang
  Journal of Dentistry.2020; 94: 103310.     CrossRef
• Exendin-4 regulates Wnt and NF-κB signaling in lipopolysaccharide-induced human periodontal ligament stem cells to promote osteogenic differentiation
  Honghong Liu, Jiawen Zheng, Taijing Zheng, Ping Wang
  International Immunopharmacology.2019; 75: 105801.     CrossRef
• Effects of malvidin, cyanidin and delphinidin on human adipose mesenchymal stem cell differentiation into adipocytes, chondrocytes and osteocytes
  Liga Saulite, Kaspars Jekabsons, Maris Klavins, Ruta Muceniece, Una Riekstina
  Phytomedicine.2019; 53: 86.     CrossRef
• Exendin-4 relieves the inhibitory effects of high glucose on the proliferation and osteoblastic differentiation of periodontal ligament stem cells
  Zijun Guo, Rui Chen, Fujun Zhang, Ming Ding, Ping Wang
  Archives of Oral Biology.2018; 91: 9.     CrossRef
• Effects of gastric inhibitory polypeptide, glucagon‐like peptide‐1 and glucagon‐like peptide‐1 receptor agonists on Bone Cell Metabolism
  Morten S. S. Hansen, Michaela Tencerova, Jacob Frølich, Moustapha Kassem, Morten Frost
  Basic & Clinical Pharmacology & Toxicology.2018; 122(1): 25.     CrossRef
• Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), extracellular signal-related kinase (ERK)1/2, and cAMP/pro
  Xuelun Wu, Shilun Li, Peng Xue, Yukun Li
  Experimental Cell Research.2017; 360(2): 281.     CrossRef
• The Impact of Glucagon-Like Peptide-1 on Bone Metabolism and Its Possible Mechanisms
  Chenhe Zhao, Jing Liang, Yinqiu Yang, Mingxiang Yu, Xinhua Qu
  Frontiers in Endocrinology.2017;[Epub]     CrossRef
• Pathophysiology of Bone Fragility in Patients with Diabetes
  Andrea Palermo, Luca D’Onofrio, Raffaella Buzzetti, Silvia Manfrini, Nicola Napoli
  Calcified Tissue International.2017; 100(2): 122.     CrossRef
• Activation of GLP-1 Receptor Promotes Bone Marrow Stromal Cell Osteogenic Differentiation through β-Catenin
  Jingru Meng, Xue Ma, Ning Wang, Min Jia, Long Bi, Yunying Wang, Mingkai Li, Huinan Zhang, Xiaoyan Xue, Zheng Hou, Ying Zhou, Zhibin Yu, Gonghao He, Xiaoxing Luo
  Stem Cell Reports.2016; 6(4): 579.     CrossRef
• Mechanisms for the cardiovascular effects of glucagon-like peptide-1
  H. Poudyal
  Acta Physiologica.2016; 216(3): 277.     CrossRef
• Perspectives in GLP-1 Research: New Targets, New Receptors
  Giulia Cantini, Edoardo Mannucci, Michaela Luconi
  Trends in Endocrinology & Metabolism.2016; 27(6): 427.     CrossRef
• Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice
  M. Pereira, J. Jeyabalan, C.S. Jørgensen, M. Hopkinson, A. Al-Jazzar, J.P. Roux, P. Chavassieux, I.R. Orriss, M.E. Cleasby, C. Chenu
  Bone.2015; 81: 459.     CrossRef
• Articles in 'Endocrinology and Metabolism' in 2014
  Won-Young Lee
  Endocrinology and Metabolism.2015; 30(1): 47.     CrossRef
• Impact of Anti-hyperglycemic Medications on Bone Health
  Naim M. Maalouf
  Clinical Reviews in Bone and Mineral Metabolism.2015; 13(1): 43.     CrossRef

Citations

Citations to this article as recorded by  

• Exposure to GLP-1RA and Risk of Structural Progression in Differentiated Thyroid Cancer
  Armando Patrizio, Audrey Mauguen, James A Fagin, Azeez Farooki, Stephanie S Fish, James Flory, Samantha Newman, Lubaina Presswala, Mona M Sabra, R Michael Tuttle, Laura Boucai
  The Journal of Clinical Endocrinology & Metabolism.2026; 111(7): e1795.     CrossRef
• Glucagon-like peptide-1 receptor agonists and the risk of obesity-related cancers: a systematic review and meta-analysis
  Yousef A. Ateiwi, Rahil Mahmood, Hon Jen Wong, Chen Ee Low, Chun En Yau, Ainsley Ryan Yan Bin Lee, Pei Chia Eng, Matilda Lee, Mark Y. Chan, Ching-Hui Sia
  Diabetes Research and Clinical Practice.2026; 234: 113158.     CrossRef
• Papillary thyroid carcinoma discovered in a patient on semaglutide therapy for metabolic syndrome: a case presentation and review of current evidence
  Jawad Haddadin, Aus Haddad, Lina Nahar, Osama Hamarneh, Fares Haddad
  Hormones.2026;[Epub]     CrossRef
• Approach to the Patient With Thyroid Nodules: Considering GLP-1 Receptor Agonists
  Clare A Kelly, Jennifer A Sipos
  The Journal of Clinical Endocrinology & Metabolism.2025; 110(6): e2080.     CrossRef
• Prognostic impact of glucagon-like peptide-1 receptor (GLP1R) expression on cancer survival and its implications for GLP-1R agonist therapy: an integrative analysis across multiple tumor types
  Zoltan Ungvari, Áron Bartha, Anna Ungvari, Monika Fekete, Giampaolo Bianchini, Balázs Győrffy
  GeroScience.2025; 47(3): 4413.     CrossRef
• Thyroid Cancer Risk with GLP-1 Receptor Agonists: Evidence, Knowledge Gaps, and the Path Forward
  David Toro-Tobon, Naykky Singh Ospina, Juan P. Brito
  Thyroid®.2025; 35(1): 3.     CrossRef
• Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Cohort Study
  Sarah M. Baxter, Lars Christian Lund, Jacob H. Andersen, Thomas H. Brix, Laszlo Hegedüs, Miyuki Hsing-Chun Hsieh, Chris Tzu-Ting Su, Michael Chun-Yuan Cheng, Zoe Chi-Jui Chang, Edward Chia-Cheng Lai, Swaleh Hussain, Cherry Chu, Tara Gomes, Tony Antoniou,
  Thyroid®.2025; 35(1): 69.     CrossRef
• GLP-1RA Use and Thyroid Cancer Risk
  Juan P. Brito, Jeph Herrin, Kavya Sindhu Swarna, Naykky M. Singh Ospina, Victor M. Montori, David Toro-Tobon, Guillermo E. Umpierrez, Rodolfo J. Galindo, Yihong Deng, Mindy M. Mickelson, Hui Shao, Eric C. Polley, Rozalina G. McCoy
  JAMA Otolaryngology–Head & Neck Surgery.2025; 151(3): 243.     CrossRef
• Increased Incidence or Detection Bias? Global Cohort Study Finds No Link between GLP1-RAs and Thyroid Cancer Risk
  Omar El Kawkgi
  Clinical Thyroidology®.2025; 37(1): 33.     CrossRef
• Semaglutide Reprograms Macrophages via the GLP-1R/PPARG/ACSL1 Pathway to Suppress Papillary Thyroid Carcinoma Growth
  Longlong Wang, Lele Zhang, Runsheng Ma, Yifei Zhang, Qungang Chang, Detao Yin
  The Journal of Clinical Endocrinology & Metabolism.2025; 110(10): 2777.     CrossRef
• GLP‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials
  Giovanni Antonio Silverii, Christian Marinelli, Costanza Bettarini, Gloria Giovanna Del Vescovo, Matteo Monami, Edoardo Mannucci
  Diabetes, Obesity and Metabolism.2025; 27(8): 4454.     CrossRef
• Assessing the Oncological Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Review and Meta-Analysis
  Jaber H Jaradat, Rawan I Al-Ahmad, Maha Al Jaghbeer, Ahlam A Abdelaziz, Nour M Abu Afifeh, Ghazi Abu Afifeh, Asad Rao, Amjad Alzoubi, Abdulqadir J Nashwan
  Cureus.2025;[Epub]     CrossRef
• Long‐Term Glucagon‐Like Peptide 1 Receptor Agonist Use Is Not Associated With Increased Risk of Thyroid Cancer in Adults With Type 2 Diabetes
  Rena Pollack, Joshua Stokar
  Diabetes/Metabolism Research and Reviews.2025;[Epub]     CrossRef
• Effect of GLP-1 Receptor Agonists on Patients with Thyroid Carcinomas Undergoing Active Surveillance
  Armando Patrizio, Samantha K Newman, R Michael Tuttle, Laura Boucai
  Journal of the Endocrine Society.2025;[Epub]     CrossRef
• Expression and functional diversity of the glucagon-like peptide-1 receptor across tumor types
  Mario M. Alba, Wilson H. Lee, Jerry S. H. Lee, Zhipeng Lu, Bangyan Stiles, Hagai Ligumsky
  Discover Oncology.2025;[Epub]     CrossRef
• Risk of thyroid cancer associated with glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: A population‐based cohort study
  Sungho Bea, Heejun Son, Jae Hyun Bae, Sun Wook Cho, Ju‐Young Shin, Young Min Cho
  Diabetes, Obesity and Metabolism.2024; 26(1): 108.     CrossRef
• Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials
  Giovanni Antonio Silverii, Matteo Monami, Marco Gallo, Alberto Ragni, Francesco Prattichizzo, Valerio Renzelli, Antonio Ceriello, Edoardo Mannucci
  Diabetes, Obesity and Metabolism.2024; 26(3): 891.     CrossRef
• Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review
  Ana E. Espinosa De Ycaza, Juan P. Brito, Rozalina G. McCoy, Hui Shao, Naykky Singh Ospina
  Thyroid®.2024;[Epub]     CrossRef
• Implications of GLP-1 Receptor Agonist on Thyroid Function: A Literature Review of Its Effects on Thyroid Volume, Risk of Cancer, Functionality and TSH Levels
  Stefania Capuccio, Sabrina Scilletta, Francesca La Rocca, Nicoletta Miano, Maurizio Di Marco, Giosiana Bosco, Francesco Di Giacomo Barbagallo, Roberto Scicali, Salvatore Piro, Antonino Di Pino
  Biomolecules.2024; 14(6): 687.     CrossRef
• GLP-1 Receptor Agonists: A Promising Therapy for Modern Lifestyle Diseases with Unforeseen Challenges
  Patrycja Kupnicka, Małgorzata Król, Justyna Żychowska, Ryszard Łagowski, Eryk Prajwos, Anna Surówka, Dariusz Chlubek
  Pharmaceuticals.2024; 17(11): 1470.     CrossRef
• Investigation the impact of liraglutide on the thyroid function tests
  Emre URHAN
  Turkish Journal of Clinics and Laboratory.2023; 14(2): 339.     CrossRef
• GLP-1R polymorphism (rs1042044) and expression are associated with the risk of papillary thyroid cancer among the Egyptian population
  Rehab S. Abdul-Maksoud, Walid S.H. Elsayed, Nearmeen M. Rashad, Rasha S. Elsayed, Shereen Elshorbagy, Mohamed G. Hamed
  Gene.2022; 834: 146597.     CrossRef
• Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials
  Weiting Hu, Rui Song, Rui Cheng, Caihong Liu, Rui Guo, Wei Tang, Jie Zhang, Qian Zhao, Xing Li, Jing Liu
  Frontiers in Endocrinology.2022;[Epub]     CrossRef
• GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS
  Zheng Yang, Yuhuan Lv, Meng Yu, Mei Mei, Linyu Xiang, Subei Zhao, Rong Li
  Frontiers in Pharmacology.2022;[Epub]     CrossRef
• The Effect of Exenatide on Thyroid-Stimulating Hormone and Thyroid Volume
  Muhammed Erkam Sencar, Davut Sakiz, Murat Calapkulu, Sema Hepsen, Muhammed Kizilgul, Ilknur Unsal Ozturk, Bekir Ucan, Murat Bayram, Busra Betul Cagir, Safak Akin, Mustafa Ozbek, Erman Cakal
  European Thyroid Journal.2019; 8(6): 307.     CrossRef
• Expression of GLP-1 receptor and CD26 in human thyroid C-cells: The association of thyroid C-cell tumorigenesis with incretin-based medicine
  Yuejia Song, Min Zhou, Yang Cao, Jiping Qi, Jingshu Geng, Xiaomin Liu
  Oncology Letters.2017; 13(4): 2684.     CrossRef
• Exendin-4 does not modify growth or apoptosis of human colon cancer cells
  He Wenjing, Yu Shuang, Li Weisong, Xiao Haipeng
  Endocrine Research.2017; : 1.     CrossRef
• GLP-1 receptor agonist as treatment for cancer as well as diabetes: beyond blood glucose control
  Takashi Nomiyama, Toshihiko Yanase
  Expert Review of Endocrinology & Metabolism.2016; : 1.     CrossRef
• Exendin-4 inhibits growth and augments apoptosis of ovarian cancer cells
  Wenjing He, Shuang Yu, Liantang Wang, Mian He, Xiaopei Cao, Yanbing Li, Haipeng Xiao
  Molecular and Cellular Endocrinology.2016; 436: 240.     CrossRef
• Expression of PACAP and PAC1 Receptor in Normal Human Thyroid Gland and in Thyroid Papillary Carcinoma
  Sebastian Bardosi, Attila Bardosi, Zsuzsanna Nagy, Dora Reglodi
  Journal of Molecular Neuroscience.2016; 60(2): 171.     CrossRef
• Sitagliptin use and thyroid cancer risk in patients with type 2 diabetes
  Chin-Hsiao Tseng
  Oncotarget.2016; 7(17): 24871.     CrossRef
• Articles in 'Endocrinology and Metabolism' in 2014
  Won-Young Lee
  Endocrinology and Metabolism.2015; 30(1): 47.     CrossRef
• Response: Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance (Endocrinol Metab2014;29:536-44, Min Jung Jung et al.)
  Min Jung Jung, Su Kyoung Kwon
  Endocrinology and Metabolism.2015; 30(2): 233.     CrossRef
• Letter: Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance (Endocrinol Metab2014;29:536-44, Min Jung Jung et al.)
  Daeyoon Park, Eun Kyung Lee
  Endocrinology and Metabolism.2015; 30(2): 231.     CrossRef

Citations

Citations to this article as recorded by  

• Animal Venoms Targeting Cellular Mechanisms: Advances and Implications for Drug Discovery and Disease Therapy
  Lucienne Mathai, Bipin G. Nair, Aswathy Alangode
  Toxins.2026; 18(7): 286.     CrossRef
• Salivary proteomics and metaproteomics identifies distinct molecular and taxonomic signatures of type-2 diabetes
  Diana Samodova, Evelina Stankevic, Mathilde Sonne Søndergaard, Naiyu Hu, Tarunveer S. Ahluwalia, Daniel R. Witte, Daniel Belstrøm, Anniek Frederike Lubberding, Pratik D. Jagtap, Torben Hansen, Atul S. Deshmukh
  Microbiome.2025;[Epub]     CrossRef
• Development of a HiBiT Peptide-Based NanoBRET Ligand Binding Assay for Galanin Receptor 1 in Live Cells
  Hu Zhu, Harrison C. Daly, Tae Gyun Yang, Josh Born, Gisela Andrea Camacho-Hernandez, Mingyang Yuan, Mari Inglese, Vinoth Kumar Chenniappan, Kris Zimmerman, Robin Hurst, Xin Hu, Amy Hauck Newman, Sergi Ferré, Rachel Friedman Ohana, Matthew D. Hall, Samarji
  ACS Chemical Biology.2025; 20(7): 1594.     CrossRef
• Exploring nondegrading molecular glues for protein–protein interactions
  Sitong Yu, Lixin Zhou, Jing Yang, Jian Zhang, Wenchao Lu
  Trends in Biochemical Sciences.2025; 50(10): 845.     CrossRef
• Novel GLP-1(28–36) amide-derived hybrid peptide A3 with weight loss and hypoglycemic activities
  Chen Wang, Binbin Gong, Qianqian Zhu, Jing Han, Lidan Sun
  European Journal of Pharmacology.2023; 961: 176200.     CrossRef
• Intranasal Delivery of a Methyllanthionine-Stabilized Galanin Receptor-2-Selective Agonist Reduces Acute Food Intake
  Anneke Kuipers, Márta Balaskó, Erika Pétervári, Andreas Koller, Susanne M. Brunner, Gert N. Moll, Barbara Kofler
  Neurotherapeutics.2021; 18(4): 2737.     CrossRef
• Low-Dose Decitabine Assists Human Umbilical Cord-Derived Mesenchymal Stem Cells in ProtectingβCells via the Modulation of the Macrophage Phenotype in Type 2 Diabetic Mice
  Jing Xue, Yu Cheng, Haojie Hao, Jieqing Gao, Yaqi Yin, Songyan Yu, Junyan Zou, Jiejie Liu, Qi Zhang, Yiming Mu
  Stem Cells International.2020; 2020: 1.     CrossRef
• DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus
  W. Wang, X. Wen, W. Duan, X. Wang, Y. Chen, J. Dong, Z. Yang, J. Fang, Z. Zhou, G. Yao, Y. Fang, Y. Huang
  Journal of Endocrinological Investigation.2020; 43(5): 653.     CrossRef
• Evolutionary and Comparative Genomics to Drive Rational Drug Design, with Particular Focus on Neuropeptide Seven-Transmembrane Receptors
  Michael Furlong, Jae Young Seong
  Biomolecules & Therapeutics.2017; 25(1): 57.     CrossRef
• Comparison of exenatide and acarbose on intra-abdominal fat content in patients with obesity and type-2 diabetes: A randomized controlled trial
  Li Shi, Jing Zhu, Ping Yang, Xiaoqiang Tang, Wenlong Yu, Changjie Pan, Moyu Shen, Dalong Zhu, Jinluo Cheng, Xinhua Ye
  Obesity Research & Clinical Practice.2017; 11(5): 607.     CrossRef
• Mesenchymal stem cell therapy in type 2 diabetes mellitus
  Li Zang, Haojie Hao, Jiejie Liu, Yijun Li, Weidong Han, Yiming Mu
  Diabetology & Metabolic Syndrome.2017;[Epub]     CrossRef
• Exendin-4 Inhibits Hepatic Lipogenesis by Increasing β-Catenin Signaling
  Mi Hae Seo, Jinmi Lee, Seok-Woo Hong, Eun-Jung Rhee, Se Eun Park, Cheol Young Park, Ki Won Oh, Sung Woo Park, Won-Young Lee, Catherine Mounier
  PLOS ONE.2016; 11(12): e0166913.     CrossRef
• Development of Spexin-based Human Galanin Receptor Type II-Specific Agonists with Increased Stability in Serum and Anxiolytic Effect in Mice
  Arfaxad Reyes-Alcaraz, Yoo-Na Lee, Gi Hoon Son, Nam Hoon Kim, Dong-Kyu Kim, Seongsik Yun, Dong-Hoon Kim, Jong-Ik Hwang, Jae Young Seong
  Scientific Reports.2016;[Epub]     CrossRef
• Articles in 'Endocrinology and Metabolism' in 2014
  Won-Young Lee
  Endocrinology and Metabolism.2015; 30(1): 47.     CrossRef
• Biased signalling: the instinctive skill of the cell in the selection of appropriate signalling pathways
  Ying Liu, Yang Yang, Richard Ward, Su An, Xiao-Xi Guo, Wei Li, Tian-Rui Xu
  Biochemical Journal.2015; 470(2): 155.     CrossRef

Glucagon-like peptide 1 (GLP-1) is secreted from enteroendocrine L-cells in response to oral nutrient intake and elicits glucose-stimulated insulin secretion while suppressing glucagon secretion. It also slows gastric emptying, which contributes to decreased postprandial glycemic excursions. In the 1990s, chronic subcutaneous infusion of GLP-1 was found to lower blood glucose levels in patients with type 2 diabetes. However, GLP-1's very short half-life, arising from cleavage by the enzyme dipeptidyl peptidase 4 (DPP-4) and glomerular filtration by the kidneys, presented challenges for clinical use. Hence, DPP-4 inhibitors were developed, as well as several GLP-1 analogs engineered to circumvent DPP-4-mediated breakdown and/or rapid renal elimination. Three categories of GLP-1 analogs, are being developed and/or are in clinical use: short-acting, long-acting, and prolonged-acting GLP-1 analogs. Each class has different plasma half-lives, molecular size, and homology to native GLP-1, and consequently different characteristic effects on glucose metabolism. In this article, we review current clinical data derived from each class of GLP-1 analogs, and consider the clinical effects reported for each category in recent head to head comparison studies. Given the relatively brief clinical history of these compounds, we also highlight several important efficacy and safety issues which will require further investigation.

Citations

Citations to this article as recorded by  

• Poly(l-threonine-co-l-threonine Succinate) Thermogels for Sustained Release of Lixisenatide
  Jin Kyung Park, Zhengyu Piao, Hyun Jung Lee, Byeongmoon Jeong
  Biomacromolecules.2024; 25(8): 4946.     CrossRef
• The efficacy and safety of combined GLP-1RA and basal insulin therapy among inadequately controlled T2D with premixed insulin therapy
  Jhih-Syuan Liu, Sheng-Chiang Su, Feng-Chih Kuo, Peng-Fei Li, Chia-Luen Huang, Li-Ju Ho, Kuan-Chan Chen, Yi-Chen Liu, Chih-Ping Lin, An-Che Cheng, Chien-Hsing Lee, Fu-Huang Lin, Yi-Jen Hung, Hsin-Ya Liu, Chieh-Hua Lu, Chang-Hsun Hsieh
  Medicine.2023; 102(10): e33167.     CrossRef
• Pharmacogenetics of Glucagon-like-peptide-1 receptor in diabetes management
  Mariya Kalinkova, Tanya Kadiyska, Teodora Handjieva-Darlenska
  Pharmacia.2023; 70(2): 383.     CrossRef
• Pharmacogenetic Insights into Glucagon-Like Peptide-1 Receptor and Its Role in Diabetes Therapy
  Chloe Davis, Liam Taylor, Isabella Moore
  Annals of Pharmacy Practice and Pharmacotherapy.2023; 3(1): 145.     CrossRef
• Anti-inflammatory potential of liraglutide, a glucagon-like peptide-1 receptor agonist, in rats with peripheral acute inflammation
  Irem Mert, Ayhan Cetinkaya, Mujgan Gurler, Canan Akünal Turel, Humeyra Celik, Ibrahim Ethem Torun, Idris Turel
  Inflammopharmacology.2022; 30(3): 1093.     CrossRef
• Exenatide improves hepatocyte insulin resistance induced by different regional adipose tissue
  Chuanmin Bai, Yujun Wang, Zhi Niu, Yaxin Guan, Jingshan Huang, Xin Nian, Fan Zuo, Juan Zhao, Tsutomu Kazumi, Bin Wu
  Frontiers in Endocrinology.2022;[Epub]     CrossRef
• Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists
  Hun Jee Choe, Young Min Cho
  Endocrinology and Metabolism.2021; 36(1): 22.     CrossRef
• Glucagon-like Peptide-1 Improves Fatty Liver and Enhances Thermogenesis in Brown Adipose Tissue via Inhibiting BMP4-Related Signaling Pathway in High-Fat-Diet-Induced Obese Mice
  Xingchun Wang, Bingwei Ma, Jiaqi Chen, Hui You, Chunjun Sheng, Peng Yang, Shen Qu, Vito Angelo Giagulli
  International Journal of Endocrinology.2021; 2021: 1.     CrossRef
• Exenatide ameliorates experimental non-alcoholic fatty liver in rats via suppression of toll-like receptor 4/NFκB signaling: Comparison to metformin
  Zeinab A. Saad, Dina M. Khodeer, Sawsan A. Zaitone, Amal A.M. Ahmed, Yasser M. Moustafa
  Life Sciences.2020; 253: 117725.     CrossRef
• Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease
  Shan Li, Xiaoman Wang, Jielei Zhang, Jingyi Li, Xiaogang Liu, Yuanyuan Ma, Chao Han, Lixia Zhang, Lili Zheng
  Brazilian Journal of Medical and Biological Research.2018;[Epub]     CrossRef
• Efficacy and safety of combination therapy with an α‐glucosidase inhibitor and a dipeptidyl peptidase‐4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta‐analysis
  Se Hee Min, Jeong‐Hwa Yoon, Seokyung Hahn, Young Min Cho
  Journal of Diabetes Investigation.2018; 9(4): 893.     CrossRef
• Glucagon-like peptide-1 affects human umbilical vein endothelial cells in high glucose by the PI3K/Akt/eNOS signaling pathway
  Jie Wu, Pingfan Guo, Tianmin He, Fanggang Cai
  Turkish Journal of Biochemistry.2018; 43(2): 119.     CrossRef
• What next after basal insulin? Treatment intensification with lixisenatide in Asian patients with type 2 diabetes mellitus
  Wing B. Chan, Andrea Luk, Wing S. Chow, Vincent T.F. Yeung
  Journal of Diabetes.2017; 9(6): 562.     CrossRef
• Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review
  L. Østergaard, Christian S. Frandsen, S. Madsbad
  Expert Review of Clinical Pharmacology.2016; 9(2): 241.     CrossRef
• Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program
  Johan Jendle, George Grunberger, Thomas Blevins, Francesco Giorgino, Ryan T. Hietpas, Fady T. Botros
  Diabetes/Metabolism Research and Reviews.2016; 32(8): 776.     CrossRef
• Glucagon‐like peptide‐1(GLP‐1) receptor agonists: potential to reduce fracture risk in diabetic patients?
  Guojing Luo, Hong Liu, Hongyun Lu
  British Journal of Clinical Pharmacology.2016; 81(1): 78.     CrossRef
• Impact of postprandial glucose control on diabetes-related complications: How is the evidence evolving?
  Sten Madsbad
  Journal of Diabetes and its Complications.2016; 30(2): 374.     CrossRef
• Risk assessment and management of post-transplant diabetes mellitus
  Eugene Han, Myoung Soo Kim, Yu Seun Kim, Eun Seok Kang
  Metabolism.2016; 65(10): 1559.     CrossRef
• Recent advances in oral delivery of peptide hormones
  Pegah Varamini, Istvan Toth
  Expert Opinion on Drug Delivery.2016; 13(4): 507.     CrossRef
• Exendin-4 Inhibits Hepatic Lipogenesis by Increasing β-Catenin Signaling
  Mi Hae Seo, Jinmi Lee, Seok-Woo Hong, Eun-Jung Rhee, Se Eun Park, Cheol Young Park, Ki Won Oh, Sung Woo Park, Won-Young Lee, Catherine Mounier
  PLOS ONE.2016; 11(12): e0166913.     CrossRef
• Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
  Sten Madsbad
  Diabetes, Obesity and Metabolism.2016; 18(4): 317.     CrossRef
• Does Bosentan Protect Diabetic Brain Alterations in Rats? The Role of Endothelin‐1 in the Diabetic Brain
  Recep Demir, Elif Cadirci, Erol Akpinar, Yasemin Cayir, Hasan Tarik Atmaca, Harun Un, Celalettin Semih Kunak, Muhammed Yayla, Zafer Bayraktutan, Ilknur Demir
  Basic & Clinical Pharmacology & Toxicology.2015; 116(3): 236.     CrossRef
• Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5
  P. D. Home, P. Shamanna, M. Stewart, F. Yang, M. Miller, C. Perry, M. C. Carr
  Diabetes, Obesity and Metabolism.2015; 17(2): 179.     CrossRef
• Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy
  Jaime A. Davidson
  Postgraduate Medicine.2015; 127(8): 827.     CrossRef
• GLP‐1 receptor agonists: effects on the progression of non‐alcoholic fatty liver disease
  Jia Liu, Guang Wang, Yumei Jia, Yuan Xu
  Diabetes/Metabolism Research and Reviews.2015; 31(4): 329.     CrossRef
• Efficacy and safety of teneligliptin, a dipeptidyl peptidase‐4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16‐week, randomized, double‐blind, placebo‐controlled phase III trial
  M. K. Kim, E.‐J. Rhee, K. A. Han, A. C. Woo, M.‐K. Lee, B. J. Ku, C. H. Chung, K.‐A. Kim, H. W. Lee, I. B. Park, J. Y. Park, H. C. Chul Jang, K. S. Park, W. I. Jang, B. Y. Cha
  Diabetes, Obesity and Metabolism.2015; 17(3): 309.     CrossRef
• Incretin physiology and pathophysiology from an Asian perspective
  Young Min Cho
  Journal of Diabetes Investigation.2015; 6(5): 495.     CrossRef
• Response: Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients (Diabetes Metab J2015;39:74-81)
  Antoni Sicras-Mainar, Ruth Navarro-Artieda
  Diabetes & Metabolism Journal.2015; 39(2): 173.     CrossRef
• Clinical Application of Glucagon-Like Peptide-1 Receptor Agonists
  Se Hee Min, Young Min Cho
  The Journal of Korean Diabetes.2015; 16(4): 252.     CrossRef
• Autophagy deficiency in β cells blunts incretin-induced suppression of glucagon release from α cells
  Min Joo Kim, Ok Kyong Choi, Kyung Sil Chae, Hakmo Lee, Sung Soo Chung, Dong-Sik Ham, Ji-Won Kim, Kun-Ho Yoon, Kyong Soo Park, Hye Seung Jung
  Islets.2015; 7(5): e1129096.     CrossRef
• Glucagon-Like Peptide-1 Increases Mitochondrial Biogenesis and Function in INS-1 Rat Insulinoma Cells
  Mi Yeon Kang, Tae Jung Oh, Young Min Cho
  Endocrinology and Metabolism.2015; 30(2): 216.     CrossRef
• Interleukin-6 CpG Methylation and Body Weight Correlate Differently in Type 2 Diabetes Patients Compared to Obese and Lean Controls
  Eva Aumueller, Marlene Remely, Hanna Baeck, Berit Hippe, Helmut Brath, Alexander G. Haslberger
  Lifestyle Genomics.2015; 8(1): 26.     CrossRef
• The glucagon-like peptide 1 receptor agonist enhances intrinsic peroxisome proliferator-activated receptor γ activity in endothelial cells
  Hirohisa Onuma, Kouichi Inukai, Atsuko Kitahara, Rie Moriya, Susumu Nishida, Toshiaki Tanaka, Hidenori Katsuta, Kazuto Takahashi, Yoshikazu Sumitani, Toshio Hosaka, Hitoshi Ishida
  Biochemical and Biophysical Research Communications.2014; 451(2): 339.     CrossRef
• Brief Review of Articles in 'Endocrinology and Metabolism' in 2013
  Won-Young Lee
  Endocrinology and Metabolism.2014; 29(3): 251.     CrossRef
• Cytokines and Hormones That Contribute to the Positive Association between Fat and Bone
  Dorit Naot, Jillian Cornish
  Frontiers in Endocrinology.2014;[Epub]     CrossRef
• Study of Postprandial Lipaemia in Type 2 Diabetes Mellitus: Exenatide versus Liraglutide
  Maria Voukali, Irene Kastrinelli, Sapfo Stragalinou, Dimitra Tasiopoulou, Pinelopi Paraskevopoulou, Nicholas Katsilambros, Alexandros Kokkinos, Nicholas Tentolouris, Ioannis Ioannidis
  Journal of Diabetes Research.2014; 2014: 1.     CrossRef
• The cardiometabolic benefits of glycine: Is glycine an ‘antidote’ to dietary fructose?
  Mark F McCarty, James J DiNicolantonio
  Open Heart.2014; 1(1): e000103.     CrossRef
• Nuevos fármacos antidiabéticos: avanzando hacia el control integral de la diabesidad
  J.J. Gorgojo-Martínez
  Hipertensión y Riesgo Vascular.2014; 31(2): 45.     CrossRef
• Managing Loss of Glycemic Control in Middle-Aged Patients With Diabetes: The Role of GLP-1 Receptor Agonists in Combination-Therapy Regimens
  Thomas B. Repas
  Journal of Osteopathic Medicine.2014; 114(s52): 14.     CrossRef

Citations

Citations to this article as recorded by  

• Glycogenic hepatopathy in a Korean girl with poorly controlled type 1 diabetes mellitus
  Hwal Rim Jeong, Young Seok Shim, Young Bae Kim, Hae Sang Lee, Jin Soon Hwang
  Annals of Pediatric Endocrinology & Metabolism.2014; 19(1): 49.     CrossRef
• Glucose Counterregulatory Hormone Response During Hypoglycemia due to Endogenous Hyperinsulinemia
  Jung Guk Kim
  Journal of Korean Endocrine Society.2009; 24(3): 162.     CrossRef